

Update tot 30-04-2020

1. **Some drugs for COVID-19.** The Medical letter on drugs and therapeutics. 2020;62(1595):49-50.
2. **Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - the 2020 COVID-19 pandemic.** Brough HA, Kalayci O, Sediva A, Untersmayr E, Munblit D, Rodriquez Del Rio P, et al. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2020. <http://dx.doi.org/10.1111/pai.13262>.
3. **Successful Treatment of Preterm Labor in Association with Acute COVID-19 Infection.** Browne PC, Linfert JB, Perez-Jorge E. American journal of perinatology. 2020. <http://dx.doi.org/10.1055/s-0040-1709993>.
4. **Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD.** Burgueno JF, Reich A, Hazime H, Quintero MA, Irina F, Fritsch J, et al. Inflammatory bowel diseases. 2020. <http://dx.doi.org/10.1093/ibd/izaa085>.
5. **One month of the novel coronavirus 2019 outbreak: Is it still a threat?** Chowdhury A, Jahan N, Wang S. Virusdisease. 2020:1-5. <http://dx.doi.org/10.1007/s13337-020-00579-x>.
6. **2019 novel coronavirus: an emerging global threat.** Columbus C, Brust KB, Arroliga AC. Proceedings (Baylor University Medical Center). 2020;33(2):209-12. <http://dx.doi.org/10.1080/08998280.2020.1731272>. eCollection 2020 Apr.
7. **Cardiac Tamponade Secondary to COVID-19.** Dabbagh MF, Aurora L, D'Souza P, Weinmann AJ, Bhargava P, Basir MB. JACC Case reports. 2020. <http://dx.doi.org/10.1016/j.jaccas.2020.04.009>.
8. **COVID-19 infection and rheumatoid arthritis: Faraway, so close!** Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. Autoimmun Rev. 2020;19(5):102523. <http://dx.doi.org/10.1016/j.autrev.2020.102523>. Epub 2020 Mar 20.
9. **The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis.** Gangopadhyay KK, Mukherjee JJ, Sinha B, Ghosal S. medRxiv. 2020:2020.04.17.20069773.
10. **Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID).** Giollo A, Adami G, Gatti D, Idolazzi L, Rossini M. Ann Rheum Dis. 2020. <http://dx.doi.org/10.1136/annrheumdis-2020-217598>.
11. **COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency.** Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, et al. Journal of endocrinological investigation. 2020. <http://dx.doi.org/10.1007/s40618-020-01266-w>.
12. **Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection.** Isidori AM, Pofi R, Hasenmajer V, Lenzi A, Pivonello R. The lancet Diabetes & endocrinology. 2020. [http://dx.doi.org/10.1016/S2213-8587\(20\)30149-2](http://dx.doi.org/10.1016/S2213-8587(20)30149-2).
13. **Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients.** Jacobs JP, Stammers AH, St Louis J, Hayanga JWA, Firstenberg MS, Mongero LB, et al. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2020. <http://dx.doi.org/10.1097/MAT.0000000000001185>.
14. **Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.** Kasperkiewicz M, Schmidt E, Fairley JA, Joly P, Payne AS, Yale ML, et al. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020. <http://dx.doi.org/10.1111/jdv.16525>.

15. **Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review).** Lehrer S. World Academy of Sciences journal. 2020;2(3). <http://dx.doi.org/10.3892/wasj.2020.42>. Epub 2020 Mar 29.
16. **Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis.** Lu S, Zhou Q, Huang L, Shi Q, Zhao S, Wang Z, et al. medRxiv. 2020:2020.04.17.20064469.
17. **PAK1-blockers: Potential Therapeutics against COVID-19.** Maruta H, He H. Medicine in drug discovery. 2020:100039. <http://dx.doi.org/10.1016/j.medidd.2020.100039>.
18. **Corticosteroid use for 2019-nCoV infection: A double-edged sword.** Nasim S, Kumar S, Azim D, Ashraf Z, Azeem Q. Infect Control Hosp Epidemiol. 2020:1-6. <http://dx.doi.org/10.1017/ice.2020.165>.
19. **COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter.** Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2020. <http://dx.doi.org/10.1111/ajt.15941>.
20. **Systemic Immunosuppressive Therapy for Inflammatory Skin Diseases in Children: Expert-Consensus-Based Guidance for Clinical Decision Making During the COVID-19 Pandemic.** Reynolds SD, Mathur AN, Chiu YE, Brandling-Bennett HA, Pope E, Siegel MP, et al. Pediatric dermatology. 2020. <http://dx.doi.org/10.1111/pde.14202>.
21. **Case study : a patient with asthma, Covid-19 pneumonia and cytokine release syndrome treated with corticosteroids and tocilizumab.** Schleicher GK, Lowman W, Richards GA. Wits Journal of Clinical Medicine. 2020;2:47-52.
22. **Clinical Characteristics of 20,662 Patients with COVID-19 Described in 147 Articles: A Systemic Review and Meta-Analysis.** Tang C, Zhang K, Wang W, Pei Z, Liu Z, Yuan P, et al. The Lancet Infectious Diseases. 2020.
23. **COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs.** Tufan A, Avanoğlu Guler A, Matucci-Cerinic M. Turkish journal of medical sciences. 2020;50:620-32. <http://dx.doi.org/10.3906/sag-2004-168>.
24. **The care of patients with Duchenne, Becker and other muscular dystrophies in the COVID-19 pandemic.** Veerapandiyam A, Wagner KR, Apkon S, McDonald CM, Mathews KD, Parsons JA, et al. Muscle Nerve. 2020. <http://dx.doi.org/10.1002/mus.26902>.
25. **Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China.** Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. medRxiv. 2020:2020.03.06.20032342.
26. **COVID-19: Melatonin as a potential adjuvant treatment.** Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. Life sciences. 2020;250:117583. <http://dx.doi.org/10.1016/j.lfs.2020.117583>. Epub 2020 Mar 23.
27. **Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia.** Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Signal transduction and targeted therapy. 2020;5(1):18. <http://dx.doi.org/10.1038/s41392-020-0127-9>.

Literatuuroverzicht tot 30-04-2020

1. **Consensus for the management of severe acute respiratory syndrome.** Chinese Medical Journal. 2003;116(11):1603-36.
2. **Management of SARS relies on supportive measures and preventing the spread of infection.** Drugs and Therapy Perspectives. 2006;22(3):16-9.
3. **Family cluster of middle east respiratory syndrome coronavirus infections, Tunisia, 2013.** Abroug F, Slim A, Ouanes-Besbes L, Kacem MAH, Dachraoui F, Ouanes I, et al. Emerging Infectious Diseases. 2014;20(9):1527-30.
4. **Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.** Adhikari N, Amin SA, Saha A, Jha T. European journal of medicinal chemistry. 2017;137:365-438. <http://dx.doi.org/10.1016/j.ejmech.2017.05.041>. Epub 2017 May 30.
5. **Spectral quality and UV-B stress stimulate glycyrrhizin concentration of Glycyrrhiza uralensis in hydroponic and pot system.** Afreen F, Zobayed SM, Kozai T. Plant physiology and biochemistry : PPB. 2005;43(12):1074-81. <http://dx.doi.org/10.1016/j.plaphy.2005.11.005>. Epub 2005 Dec 13.
6. **Vitamin D analogs as anti-carcinogenic agents.** Agoston ES, Hatcher MA, Kensler TW, Posner GH. Anti-cancer agents in medicinal chemistry. 2006;6(1):53-71. <http://dx.doi.org/10.2174/187152006784111369>.
7. **Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moieties.** Akhtar MJ, Yar MS, Khan AA, Ali Z, Haider MR. Mini reviews in medicinal chemistry. 2017;17(17):1602-32. <http://dx.doi.org/10.2174/1389557516666161031121639>.
8. **Severe acute respiratory syndrome (SARS): The first pandemic of the new century.** Akova M. Turkish Journal of Medical Sciences. 2003;33(5):265-70.
9. **Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia.** Al Ghamdi M, Alghamdi KM, Ghandooria Y, Alzahrani A, Salah F, Alsulami A, et al. BMC Infectious Diseases. 2016;16(1).
10. **An overview of quinazolines: Pharmacological significance and recent developments.** Alagarsamy V, Chitra K, Saravanan G, Solomon VR, Sulthana MT, Narendhar B. European journal of medicinal chemistry. 2018;151:628-85. <http://dx.doi.org/10.1016/j.ejmech.2018.03.076>. Epub 2018 Mar 30.
11. **SARS: The emergence of a new epidemic.** Al-Ateeg FA. Saudi Medical Journal. 2003;24(7):794-8.
12. **Severe acute respiratory syndrome: The evolution of a new epidemic.** Al-Ateeg FAA. Annals of Saudi Medicine. 2003;23(3):118-26.
13. **Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort study.** Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Travel Med Infect Dis. 2019;29:48-50. <http://dx.doi.org/10.1016/j.tmaid.2019.03.004>. Epub 2019 Mar 11.
14. **MERS CoV infection in two renal transplant recipients: Case report.** Alghamdi M, Mushtaq F, Awn N, Shalhoub S. American Journal of Transplantation. 2015;15(4):1101-4.
15. **Spontaneous intracranial hemorrhage in a patient with Middle East respiratory syndrome corona virus.** Al-Hameed FM. Saudi Medical Journal. 2017;38(2):196-200.
16. **MERS-coV transmitted from animal-to-human vs MERS-CoV transmitted from human-to-human:**

- Comparison of virulence and therapeutic outcomes in a Saudi Hospital.** Alhumaid S, Tobaiqy M, Albagshi M, Alrubaya A, Algharib F, Aldera A, et al. *Tropical Journal of Pharmaceutical Research*. 2018;17(6):1155-64.
17. **Histopathology of Middle East respiratory syndrome coronavirus (MERS-CoV) infection – clinicopathological and ultrastructural study.** Alsaad KO, Hajeer AH, Al Balwi M, Al Moaiqel M, Al Oudah N, Al Ajlan A, et al. *Histopathology*. 2018;72(3):516-24.
18. **Impact of Middle East Respiratory Syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome.** Alserahi H, Wali G, Alshukairi A, Alraddadi B. *BMC Infectious Diseases*. 2016;16(1).
19. **The calm before the storm: clinical observations of Middle East respiratory syndrome (MERS) patients.** Al-Tawfiq JA, Hinedi K. *Journal of Chemotherapy*. 2018;30(3):179-82.
20. **Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).** Al-Tawfiq JA, Memish ZA. *Expert Review of Anti-Infective Therapy*. 2017;15(3):269-75.
21. **Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.** Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2014;20:42-6. <http://dx.doi.org/10.1016/j.ijid.2013.12.003>. Epub 2014 Jan 6.
22. **Indomethacin has a potent antiviral activity against SARS coronavirus.** Amici C, Di Caro A, Ciucci A, Chiappa L, Castilletti C, Martella V, et al. *Antivir Ther*. 2006;11(8):1021-30.
23. **Anti-inflammatory, anti-oxidant, and apoptotic activities of four plant species used in folk medicine in the Mediterranean basin.** Amira S, Dade M, Schinella G, Rios JL. *Pakistan journal of pharmaceutical sciences*. 2012;25(1):65-72.
24. **Radiographic-clinical correlation in severe acute respiratory syndrome: study of 1373 patients in Hong Kong.** Antonio GE, Ooi CG, Wong KT, Tsui EL, Wong JS, Sy AN, et al. *Radiology*. 2005;237(3):1081-90. <http://dx.doi.org/10.1148/radiol.2373041919>.
25. **Imaging in severe acute respiratory syndrome (SARS).** Antonio GE, Wong KT, Chu WCW, Hui DSC, Cheng FWT, Yuen EHY, et al. *Clinical Radiology*. 2003;58(11):825-32.
26. **Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience.** Antonio GE, Wong KT, Hui DS, Wu A, Lee N, Yuen EH, et al. *Radiology*. 2003;228(3):810-5. <http://dx.doi.org/10.1148/radiol.2283030726>. Epub 2003 Jun 12.
27. **Value of CT in assessing probable severe acute respiratory syndrome.** Anuradha Rao TN, Paul N, Chung T, Mazzulli T, Walmsley S, Boylan CE, et al. *American Journal of Roentgenology*. 2003;181(2):317-9.
28. **Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection.** Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, et al. *Annals of internal medicine*. 2014;160(6):389-97. <http://dx.doi.org/10.7326/M13-2486>.
29. **Middle east respiratory syndrome.** Arabi YM, Balkhy HH, Hayden FG, Bouchama A, Luke T, Baillie JK, et al. *New England Journal of Medicine*. 2017;376(6):584-94.
30. **Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV).** Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, et al. *Infection*. 2015;43(4):495-501.
31. **Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome.** Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. *Am J Respir Crit Care Med*.

2018;197(6):757-67. <http://dx.doi.org/10.1164/rccm.201706-1172OC>.

32. **The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study.** Auyeung TW, Lee JS, Lai WK, Choi CH, Lee HK, Lee JS, et al. *J Infect.* 2005;51(2):98-102. <http://dx.doi.org/10.1016/j.jinf.2004.09.008>.
33. **Clinical course and management of SARS in health care workers in Toronto: a case series.** Avendano M, Derkach P, Swan S. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.* 2003;168(13):1649-60.
34. **Clinical application of radionuclide bone scintigraphy in diagnosis of avascular osteonecrosis in patients with severe acute respiratory syndrome in convalescence.** Ba JT, Zhu ZH, Li F, Xing HQ, Ma YR, Jing HL, et al. *Acta Academiae Medicinae Sinicae.* 2008;30(3):318-22.
35. **Evaluation of pH and calcium ion release in capseal I and II and in two other root canal sealers.** Bae KH, Chang SW, Bae KS, Park DS. *Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.* 2011;112(5):e23-8. <http://dx.doi.org/10.1016/j.tripleo.2011.04.031>. Epub 2011 Aug 26.
36. **Emerging Viral Infections.** Bale JF. *Seminars in Pediatric Neurology.* 2012;19(3):115-8.
37. **The apoptotic effect of sarsasapogenin from *Anemarrhena asphodeloides* on HepG2 human hepatoma cells.** Bao W, Pan H, Lu M, Ni Y, Zhang R, Gong X. *Cell biology international.* 2007;31(9):887-92. <http://dx.doi.org/10.1016/j.cellbi.2007.02.001>. Epub 2007 Feb 25.
38. **Effects of integrative Chinese and Western medicine on arterial oxygen saturation in patients with severe acute respiratory syndrome.** Bao-yan L, Jing-qing H, Yan-ming X, Wei-liang W, Rong-bing W, Yan-ping Z, et al. *Chinese Journal of Integrative Medicine.* 2004;10(2):117-22.
39. **Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.** Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, et al. *Antiviral Res.* 2006;71(1):53-63. <http://dx.doi.org/10.1016/j.antiviral.2006.03.001>. Epub 2006 Mar 24.
40. **Septic shock, necrotizing pneumonitis, and meningoencephalitis caused by mycoplasma pneumoniae in a child: A case report.** Barreira ER, Souza DC, Gáes PF, Bousso A. *Clinical Pediatrics.* 2009;48(3):320-2.
41. **Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing's syndrome.** Belaya ZE, Ilijin AV, Melnichenko GA, Rozhinskaya LY, Dragunova NV, Dzeranova LK, et al. *Endocrine.* 2012;41(3):494-500. <http://dx.doi.org/10.1007/s12020-012-9658-3>. Epub 2012 Mar 25.
42. **Severe acute respiratory syndrome, a pathological immune response to the new coronavirus - Implications for understanding of pathogenesis, therapy, design of vaccines, and epidemiology.** Bermejo JF, Muñoz-Fernandez MA. *Viral Immunology.* 2004;17(4):535-44.
43. **Pentoxifylline and severe acute respiratory syndrome (SARS): A drug to be considered.** Bermejo Martín JF, Jiménez JL, Muñoz-Fernández MA. *Medical Science Monitor.* 2003;9(6):SR29-SR34.
44. **Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012.** Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, et al. *Eurosurveillance.* 2012;17(40).
45. **Steroidal saponins from *Smilax officinalis*.** Bernardo RR, Pinto AV, Parente JP. *Phytochemistry.* 1996;43(2):465-9. [http://dx.doi.org/10.1016/0031-9422\(96\)00274-9](http://dx.doi.org/10.1016/0031-9422(96)00274-9).

46. **Serious adverse reactions of bupropion for smoking cessation: Analysis of the French pharmacovigilance database from 2001 to 2004.** Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M. *Drug Safety*. 2008;31(11):1017-26.
47. **Apoptosis inducing activity of steroidal constituents from *Solanum xanthocarpum* and *Asparagus racemosus*.** Bhutani KK, Paul AT, Fayad W, Linder S. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2010;17(10):789-93. <http://dx.doi.org/10.1016/j.phymed.2010.01.017>. Epub 2010 Feb 21.
48. **SARS: The flying death.** Bizri ARN, Musharrafieh UM. *Journal Medical Libanais*. 2003;51(3):148-54.
49. **Supplies and equipment for pediatric emergency mass critical care.** Bohn D, Kanter RK, Burns J, Barfield WD, Kisson N. *Pediatric Critical Care Medicine*. 2011;12(6):S120-S7.
50. **Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.** Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. *Jama*. 2003;289(21):2801-9. <http://dx.doi.org/10.1001/jama.289.21.JOC30885>. Epub 2003 May 6.
51. **Severe acute respiratory syndrome and critical care medicine: The Toronto experience.** Booth CM, Stewart TE. *Critical Care Medicine*. 2005;33(1):S53-S60.
52. **Severe acute respiratory syndrome: Update.** Bossi P, Guihot A, Ansart S, Bricaire F. *Revue de Medecine Interne*. 2003;24(10):672-80.
53. **SARS: Severe acute respiratory syndrome.** Brajachand Singh N. *JMS - Journal of Medical Society*. 2003;17(2):74-7.
54. **Role of China in the quest to define and control severe acute respiratory syndrome.** Breiman RF, Evans MR, Preiser W, Maguire J, Schnur A, Li A, et al. *Emerging Infectious Diseases*. 2003;9(9):1037-41.
55. **Molecular targets for the rational design of drugs to inhibit SARS coronavirus.** Brockway SM, Denison MR. *Drug Discovery Today: Disease Mechanisms*. 2004;1(2):205-9.
56. **Emerging viral diseases in pulmonary medicine.** Brouard J, Vabret A, Nimal D, Bach N, Trippery V, Freymuth F. *Archives de Pediatrie*. 2007;14(6):649-51.
57. **Clinical efficacy of acute respiratory viral infections prevention in patients with chronic heart failure.** Budnevsky AV, Shurupova AD, Kravchenko AY, Tokmachev RE. *Terapevticheskii arkhiv*. 2019;91(3):36-41. <http://dx.doi.org/10.26442/00403660.2019.03.000111>.
58. **ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells.** Burkard C, Verheije MH, Haagmans BL, van Kuppeveld FJ, Rottier PJ, Bosch BJ, et al. *J Virol*. 2015;89(8):4434-48. <http://dx.doi.org/10.1128/JVI.03274-14>. Epub 2015 Feb 4.
59. **Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligands.** Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Ciani SM, et al. *Journal of medicinal chemistry*. 1996;39(18):3435-50. <http://dx.doi.org/10.1021/jm960251b>.
60. **The severe acute respiratory syndrome epidemic in mainland China dissected.** Cao WC, de Vlas SJ, Richardus JH. *Infectious disease reports*. 2011;3(1):e2. <http://dx.doi.org/10.4081/idr.2011.e2>. eCollection 2011 Mar 8.
61. **[A retrospective study in the treatment of five patients with severe acute respiratory syndrome].** Cao XY, Zheng XW, Zhang J, Ma SL, Wang P. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue*. 2003;15(6):371.

62. **Synthesis and anti-inflammatory activity of isoquebecol.** Cardinal S, Paquet-Cote PA, Azelmat J, Bouchard C, Grenier D, Voyer N. *Bioorganic & medicinal chemistry*. 2017;25(7):2043-56. <http://dx.doi.org/10.1016/j.bmc.2017.01.050>. Epub 2017 Feb 16.
63. **Community acquired pulmonary infection: Clinical perspectives.** Carter R, Woodhead M. *CPD Journal Radiology Update*. 2007;6(2):97-106.
64. **Steroidal saponins from the roots of Smilax sp.: structure and bioactivity.** Challinor VL, Parsons PG, Chap S, White EF, Blanchfield JT, Lehmann RP, et al. *Steroids*. 2012;77(5):504-11. <http://dx.doi.org/10.1016/j.steroids.2012.01.009>. Epub 2012 Jan 21.
65. **Osteonecrosis in children with severe acute respiratory syndrome.** Chan CW, Chiu WK, Chan CC, Chow EY, Cheung HM, Ip PL. *The Pediatric infectious disease journal*. 2004;23(9):888-90. <http://dx.doi.org/10.1097/01.inf.0000137570.37856.ea>.
66. **Clinical significance of hepatic derangement in severe acute respiratory syndrome.** Chan HLY, Kwan ACP, To KF, Lai ST, Chan PKS, Leung WK, et al. *World Journal of Gastroenterology*. 2005;11(14):2148-53.
67. **Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?** Chan JFW, Li KSM, To KKW, Cheng VCC, Chen H, Yuen KY. *Journal of Infection*. 2012;65(6):477-89.
68. **Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort study.** Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MML, et al. *Hong Kong Medical Journal*. 2003;9(6):399-406.
69. **Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy.** Chan MH, Chan PK, Griffith JF, Chan IH, Lit LC, Wong CK, et al. *Pathology*. 2006;38(3):229-35. <http://dx.doi.org/10.1080/00313020600696231>.
70. **Serum LD1 isoenzyme and blood lymphocyte subsets as prognostic indicators for severe acute respiratory syndrome.** Chan MH, Wong VW, Wong CK, Chan PK, Chu CM, Hui DS, et al. *Journal of internal medicine*. 2004;255(4):512-8. <http://dx.doi.org/10.1111/j.1365-2796.2004.01323.x>.
71. **SARS: Clinical presentation, transmission, pathogenesis and treatment options.** Chan PKS, Tang JW, Hui DSC. *Clinical Science*. 2006;110(2):193-204.
72. **Clinical manifestations of two cases with severe acute respiratory syndrome (SARS) in I-Lan County.** Chan YJ, Chen SD, Hsueh KH, Hsu NW, Perng CL, Chou NS, et al. *Journal of the Chinese Medical Association*. 2004;67(9):472-5.
73. **Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.** Channappanavar R, Perlman S. *Seminars in Immunopathology*. 2017;39(5):529-39.
74. **Severe acute respiratory syndrome.** Chan-Yeung M, Ooi GC, Hui DS, Ho PL, Tsang KW. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2003;7(12):1117-30.
75. **Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report.** Chan-Yeung M, Yu WC. *Bmj*. 2003;326(7394):850-2. <http://dx.doi.org/10.1136/bmj.326.7394.850>.
76. **Peripheral nerve disease in SARS: Report of a case.** Chao CC, Tsai LK, Chiou YH, Tseng MT, Hsieh ST, Chang SC, et al. *Neurology*. 2003;61(12):1820-1.

77. **Daboia russellii and Naja kaouthia venom neutralization by lupeol acetate isolated from the root extract of Indian sarsaparilla Hemidesmus indicus R.Br.** Chatterjee I, Chakravarty AK, Gomes A. *J Ethnopharmacol.* 2006;106(1):38-43. <http://dx.doi.org/10.1016/j.jep.2005.11.031>. Epub 2006 Jan 19.
78. **SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases.** Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, et al. *Hepatology (Baltimore, Md).* 2004;39(2):302-10. <http://dx.doi.org/10.1002/hep.20111>.
79. **Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome.** Chen CY, Lee CH, Liu CY, Wang JH, Wang LM, Perng RP. *Journal of the Chinese Medical Association.* 2005;68(1):4-10.
80. **In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.** Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, et al. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.* 2004;31(1):69-75. <http://dx.doi.org/10.1016/j.jcv.2004.03.003>.
81. **Pathogenic role of HMGB1 in SARS?** Chen G, Chen DZ, Li J, Czura CJ, Tracey KJ, Sama AE, et al. *Medical Hypotheses.* 2004;63(4):691-5.
82. **Synthesis and cytotoxicity evaluation of 4'-amino-4'-dehydroxyoleandrin derivatives.** Chen H, Lei M, Ma B, Liu M, Guo D, Liu X, et al. *Fitoterapia.* 2016;113:85-90. <http://dx.doi.org/10.1016/j.fitote.2016.07.002>. Epub 2016 Jul 16.
83. **Synthesis, structure-activity relationships and biological evaluation of dehydroandrographolide and andrographolide derivatives as novel anti-hepatitis B virus agents.** Chen H, Ma YB, Huang XY, Geng CA, Zhao Y, Wang LJ, et al. *Bioorganic & medicinal chemistry letters.* 2014;24(10):2353-9. <http://dx.doi.org/10.1016/j.bmcl.2014.03.060>. Epub 2014 Mar 28.
84. **Molecular cloning, characterization, and expression profiles of androgen receptors in spotted scat (Scatophagus argus).** Chen HP, Deng SP, Dai ML, Zhu CH, Li GL. *Genetics and molecular research : GMR.* 2016;15(2). <http://dx.doi.org/10.4238/gmr.15027838>.
85. **Synthesis and antitumor activity of feruloyl and caffeoyl derivatives.** Chen HZ, Chen YB, Lv YP, Zeng F, Zhang J, Zhou YL, et al. *Bioorganic & medicinal chemistry letters.* 2014;24(18):4367-71. <http://dx.doi.org/10.1016/j.bmcl.2014.08.024>. Epub 2014 Aug 18.
86. **[Studies on accumulation of active ingredients, N, P and K in Anemarrhena asphodeloides].** Chen J, Yang CJ, Guo YH. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.* 2007;32(15):1504-7.
87. **Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: A rescue trial in Beijing.** Chen L, Liu P, Gao H, Sun B, Chao D, Wang F, et al. *Clinical Infectious Diseases.* 2004;39(10):1531-5.
88. **Rhabdomyolysis associated with acute renal failure in patients with severe acute respiratory syndrome.** Chen LL, Hsu CW, Tian YC, Fang JT. *Int J Clin Pract.* 2005;59(10):1162-6. <http://dx.doi.org/10.1111/j.1368-5031.2005.00540.x>.
89. **Novel resveratrol-based flavonol derivatives: Synthesis and anti-inflammatory activity in vitro and in vivo.** Chen LZ, Yao L, Jiao MM, Shi JB, Tan Y, Ruan BF, et al. *European journal of medicinal chemistry.* 2019;175:114-28. <http://dx.doi.org/10.1016/j.ejmech.2019.05.004>. Epub 2019 May 3.
90. **One unique steroidal sapogenin obtained through the microbial transformation of ruscogenin by Phytophthora cactorum ATCC 32134 and its potential inhibitory effect on tissue factor (TF) procoagulant activity.** Chen ND, Yue L, Zhang J, Kou JP, Yu BY. *Bioorganic & medicinal chemistry letters.* 2010;20(14):4015-7.

<http://dx.doi.org/10.1016/j.bmcl.2010.05.103>. Epub 2010 Jun 1.

91. **[Temperature changes of patients with severe acute respiratory syndrome: a comparative study].** Chen PY, Liu L, Liu DL, Mo YX, Zhang C, Ou CQ, et al. *Di Yi Jun Yi Da Xue Xue Bao*. 2005;25(9):1095-9.
92. **Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience.** Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, et al. *Chest*. 2006;129(6):1441-52. <http://dx.doi.org/10.1378/chest.129.6.1441>.
93. **Diffusing capacity of the lung for carbon monoxide in patients with severe acute respiratory syndrome at convalescence.** Chen TS, Chen LA, Xie LX, Liu YN, Hao FY, Tian Q, et al. *Chinese Journal of Clinical Rehabilitation*. 2005;9(23):98-100.
94. **Reversible splenic lesion syndrome in children: Retrospective study and summary of case series.** Chen WX, Liu HS, Yang SD, Zeng SH, Gao YY, Du ZH, et al. *Brain Dev*. 2016;38(10):915-27. <http://dx.doi.org/10.1016/j.braindev.2016.04.011>. Epub 2016 Aug 30.
95. **Effect of integrated traditional Chinese medicine and western medicine on the treatment of severe acute respiratory syndrome: A meta-analysis.** Chen Y, Guo JJ, Healy DP, Zhan S. *Pharmacy Practice*. 2007;5(1):1-9.
96. **Clinical, virologic and immunologic profiles of a young infant with severe acute respiratory syndrome.** Cheng FWT, Ng EKO, Li AM, Hon EKL, Chiu RWK, Dennis Lo YM, et al. *Pediatric Infectious Disease Journal*. 2005;24(6):567-8.
97. **Adjustment outcomes in Chinese patients following one-month recovery from severe acute respiratory syndrome in Hong Kong.** Cheng SK, Sheng B, Lau KK, Wong CW, Ng YK, Li HL, et al. *The Journal of nervous and mental disease*. 2004;192(12):868-71. <http://dx.doi.org/10.1097/01.nmd.0000147169.03998.dc>.
98. **Psychiatric complications in patients with severe acute respiratory syndrome (SARS) during the acute treatment phase: a series of 10 cases.** Cheng SK, Tsang JS, Ku KH, Wong CW, Ng YK. *The British journal of psychiatry : the journal of mental science*. 2004;184:359-60. <http://dx.doi.org/10.1192/bjp.184.4.359>.
99. **Clinical management and infection control of SARS: Lessons learned.** Cheng VCC, Chan JFW, To KKW, Yuen KY. *Antiviral Research*. 2013;100(2):407-19.
100. **Viral Replication in the Nasopharynx Is Associated with Diarrhea in Patients with Severe Acute Respiratory Syndrome.** Cheng VCC, Hung IFN, Tang BSF, Chu CM, Wong MML, Chan KH, et al. *Clinical Infectious Diseases*. 2004;38(4):467-75.
101. **Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection.** Cheng VCC, Lau SKP, Woo PCY, Kwok YY. *Clinical Microbiology Reviews*. 2007;20(4):660-94.
102. **Medical treatment of viral pneumonia including SARS in immunocompetent adult.** Cheng VCC, Tang BSF, Wu AKL, Chu CM, Yuen KY. *Journal of Infection*. 2004;49(4):262-73.
103. **Two years after pandemic influenza A/2009/H1N1: What have we learned?** Cheng VCC, To KKW, Tse H, Hung IFN, Yuen KY. *Clinical Microbiology Reviews*. 2012;25(2):223-63.
104. **Ribavirin for SARS in Children.** Cheng WTF, Li CK, Leung TF, Li AMC, Hon KLE, Ng PC, et al. *Clinical Pediatrics*. 2004;43(2):193-6.
105. **[Analysis on factors related to X-ray outcomes in 93 SARS patients].** Cheng YQ, Zhang WJ, Wang XF, Zhao P, Jin XY. *Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology*. 2004;18(3):265-7.

106. **Progressive docking: a hybrid QSAR/docking approach for accelerating in silico high throughput screening.** Cherkasov A, Ban F, Li Y, Fallahi M, Hammond GL. *Journal of medicinal chemistry*. 2006;49(25):7466-78. <http://dx.doi.org/10.1021/jm060961+>.
107. **Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome.** Cheung TMT, Yam LYC, So LKY, Lau ACW, Poon E, Kong BMH, et al. *Chest*. 2004;126(3):845-50.
108. **Management of hospital-acquired severe acute respiratory syndrome with different disease spectrum.** Chiang CH, Chen HM, Shih JF, Su WJ, Perng RP. *Journal of the Chinese Medical Association*. 2003;66(6):328-38.
109. **Relapse of SARS upon tapering corticosteroid.** Chien JY, Hsueh PR, Chang SC, Hwang JJ, Yu CJ, Yang PC. *Intensive Care Med*. 2004;30(6):1240-1. <http://dx.doi.org/10.1007/s00134-004-2287-4>. Epub 2004 May 1.
110. **Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome.** Chien JY, Hsueh PR, Cheng WC, Yu CJ, Yang PC. *Respirology*. 2006;11(6):715-22.
111. **Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome.** Chihrin S, Loutfy MR. *Expert Review of Anti-Infective Therapy*. 2005;3(2):251-62.
112. **Synthesis of α -santonin derivatives for diminutive effect on T and B-cell proliferation and their structure activity relationships.** Chinthakindi PK, Singh J, Gupta S, Nargotra A, Mahajan P, Kaul A, et al. *European Journal of Medicinal Chemistry*. 2017;127:1047-58.
113. **Synthesis of alpha-santonin derivatives for diminutive effect on T and B-cell proliferation and their structure activity relationships.** Chinthakindi PK, Singh J, Gupta S, Nargotra A, Mahajan P, Kaul A, et al. *European journal of medicinal chemistry*. 2017;127:1047-58. <http://dx.doi.org/10.1016/j.ejmech.2016.11.018>. Epub 2016 Nov 9.
114. **Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: Experience in two medical centers.** Chiou HE, Liu CL, Buttrey MJ, Kuo HP, Liu HW, Kuo HT, et al. *Chest*. 2005;128(1):263-72.
115. **Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong.** Chiu WK, Cheung PC, Ng KL, Ip PL, Sugunan VK, Luk DC, et al. *Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies*. 2003;4(3):279-83. <http://dx.doi.org/10.1097/01.PCC.0000077079.42302.81>.
116. **Diarrhea in medical care workers with severe acute respiratory syndrome.** Chiu YC, Wu KL, Chou YP, Fong TV, Tsai TL, Kuo CM, et al. *Journal of Clinical Gastroenterology*. 2004;38(10):880-2.
117. **Outcomes and Prognostic Factors in 267 Patients with Severe Acute Respiratory Syndrome in Hong Kong.** Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, et al. *Annals of Internal Medicine*. 2003;139(9):715-23+115.
118. **Severe acute respiratory syndrome.** Christian MD, Poutanen SM, Loutfy MR, Muller MP, Low DE. *Clinical Infectious Diseases*. 2004;38(10):1420-7.
119. **Post-SARS sickness syndrome manifestations and endocrinopathy: how, why, and so what?** Chrousos GP, Kaltsas G. *Clinical endocrinology*. 2005;63(4):363-5. <http://dx.doi.org/10.1111/j.1365-2265.2005.02361.x>.
120. **Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-CoV).** Chu CK, Gadthula S, Chen X, Choo H, Olgen S, Barnard DL, et al. *Antiviral Chemistry and Chemotherapy*. 2006;17(5):285-9.
121. **Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings.** Chu CM,

Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. *Thorax*. 2004;59(3):252-6.

122. **Spontaneous pneumomediastinum in patients with severe acute respiratory syndrome.** Chu CM, Leung YY, Hui JYH, Hung IFN, Chan VL, Leung WS, et al. *European Respiratory Journal*. 2004;23(6):802-4.

123. **Thin-section CT 12 months after the diagnosis of severe acute respiratory syndrome in pediatric patients.** Chu WCW, Li AM, Ng AWH, So HK, Lam WWM, Lo KL, et al. *American Journal of Roentgenology*. 2006;186(6):1707-14.

124. **Response to published article, "The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study."** Chun-Wing Lau A, So LK, Yam LY, Chan KS. *J Infect*. 2006;52(4):309-10. <http://dx.doi.org/10.1016/j.jinf.2005.08.004>. Epub 2005 Oct 4.

125. **Structural Probing and Molecular Modeling of the A(3) Adenosine Receptor: A Focus on Agonist Binding.** Ciancetta A, Jacobson KA. *Molecules (Basel, Switzerland)*. 2017;22(3). <http://dx.doi.org/10.3390/molecules22030449>.

126. **The protective potential of Yucca schidigera (Sarsaponin 30) against nitrite-induced oxidative stress in rats.** Cigerci IH, Fidan AF, Konuk M, Yuksel H, Kucukkurt I, Eryavuz A, et al. *Journal of natural medicines*. 2009;63(3):311-7. <http://dx.doi.org/10.1007/s11418-009-0338-4>. Epub 2009 May 12.

127. **Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.** Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. *Lancet*. 2003;361(9374):2045-6. [http://dx.doi.org/10.1016/s0140-6736\(03\)13615-x](http://dx.doi.org/10.1016/s0140-6736(03)13615-x).

128. **Development of antiviral therapy for severe acute respiratory syndrome.** Cinatl Jr J, Michaelis M, Hoever G, Preiser W, Doerr HW. *Antiviral Research*. 2005;66(2):81-97.

129. **High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells.** Cinatl Jr J, Michaelis M, Morgenstern B, Doerr HW. *International journal of molecular medicine*. 2005;15(2):323-7.

130. **The effects of pregnancy on the mouse thymic epithelium.** Clarke AG, Gil AL, Kendall MD. *Cell and tissue research*. 1994;275(2):309-18. <http://dx.doi.org/10.1007/bf00319429>.

131. **Oestrogen administration and the expression of the kallikrein gene family in the rat submandibular gland.** Clements JA, Matheson BA, MacDonald RJ, Funder JW. *Journal of steroid biochemistry*. 1990;35(1):55-60. [http://dx.doi.org/10.1016/0022-4731\(90\)90145-i](http://dx.doi.org/10.1016/0022-4731(90)90145-i).

132. **Severe Acute Respiratory Syndrome (SARS).** Cleri DJ, Ricketti AJ, Vernaleo JR. *Infectious Disease Clinics of North America*. 2010;24(1):175-202.

133. **Differential effects of lecithin and cholesterol on the immunoreactivity and conformation of apolipoprotein A-I in high density lipoproteins.** Collet X, Perret B, Simard G, Raffai E, Marcel YL. *The Journal of biological chemistry*. 1991;266(14):9145-52.

134. **SARS: A tale of two epidemics.** Conly JM, Johnston BL. *Canadian Journal of Infectious Diseases*. 2003;14(3):147-9.

135. **Ipilimumab-induced encephalopathy with a reversible splenic lesion.** Conry RM, Sullivan JC, Nabors ILB. *Cancer Immunology Research*. 2015;3(6):598-601.

136. **Coronavirus nsp6 proteins generate autophagosomes from the endoplasmic reticulum via an omegasome intermediate.** Cottam EM, Maier HJ, Manifava M, Vaux LC, Chandra-Schoenfelder P, Gerner W, et al.

Autophagy. 2011;7(11):1335-47. <http://dx.doi.org/10.4161/auto.7.11.16642>. Epub 2011 Nov 1.

137. **Isolation of steroidal saponins implicated in experimentally induced cholangiopathy of sheep grazing *Brachiaria decumbens* in Brazil.** Cruz C, Driemeier D, Pires VS, Colodel EM, Taketa AT, Schenkel EP. *Veterinary and human toxicology*. 2000;42(3):142-5.
138. **Serum hepatic enzyme manifestations in patients with severe acute respiratory syndrome: Retrospective analysis.** Cui HJ, Tong XL, Li P, Hao YX, Chen XG, Li AG, et al. *World Journal of Gastroenterology*. 2004;10(11):1652-5.
139. **HHV6-related mild encephalopathy with reversible splenic lesion (MERS) presenting with urinary and fecal retention in an Italian adolescent.** Cursi L, Boccuzzi E, Lancellata L, Longo D, Talamanca LF, Bozzola E, et al. *Infezioni in Medicina*. 2019;27(1):97-102.
140. **Critics slam treatment for SARS as ineffective and perhaps dangerous.** Cyranoski D. *Nature*. 2003;423(6935):4. <http://dx.doi.org/10.1038/423004a>.
141. **Targeting RORs nuclear receptors by novel synthetic steroidal inverse agonists for autoimmune disorders.** Dal Pra M, Carta D, Szabadkai G, Suman M, Frion-Herrera Y, Paccagnella N, et al. *Bioorganic & medicinal chemistry*. 2018;26(8):1686-704. <http://dx.doi.org/10.1016/j.bmc.2018.02.018>. Epub 2018 Feb 15.
142. **Antidiarrhoeal effects of methanolic root extract of *Hemidesmus indicus* (Indian sarsaparilla)--an in vitro and in vivo study.** Das S, Prakash R, Devaraj SN. *Indian journal of experimental biology*. 2003;41(4):363-6.
143. **The role of disposable inhalers in pulmonary drug delivery.** De Boer AH, Hagedoorn P. *Expert Opinion on Drug Delivery*. 2015;12(1):143-57.
144. **Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).** De Lucca GV, Shi Q, Liu Q, Batt DG, Beaudoin Bertrand M, Rampulla R, et al. *Journal of Medicinal Chemistry*. 2016;59(17):7915-35.
145. **Progress towards the identification of new aggrecanase inhibitors.** De Rienzo F, Saxena P, Filomia F, Caselli G, Colace F, Stasi L, et al. *Curr Med Chem*. 2009;16(19):2395-415. <http://dx.doi.org/10.2174/092986709788682092>.
146. **In Vitro Colonic Fermentation of Saponin-Rich Extracts from Quinoa, Lentil, and Fenugreek. Effect on Saponins Yield and Human Gut Microbiota.** Del Hierro JN, Cueva C, Tamargo A, Nunez-Gomez E, Moreno-Arribas MV, Reglero G, et al. *Journal of agricultural and food chemistry*. 2020;68(1):106-16. <http://dx.doi.org/10.1021/acs.jafc.9b05659>. Epub 2019 Dec 24.
147. **Identification and quantitative analysis of carotenoids and their esters from sarsaparilla (*Smilax aspera* L.) berries.** Delgado-Pelayo R, Hornero-Mendez D. *Journal of agricultural and food chemistry*. 2012;60(33):8225-32. <http://dx.doi.org/10.1021/jf302719g>. Epub 2012 Aug 14.
148. **Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.** Deng G, Zhou B, Wang J, Chen Z, Gong L, Gong Y, et al. *European journal of medicinal chemistry*. 2019;168:232-52. <http://dx.doi.org/10.1016/j.ejmech.2019.02.025>. Epub 2019 Feb 11.
149. **[Steroidal saponins from *Asparagus filicinus*].** Ding Y, Yang CR. *Yao xue xue bao = Acta pharmaceutica Sinica*. 1990;25(7):509-14.
150. **Severe acute respiratory syndrome-coronavirus and human coronavirus-NL63: An updated overview.**

Ditt V, Schildgen O. *Reviews in Medical Microbiology*. 2009;20(2):19-28.

151. **Ecdysterone regulatory elements function as both transcriptional activators and repressors.** Dobens L, Rudolph K, Berger EM. *Mol Cell Biol*. 1991;11(4):1846-53. <http://dx.doi.org/10.1128/mcb.11.4.1846>.
152. **Severe acute respiratory syndrome epidemics: End or parenthesis of epidemics?** Domínguez À, Gudiol F, Pumarola T, Salleras L. *Medicina Clinica*. 2003;121(9):340-6.
153. **Sarsasapogenin-AA13 inhibits LPS-induced inflammatory responses in macrophage cells in vitro and relieves dimethylbenzene-induced ear edema in mice.** Dong D, Zhou NN, Liu RX, Xiong JW, Pan H, Sun SQ, et al. *Acta pharmacologica Sinica*. 2017;38(5):699-709. <http://dx.doi.org/10.1038/aps.2016.180>. Epub 2017 Feb 27.
154. **Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection.** Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, et al. *The Lancet Infectious Diseases*. 2013;13(9):745-51.
155. **Measurement of bile salt aggregation equilibria using kinetic dialysis and spreadsheet modeling.** Duane WC, Gilboe DP. *Analytical biochemistry*. 1995;229(1):15-9. <http://dx.doi.org/10.1006/abio.1995.1372>.
156. **Comprehensive study of the phenolics and saponins from Helleborus niger L. Leaves and stems by liquid chromatography/tandem mass spectrometry.** Duckstein SM, Stintzing FC. *Chemistry & biodiversity*. 2014;11(2):276-98. <http://dx.doi.org/10.1002/cbdv.201300267>.
157. **LC-MS(n) characterization of steroidal saponins in Helleborus niger L. roots and their conversion products during fermentation.** Duckstein SM, Stintzing FC. *Steroids*. 2015;93:47-59. <http://dx.doi.org/10.1016/j.steroids.2014.09.011>. Epub 2014 Nov 20.
158. **Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.** Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG, Hensley LE, et al. *Drugs*. 2017;77(18):1935-66.
159. **Evaluating the oestrogenic activities of aqueous root extract of Asparagus africanus Lam in female Sprague-Dawley rats and its phytochemical screening using Gas Chromatography-Mass Spectrometry (GC/MS).** El-Ishaq A, Alshawsh MA, Chik ZB. *PeerJ*. 2019;7:e7254. <http://dx.doi.org/10.7717/peerj.7254>. eCollection 2019.
160. **Cloning, expression and characterization of rhesus macaque types 1 and 2 5alpha-reductase: evidence for mechanism-based inhibition by finasteride.** Ellsworth KP, Azzolina BA, Cimis G, Bull HG, Harris GS. *The Journal of steroid biochemistry and molecular biology*. 1998;66(5):271-9. [http://dx.doi.org/10.1016/s0960-0760\(98\)00059-4](http://dx.doi.org/10.1016/s0960-0760(98)00059-4).
161. **Clinically mild encephalitis/encephalopathy with a reversible splenic lesion of corpus callosum in Chinese children.** Fang Q, Chen L, Chen Q, Lin Z, Yang F. *Brain Dev*. 2017;39(4):321-6. <http://dx.doi.org/10.1016/j.braindev.2016.10.009>. Epub 2016 Nov 4.
162. **[SARS--the facts. Transmission, diagnosis and managing suspected cases].** Feldt T, Oette M, Kroidl A, Gobels K, Richter J, Haussinger D. *MMW Fortschritte der Medizin*. 2003;145(19):36-40.
163. **Sarsasapogenin reverses depressive-like behaviors and nicotinic acetylcholine receptors induced by olfactory bulbectomy.** Feng B, Zhao XY, Song YZ, Liang WN, Liu JL. *Neuroscience letters*. 2017;639:173-8. <http://dx.doi.org/10.1016/j.neulet.2016.12.025>. Epub 2016 Dec 14.
164. **Inhibition of human neutrophil elastase by pentacyclic triterpenes.** Feng L, Liu X, Zhu W, Guo F, Wu Y, Wang R, et al. *PLoS One*. 2013;8(12):e82794. <http://dx.doi.org/10.1371/journal.pone.0082794>. eCollection 2013.

165. **Severe acute respiratory syndrome (SARS) in children.** Filchev S. *Pediatrics*. 2004;44(3):7-12+3.
166. **The challenge of SARS: A clinical review.** File Jr TM. *Journal of Respiratory Diseases*. 2004;25(4):147-55.
167. **Severe acute respiratory syndrome: Pertinent clinical characteristics and therapy.** File Jr TM, Tsang KWT. *Treatments in Respiratory Medicine*. 2005;4(2):95-106.
168. **Antiviral effects of Glycyrrhiza species.** Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D, et al. *Phytotherapy research : PTR*. 2008;22(2):141-8. <http://dx.doi.org/10.1002/ptr.2295>.
169. **Ovine metabolism of saponins: evaluation of a method for estimating the ovine uptake of steroidal saponins from Narthecium ossifragum.** Flaoyen A, Wilkins AL, Deng D, Brekke T. *Veterinary research communications*. 2001;25(3):225-38. <http://dx.doi.org/10.1023/a:1006485726523>.
170. **Severe acute respiratory syndrome.** Franas A, Płusa T. *Polski Merkuriusz Lekarski*. 2006;21(123):205-10.
171. **Current concepts in SARS treatment.** Fujii T, Nakamura T, Iwamoto A. *Journal of Infection and Chemotherapy*. 2004;10(1):1-7.
172. **Heparinoids activate a protease, secreted by mucosa and tumors, via tethering supplemented by allostery.** Fulcher YG, Sanganna Gari RR, Frey NC, Zhang F, Linhardt RJ, King GM, et al. *ACS chemical biology*. 2014;9(4):957-66. <http://dx.doi.org/10.1021/cb400898t>. Epub 2014 Feb 10.
173. **Rapid creation of a temporary isolation ward for patients with severe acute respiratory syndrome in Taiwan.** Fung CP, Hsieh TL, Tan KH, Loh CH, Wu JS, Li CC, et al. *Infection Control and Hospital Epidemiology*. 2004;25(12):1026-32.
174. **[Analysis of relation between the usage of corticosteroid in treatment and arthralgia as a sequela of SARS patients].** Gao HS, Wang SX, Chen LM, Li YM, Yuan SL, Jiao ZS, et al. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue*. 2004;16(5):277-80.
175. **Human coronaviruses: Insights into environmental resistance and its influence on the development of new antiseptic strategies.** Geller C, Varbanov M, Duval RE. *Viruses*. 2012;4(11):3044-68.
176. **CORTISOL LEVELS AND SUICIDE IN BIPOLAR I DISORDER.** Giurgiucă A, Nemes B, Schipor S, Carageorghopol A, Boscaiu V, Cozman D, et al. *Acta endocrinologica (Bucharest, Romania : 2005)*. 2017;13(2):188-94. <http://dx.doi.org/10.4183/aeb.2017.188>.
177. **SARS - The first pandemic of XXI century.** Gładysz A, Inglot M, Knysz B, Gasiorowski J, Szymczak A, Serafińska S. *Advances in Clinical and Experimental Medicine*. 2003;12(4):409-14.
178. **Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2.** Glende J, Schwegmann-Wessels C, Al-Falah M, Pfeifferle S, Qu X, Deng H, et al. *Virology*. 2008;381(2):215-21. <http://dx.doi.org/10.1016/j.virol.2008.08.026>. Epub 2008 Sep 23.
179. **Effects of sarsaponin on digestion and passage rates in cattle fed medium to low concentrate.** Goetsch AL, Owens FN. *Journal of dairy science*. 1985;68(9):2377-84. [http://dx.doi.org/10.3168/jds.S0022-0302\(85\)81112-7](http://dx.doi.org/10.3168/jds.S0022-0302(85)81112-7).
180. **Pro/con clinical debate: steroids are a key component in the treatment of SARS. Pro: Yes, steroids are a key component of the treatment regimen for SARS.** Gomersall CD. *Crit Care*. 2004;8(2):105-7. <http://dx.doi.org/10.1186/cc2452>. Epub 2004 Jan 26.
181. **Short-term outcome of critically ill patients with severe acute respiratory syndrome.** Gomersall CD,

Joynt GM, Lam P, Li T, Yap F, Lam D, et al. *Intensive Care Med.* 2004;30(3):381-7. <http://dx.doi.org/10.1007/s00134-003-2143-y>. Epub 2004 Jan 23.

182. **Pro/con clinical debate: Steroids are a key component in the treatment of SARS.** Gomersall CD, Kargel MJ, Lapinsky SE. *Critical Care.* 2004;8(2):105-7.

183. **SARS: Here to stay? Monkeypox: Beware of exotic pets.** Gordon SM, Longworth DL. *Cleveland Clinic Journal of Medicine.* 2003;70(10):889-95.

184. **SARS: A "microbiological" pollution?** Grassi C, Allegra L. *GIMT - Giornale Italiano delle Malattie del Torace.* 2003;57(5):374-86.

185. **Musculoskeletal complications of severe acute respiratory syndrome.** Griffith JF. *Seminars in musculoskeletal radiology.* 2011;15(5):554-60. <http://dx.doi.org/10.1055/s-0031-1293500>. Epub 2011 Nov 11.

186. **Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids.** Griffith JF, Antonio GE, Kumta SM, Hui DS, Wong JK, Joynt GM, et al. *Radiology.* 2005;235(1):168-75. <http://dx.doi.org/10.1148/radiol.2351040100>. Epub 2005 Feb 9.

187. **Molecular mechanisms of severe acute respiratory syndrome (SARS).** Groneberg DA, Hilgenfeld R, Zabel P. *Respiratory Research.* 2005;6.

188. **Influence of commercial collection devices for saliva on the reliability of salivary steroids analysis.** Gröschl M, Rauh M. *Steroids.* 2006;71(13):1097-100.

189. **Concise synthesis and antitumor activities of trisaccharide steroidal saponins.** Gu G, Fang M, Liu J, Gu L. *Carbohydrate research.* 2011;346(15):2406-13. <http://dx.doi.org/10.1016/j.carres.2011.08.026>. Epub 2011 Sep 1.

190. **Pathology and pathogenesis of severe acute respiratory syndrome.** Gu J, Korteweg C. *American Journal of Pathology.* 2007;170(4):1136-47.

191. **A patient with severe respiratory failure caused by novel human coronavirus.** Guberina H, Witzke O, Timm J, Dittmer U, Müller MA, Drosten C, et al. *Infection.* 2014;42(1):203-6.

192. **Acute respiratory distress syndrome and severe acute respiratory syndrome: Circulating interleukin 4 level could be a marker.** Guery B, Georges H, Labalette M, Leroy O, D'Escrivan T, Gonin X, et al. *Medecine et Maladies Infectieuses.* 2004;34(7):328-30.

193. **Severe acute respiratory syndrome: A singular epidemic of viral pneumonia.** Guihot A, Bricaire F, Li T, Bossi P. *Presse Medicale.* 2004;33(5):344-51.

194. **The influence of age, gender and treatment with steroids on the incidence of osteonecrosis of the femoral head during the management of severe acute respiratory syndrome: a retrospective study.** Guo KJ, Zhao FC, Guo Y, Li FL, Zhu L, Zheng W. *The bone & joint journal.* 2014;96(2):259-62. <http://dx.doi.org/10.1302/0301-620X.96B2.31935>.

195. **Long-term outcomes in patients with severe acute respiratory syndrome treated with oseltamivir: A 12-year longitudinal study.** Guo L, Han Y, Li J, Chen Q, Ren Y, Wu Q, et al. *International Journal of Clinical and Experimental Medicine.* 2019;12(10):12464-71.

196. **Discovery and synthesis of 3- and 21-substituted fusidic acid derivatives as reversal agents of P-glycoprotein-mediated multidrug resistance.** Guo M, Ren Q, Wang B, Ji W, Ni J, Feng Y, et al. *European journal of medicinal chemistry.* 2019;182:111668. <http://dx.doi.org/10.1016/j.ejmech.2019.111668>. Epub 2019 Aug 31.

197. **Clinical uses of cortisone in the treatment of severe acute respiratory syndrome.** Guo YB, Li XM, Wang W, Jin Y, Liao HY, Ma HB, et al. *Zhonghua yi xue za zhi*. 2004;84(13):1082-4.
198. **Encephalitis with reversible splenial and deep cerebral white matter lesions associated with Epstein-Barr virus infection in adults.** Guo YJ, Wang SH, Jiang B, Li JL, Liu L, Wang J, et al. *Neuropsychiatric Disease and Treatment*. 2017;13:2085-92.
199. **Differentially expressed aortic genes in cholesterol-fed rabbits.** Gyun Kim T, Kyoo Jang M, Ho Jeoung N, Sook Choi M, Bok SH, Kwak JW, et al. *Molecules and cells*. 1998;8(3):324-9.
200. **Coronaviruses and their therapy.** Haagmans BL, Osterhaus ADME. *Antiviral Research*. 2006;71(2):397-403.
201. **The emerging role of ACE2 in physiology and disease.** Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, et al. *The Journal of pathology*. 2007;212(1):1-11. <http://dx.doi.org/10.1002/path.2162>.
202. **Noninvasive positive pressure ventilation treatment for acute respiratory failure in SARS.** Han F, Jiang YY, Zheng JH, Gao ZC, He QY. *Sleep and Breathing*. 2004;8(2):97-106.
203. **[Quality of rhizoma Anemarrhenae grown for different periods of time and gathered in different seasons].** Han GR, Xu RL, Dai J, Feng L, Wang YD, Yang JH. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica*. 1993;18(8):467-8, 509.
204. **The role of corticosteroids in sepsis and acute respiratory distress syndrome.** Han MK, Hyzy RC. *Current Respiratory Medicine Reviews*. 2007;3(2):141-6.
205. **A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it.** Hao D, He LX, Qu JM, Pan J, Hu BJ, Zhang J, et al. *Zhonghua nei ke za zhi [Chinese journal of internal medicine]*. 2005;44(12):890-3.
206. **Structure-activity relationships and drug allergy.** Hasdenteufel F, Luyasu S, Hougardy N, Fisher M, Boisbrun M, Mertes PM, et al. *Current Clinical Pharmacology*. 2012;7(1):15-27.
207. **Overlapping MERS and mild AESD caused by HHV-6 infection.** Hatanaka M, Kashiwagi M, Tanabe T, Nakahara H, Ohta K, Tamai H. *Brain and Development*. 2015;37(3):334-8.
208. **Design, synthesis and structure-activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs.** Hayashi S, Ueno N, Murase A, Takada J. *Journal of enzyme inhibition and medicinal chemistry*. 2014;29(6):846-67. <http://dx.doi.org/10.3109/14756366.2013.864650>. Epub 2014 Feb 11.
209. **Advances in antivirals for non-influenza respiratory virus infections.** Hayden FG. *Influenza and other Respiratory Viruses*. 2013;7:36-43.
210. **Recommendations on corticosteroid therapy in patients with severe acute respiratory syndrome.** He QY. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue*. 2003;15(6):326.
211. **Methylated Cytosines Mutate to Transcription Factor Binding Sites that Drive Tetrapod Evolution.** He X, Tillo D, Vierstra J, Syed KS, Deng C, Ray GJ, et al. *Genome biology and evolution*. 2015;7(11):3155-69.
212. **Smartphone Application Monitoring of Acceleration Forces During Pneumatic Tube System Transport of Emergency Department Patient Samples.** Heireman L, Stroobants J, Uyttenbroeck W, Goossens Y, Dreezen C, Luyts D, et al. *Clinical laboratory*. 2018;64(7):1297-304. <http://dx.doi.org/10.7754/Clin.Lab.2018.180325>.
213. **Viral pathogens and acute lung injury: Investigations inspired by the SARS epidemic and the 2009**

- H1N1 influenza pandemic.** Hendrickson CM, Matthay MA. *Seminars in Respiratory and Critical Care Medicine*. 2013;34(4):475-86.
214. **(20S,2''S)-20-[4'-(3''-Hydroxy-2''-methyl-prop-yl)-3'-methylisoxazol-5-yl]-5beta-preg-nan-3beta,16beta-diol.** Hernandez Linares MG, Sandoval Ramirez J, Meza Reyes S, Montiel Smith S, Bernes S. *Acta crystallographica Section E, Structure reports online*. 2009;65:o3265-6. <http://dx.doi.org/10.1107/S1600536809050478>.
215. **The zwitterion (23'E)-(23R,25S)-23-[1-(oxidoiminio)eth-yl]-5beta-spiro-stan-3beta-yl acetate.** Hernandez Linares MG, Sandoval Ramirez J, Meza Reyes S, Montiel Smith S, Bernes S. *Acta crystallographica Section E, Structure reports online*. 2009;65:o2954-5. <http://dx.doi.org/10.1107/S1600536809044651>.
216. **Deacylation reactions of 20-acetyl dinorcholanic lactones and 20,23-diacetyl furost-22-enes.** Hernandez-Linares MG, Sandoval-Ramirez J, Meza-Reyes S, Montiel-Smith S, Fernandez-Herrera MA, Bernes S. *Steroids*. 2010;75(3):240-4. <http://dx.doi.org/10.1016/j.steroids.2009.12.008>. Epub 2009 Dec 23.
217. **Estradiol and tamoxifen differentially regulate a plasmalemmal voltage-dependent anion channel involved in amyloid-beta induced neurotoxicity.** Herrera JL, Fernandez C, Diaz M, Cury D, Marin R. *Steroids*. 2011;76(9):840-4. <http://dx.doi.org/10.1016/j.steroids.2011.02.014>. Epub 2011 Feb 25.
218. **[A case of Legionnaires' pneumonia accompanied by clinically mild encephalitis/encephalopathy with a reversible splenic lesion (MERS) with transient altered mental status and cerebellar symptoms, which responded to treatment by antibiotics and corticosteroid].** Hibino M, Hibi M, Akazawa K, Hikino K, Oe M. *Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society*. 2011;49(9):651-7.
219. **From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.** Hilgenfeld R, Peiris M. *Antiviral Research*. 2013;100(1):286-95.
220. **High-Dose Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute Respiratory Syndrome.** Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, et al. *American Journal of Respiratory and Critical Care Medicine*. 2003;168(12):1449-56.
221. **Pentaglobin in steroid-resistant severe acute respiratory syndrome.** Ho JC, Wu AY, Lam B, Ooi GC, Khong PL, Ho PL, et al. *International Journal of Tuberculosis and Lung Disease*. 2004;8(10):1173-9.
222. **Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus.** Hoever G, Baltina L, Michaelis M, Kondratenko R, Baltina L, Tolstikov GA, et al. *Journal of medicinal chemistry*. 2005;48(4):1256-9. <http://dx.doi.org/10.1021/jm0493008>.
223. **[Severe acute respiratory syndrome (SARS)].** Hoheisel G, Luk WK, Winkler J, Gillissen A, Wirtz H, Liebert UG, et al. *Medizinische Klinik (Munich, Germany : 1983)*. 2006;101(12):957-63. <http://dx.doi.org/10.1007/s00063-006-1127-4>.
224. **Avian influenza and the Severe Acute Respiratory Syndrome (SARS) - Experiences and perspectives.** Hoheisel G, Luk WK, Winkler J, Wirtz H, Gillissen A, Hui DS, et al. *Pneumologie*. 2007;61(1):41-5.
225. **[Severe acute respiratory syndrome (SARS)].** Hoheisel G, Wu A, Lee N, Chan CH, Wong KT, Ahuja A, et al. *Pneumologie*. 2003;57(6):315-21. <http://dx.doi.org/10.1055/s-2003-40049>.
226. **SARS coronavirus: A new challenge for prevention and therapy.** Holmes KV. *Journal of Clinical Investigation*. 2003;111(11):1605-9.
227. **Modulation of human estrogen receptor alpha activity by multivalent estradiol-peptidomimetic conjugates.** Holub JM, Garabedian MJ, Kirshenbaum K. *Molecular bioSystems*. 2011;7(2):337-45.

<http://dx.doi.org/10.1039/c0mb00189a>. Epub 2011 Jan 7.

228. **Severe Childhood Respiratory Viral Infections.** Hon KL, Leung AKC. *Journal*. 2009;56(Issue):47-73.
229. **Typical or atypical pneumonia and severe acute respiratory symptoms in PICU.** Hon KL, Leung ASY, Cheung KL, Fu AC, Chu WCW, Ip M, et al. *Clinical Respiratory Journal*. 2015;9(3):366-71.
230. **Clinical presentations and outcome of severe acute respiratory syndrome in children.** Hon KL, Leung CW, Cheng WT, Chan PK, Chu WC, Kwan YW, et al. *Lancet*. 2003;361(9370):1701-3.
[http://dx.doi.org/10.1016/s0140-6736\(03\)13364-8](http://dx.doi.org/10.1016/s0140-6736(03)13364-8).
231. **Influenza and parainfluenza associated pediatric ICU morbidity.** Hon KL, Leung TF, Cheung KL, Ng PC, Chan PK. *Indian J Pediatr*. 2010;77(10):1097-101. <http://dx.doi.org/10.1007/s12098-010-0197-8>. Epub 2010 Sep 30.
232. **Avascular necrosis of bone in severe acute respiratory syndrome.** Hong N, Du XK. *Clinical radiology*. 2004;59(7):602-8. <http://dx.doi.org/10.1016/j.crad.2003.12.008>.
233. **Posttraumatic stress disorder in convalescent severe acute respiratory syndrome patients: a 4-year follow-up study.** Hong X, Currier GW, Zhao X, Jiang Y, Zhou W, Wei J. *Gen Hosp Psychiatry*. 2009;31(6):546-54.
<http://dx.doi.org/10.1016/j.genhosppsy.2009.06.008>. Epub 2009 Aug 27.
234. **Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates Pseudomonas aeruginosa-induced acute lung inflammation by regulation of PI3K/AKT and Ras/MAPK pathways.** Hou Y, Nie Y, Cheng B, Tao J, Ma X, Jiang M, et al. *Acta pharmaceutica Sinica B*. 2016;6(3):212-21.
<http://dx.doi.org/10.1016/j.apsb.2016.03.002>. Epub 2016 Mar 22.
235. **Clinicopathology of severe acute respiratory syndrome: an autopsy case report.** Hsiao CH, Wu MZ, Hsieh SW, Chien LC, Hwang KC, Su IJ. *J Formos Med Assoc*. 2004;103(10):787-92.
236. **An evaluation of the additive effect of natural herbal medicine on SARS or SARS-like infectious diseases in 2003: A randomized, double-blind, and controlled pilot study.** Hsu CH, Hwang KC, Chao CL, Chang SGN, Ho MS, Lin JG, et al. *Evidence-based Complementary and Alternative Medicine*. 2008;5(3):355-62.
237. **The lesson of supplementary treatment with Chinese medicine on severe laboratory-confirmed SARS patients.** Hsu CH, Hwang KC, Chao CL, Chang SGN, Ker CC, Chien LD, et al. *American Journal of Chinese Medicine*. 2006;34(6):927-35.
238. **Severe acute respiratory syndrome (SARS) in Singapore: Clinical features of index patient and initial contacts.** Hsu LY, Lee CC, Green JA, Ang B, Paton NI, Lee L, et al. *Emerging Infectious Diseases*. 2003;9(6):713-7.
239. **Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan.** Hsueh PR, Hsiao CH, Yeh SH, Wang WK, Chen PJ, Wang JT, et al. *Emerging Infectious Diseases*. 2003;9(9):1163-7.
240. **Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus.** Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. *Clinical Microbiology and Infection*. 2004;10(12):1062-6.
241. **Severe acute respiratory syndrome (SARS) - An emerging infection of the 21st century.** Hsueh PR, Yang PC. *Journal of the Formosan Medical Association*. 2003;102(12):825-39.
242. **Severe acute respiratory syndrome epidemic in Taiwan, 2003.** Hsueh PR, Yang PC. *Journal of Microbiology, Immunology and Infection*. 2005;38(2):82-8.

243. **Role of CREB in the regulatory action of sarsasapogenin on muscarinic M1 receptor density during cell aging.** Hu H, Zhang R, Zhang Y, Xia Z, Hu Y. *FEBS Lett.* 2010;584(8):1549-52. <http://dx.doi.org/10.1016/j.febslet.2010.03.006>. Epub 2010 Mar 6.
244. **Gq Protein-Coupled Membrane-Initiated Estrogen Signaling Rapidly Excites Corticotropin-Releasing Hormone Neurons in the Hypothalamic Paraventricular Nucleus in Female Mice.** Hu P, Liu J, Yasrebi A, Gotthardt JD, Bello NT, Pang ZP, et al. *Endocrinology.* 2016;157(9):3604-20. <http://dx.doi.org/10.1210/en.2016-1191>. Epub 2016 Jul 7.
245. **A new approach to the pharmacological regulation of memory: Sarsasapogenin improves memory by elevating the low muscarinic acetylcholine receptor density in brains of memory-deficit rat models.** Hu Y, Xia Z, Sun Q, Orsi A, Rees D. *Brain research.* 2005;1060(1):26-39. <http://dx.doi.org/10.1016/j.brainres.2005.08.019>. Epub 2005 Oct 14.
246. **Sarsasapogenin-AA13 ameliorates Abeta-induced cognitive deficits via improving neuroglial capacity on Abeta clearance and antiinflammation.** Huang C, Dong D, Jiao Q, Pan H, Ma L, Wang R. *CNS neuroscience & therapeutics.* 2017;23(6):498-509. <http://dx.doi.org/10.1111/cns.12697>. Epub 2017 May 3.
247. **Synthesis and biological evaluation of sulfur-containing shikonin oxime derivatives as potential antineoplastic agents.** Huang G, Zhao HR, Meng QQ, Zhang QJ, Dong JY, Zhu BQ, et al. *European journal of medicinal chemistry.* 2018;143:166-81. <http://dx.doi.org/10.1016/j.ejmech.2017.11.031>. Epub 2017 Nov 14.
248. **Steroidal saponins from roots of *Asparagus officinalis*.** Huang X, Kong L. *Steroids.* 2006;71(2):171-6. <http://dx.doi.org/10.1016/j.steroids.2005.09.005>. Epub 2005 Nov 8.
249. **Steroids from the roots of *Asparagus officinalis* and their cytotoxic activity.** Huang XF, Lin YY, Kong LY. *Journal of integrative plant biology.* 2008;50(6):717-22. <http://dx.doi.org/10.1111/j.1744-7909.2008.00651.x>.
250. **Observed changes in serum potassium concentration following repeat centrifugation of Sarstedt Serum Gel Safety Monovettes after storage.** Hue DP, Culank LS, Toase PD, Maguire GA. *Annals of clinical biochemistry.* 1991;28:309-10. <http://dx.doi.org/10.1177/000456329102800323>.
251. **Severe acute respiratory syndrome (SARS): Lessons learnt in Hong Kong.** Hui DS. *Journal of Thoracic Disease.* 2013;5:S122-S6.
252. **Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome).** Hui DS. *Clinics in Chest Medicine.* 2017;38(1):71-86.
253. **Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection.** Hui DS. *Am J Respir Crit Care Med.* 2018;197(6):700-1. <http://dx.doi.org/10.1164/rccm.201712-2371ED>.
254. **Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors.** Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, et al. *Thorax.* 2005;60(5):401-9.
255. **Clinical management of pandemic 2009 influenza A(H1N1) infection.** Hui DS, Lee N, Chan PK. *Chest.* 2010;137(4):916-25. <http://dx.doi.org/10.1378/chest.09-2344>. Epub 2009 Dec 18.
256. **Severe acute respiratory syndrome vs. The Middle East respiratory syndrome.** Hui DS, Memish ZA, Zumla A. *Current Opinion in Pulmonary Medicine.* 2014;20(3):233-41.
257. **Treatment of severe acute respiratory syndrome.** Hui DS, Sung JJ. *Chest.* 2004;126(3):670-4. <http://dx.doi.org/10.1378/chest.126.3.670>.

258. **Emerging respiratory tract viral infections.** Hui DS, Zumla A. *Curr Opin Pulm Med.* 2015;21(3):284-92. <http://dx.doi.org/10.1097/MCP.0000000000000153>.
259. **An overview on severe acute respiratory syndrome (SARS).** Hui DSC. *Monaldi Archives for Chest Disease - Pulmonary Series.* 2005;63(3):149-57.
260. **Severe acute respiratory syndrome and coronavirus.** Hui DSC, Chan PKS. *Infectious Disease Clinics of North America.* 2010;24(3):619-38.
261. **Adjunctive therapies and immunomodulating agents for severe influenza.** Hui DSC, Lee N. *Influenza and other Respiratory Viruses.* 2013;7:52-9.
262. **Advancements in the battle against severe acute respiratory syndrome.** Hui DSC, Wong GWK. *Expert Opinion on Pharmacotherapy.* 2004;5(8):1687-93.
263. **[The clinical characteristics and outcome of 45 early stage patients with SARS].** Huo N, Lu H, Xu X, Wang G, Li H, Wang G, et al. *Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences.* 2003;35:19-22.
264. **Overview of the 3rd isirv-Antiviral Group Conference - advances in clinical management.** Hurt AC, Hui DS, Hay A, Hayden FG. *Influenza and other Respiratory Viruses.* 2015;9(1):20-31.
265. **Severe acute respiratory syndrome. The Mount Sinai experience.** Hynes-Gay P, Bennett J, Sarjoo-Devries A, Jones H, McGeer A. *The Canadian nurse.* 2003;99(5):16-9.
266. **Gastric perforation and critical illness polyneuropathy after steroid treatment in a patient with encephalitis/encephalopathy with transient splenic lesion.** Ikeno M, Abe S, Kurahashi H, Takasu M, Shimizu T, Okumura A. *Brain Dev.* 2017;39(4):356-60. <http://dx.doi.org/10.1016/j.braindev.2016.10.014>. Epub 2016 Nov 14.
267. **The renin-angiotensin system in acute respiratory distress syndrome.** Imai Y, Kuba K, Penninger JM. *Drug Discovery Today: Disease Mechanisms.* 2006;3(2):225-9.
268. **The 1.5 GHz electromagnetic near-field used for cellular phones does not promote rat liver carcinogenesis in a medium-term liver bioassay.** Imaida K, Taki M, Watanabe S, Kamimura Y, Ito T, Yamaguchi T, et al. *Japanese journal of cancer research : Gann.* 1998;89(10):995-1002. <http://dx.doi.org/10.1111/j.1349-7006.1998.tb00487.x>.
269. **Lack of promoting effects of the electromagnetic near-field used for cellular phones (929.2 MHz) on rat liver carcinogenesis in a medium-term liver bioassay.** Imaida K, Taki M, Yamaguchi T, Ito T, Watanabe S, Wake K, et al. *Carcinogenesis.* 1998;19(2):311-4. <http://dx.doi.org/10.1093/carcin/19.2.311>.
270. **Sisters with clinically mild encephalopathy with a reversible splenic lesion (MERS)-like features; Familial MERS?** Imamura T, Takanashi Ji, Yasugi J, Terada H, Nishimura A. *Journal of the Neurological Sciences.* 2010;290(1):153-6.
271. **Combination of Sarsasapogenin and Fluticasone attenuates ovalbumin-induced airway inflammation in a mouse asthma model.** Ingawale DK, Mandlik SK, Patel SS. *Immunopharmacology and immunotoxicology.* 2020;42(2):128-37. <http://dx.doi.org/10.1080/08923973.2020.1728541>. Epub 2020 Feb 18.
272. **Virus-associated hemophagocytic syndrome in an international traveler as a differential diagnosis of SARS.** Ishii H, Asai S, Suzuki T, Eguchi K, Miyachi H. *Internal medicine (Tokyo, Japan).* 2005;44(4):342-5. <http://dx.doi.org/10.2169/internalmedicine.44.342>.

273. **Clinically mild encephalopathy with a reversible splenic lesion accompanying mumps virus infection: A 5-year-old girl report.** Ishii J, Imataka G, Kajitani S, Ichikawa J, Yoshihara S. *Dokkyo Journal of Medical Sciences*. 2017;44(3):235-8.
274. **Host resilience to emerging coronaviruses.** Jamieson AM. *Future Virology*. 2016;11(7):529-34.
275. **Emerging infectious disease outbreaks: Old lessons and new challenges for obstetrician-gynecologists.** Jamieson DJ, Ellis JE, Jernigan DB, Treadwell TA. *American Journal of Obstetrics and Gynecology*. 2006;194(6):1546-55.
276. **Severe acute respiratory syndrome in Taiwan: analysis of epidemiological characteristics in 29 cases.** Jang TN, Yeh DY, Shen SH, Huang CH, Jiang JS, Kao SJ. *J Infect*. 2004;48(1):23-31. <http://dx.doi.org/10.1016/j.jinf.2003.09.004>.
277. **New respiratory viruses and the elderly.** Jartti L, Langen H, Söderlund-Venermo M, Vuorinen T, Ruuskanen O, Jartti T. *Open Respiratory Medicine Journal*. 2011;5(1):61-9.
278. **[Dose of glucocorticosteroids in the treatment of severe acute respiratory syndrome].** Jia WD, Deng XL, Tang XP, Yin CB, Zhang FC, Yang Z, et al. *Nan fang yi ke da xue xue bao = Journal of Southern Medical University*. 2009;29(11):2284-7.
279. **Preparative purification of glycyrrhizin extracted from the root of liquorice using high-speed counter-current chromatography.** Jiang Y, Lu HT, Chen F. *Journal of chromatography A*. 2004;1033(1):183-6. <http://dx.doi.org/10.1016/j.chroma.2004.01.033>.
280. **[Effect of integrative Chinese and western medicine on T-lymphocyte subsets in treating patients with severe acute respiratory syndrome].** Jiang YY, Wnag RB, Liu JM. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine*. 2004;24(6):514-6.
281. **Mycobacterium tuberculosis infection with clinically mild encephalitis/encephalopathy accompanied by reversible splenic lesion of the corpus callosum: A case report and analysis.** Jin Y, Piao Z, Nan G. *International Journal of Clinical and Experimental Medicine*. 2017;10(4):7220-5.
282. **Clinical characteristics of 42 SARS patients and their treatment of integrative Chinese and western medicine.** Jin-pan Z, Bao-jin H, Chang-huai C, Gui-cheng X, Hao S, Yin W, et al. *Chinese Journal of Integrative Medicine*. 2003;9(3):169-74.
283. **Severe acute respiratory syndrome: What have we learned two years later?** Johnston BL, Conly JM. *Canadian Journal of Infectious Diseases*. 2004;15(6):309-12.
284. **Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids.** Jones BM, Ma ESK, Peiris JSM, Wong PC, Ho JCM, Lam B, et al. *Clinical and Experimental Immunology*. 2004;135(3):467-73.
285. **Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus.** Josset L, Menachery VD, Gralinski LE, Agnihothram S, Sova P, Carter VS, et al. *mBio*. 2013;4(3):e00165-13. <http://dx.doi.org/10.1128/mBio.00165-13>.
286. **Late-stage adult respiratory distress syndrome caused by severe acute respiratory syndrome: abnormal findings at thin-section CT.** Joynt GM, Antonio GE, Lam P, Wong KT, Li T, Gomersall CD, et al. *Radiology*. 2004;230(2):339-46. <http://dx.doi.org/10.1148/radiol.2303030894>.
287. **SARS in the intensive care unit.** Joynt GM, Yap HY. *Current Infectious Disease Reports*. 2004;6(3):228-33.

288. **Altered pathogenesis of porcine respiratory coronavirus in pigs due to immunosuppressive effects of dexamethasone: implications for corticosteroid use in treatment of severe acute respiratory syndrome coronavirus.** Jung K, Alekseev KP, Zhang X, Cheon DS, Vlasova AN, Saif LJ. *J Virol.* 2007;81(24):13681-93. <http://dx.doi.org/10.1128/JVI.01702-07>. Epub 2007 Oct 17.
289. **Mild encephalopathy with reversible splenic lesion: An important differential of encephalitis.** Ka A, Britton P, Troedson C, Webster R, Procopis P, Ging J, et al. *European Journal of Paediatric Neurology.* 2015;19(3):377-82.
290. **Intraoperative monitoring of tibialis anterior muscle motor evoked responses to transcranial electrical stimulation during partial neuromuscular blockade.** Kalkman CJ, Drummond JC, Kennelly NA, Patel PM, Partridge BL. *Anesthesia and analgesia.* 1992;75(4):584-9. <http://dx.doi.org/10.1213/00000539-199210000-00021>.
291. **Pro/con clinical debate: steroids are a key component in the treatment of SARS. Con: No, steroids are not a key component of the treatment regimen for SARS.** Kargel MJ, Lapinsky SE. *Crit Care.* 2004;8(2):105-7.
292. **Differential diagnosis of delirious behavior in children with influenza.** Kashiwagi M, Tanabe T, Ooba C, Masuda M, Shigehara S, Murata S, et al. *Brain and Development.* 2015;37(6):618-24.
293. **Clinico-radiological spectrum of reversible splenic lesions in children.** Kashiwagi M, Tanabe T, Shimakawa S, Nakamura M, Murata S, Shabana K, et al. *Brain and Development.* 2014;36(4):330-6.
294. **Sarsasapogenin: A steroidal saponin from Asparagus racemosus as multi target directed ligand in Alzheimer's disease.** Kashyap P, Muthusamy K, Niranjana M, Trikha S, Kumar S. *Steroids.* 2020;153:108529. <http://dx.doi.org/10.1016/j.steroids.2019.108529>. Epub 2019 Oct 28.
295. **Acute focal bacterial nephritis associated with central nervous system manifestations: A report of 2 cases and review of the literature.** Kasuga Y, Fuchigami T, Fukuda A, Takahashi S, Murai T, Yonezawa R, et al. *Pediatric Emergency Care.* 2017;33(6):418-21.
296. **Recent synthetic and medicinal perspectives of dihydropyrimidinones: A review.** Kaur R, Chaudhary S, Kumar K, Gupta MK, Rawal RK. *European journal of medicinal chemistry.* 2017;132:108-34. <http://dx.doi.org/10.1016/j.ejmech.2017.03.025>. Epub 2017 Mar 19.
297. **Avian influenza.** Kavaliotis J. *Hippokratia.* 2006;10(1):3-6.
298. **[SARS].** Kawana A. *Nihon Naika Gakkai zasshi The Journal of the Japanese Society of Internal Medicine.* 2004;93(11):2309-15. <http://dx.doi.org/10.2169/naika.93.2309>.
299. **Clinical and epidemiological review of SARS.** Kawana A. *Nippon rinsho Japanese journal of clinical medicine.* 2005;63(12):2121-5.
300. **Severe acute respiratory syndrome: Public health response and clinical practice update for an emerging disease.** Keeler N, Lingappa J. *Current Opinion in Pediatrics.* 2004;16(1):61-9.
301. **Ribavirin and interferon- α 2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: A preliminary report of two cases.** Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. *Antiviral Therapy.* 2015;20(1):87-91.
302. **Investigation of the anti-inflammatory and the analgesic effects of the extracts from Smilax ornata Lem. (Jamaican sarsaparilla) plant.** Khan AK, Singh PD, Reese PB, Howden J, Thomas TT. *J Ethnopharmacol.* 2019;240:111830. <http://dx.doi.org/10.1016/j.jep.2019.111830>. Epub 2019 May 4.
303. **Metered-dose inhaler with spacer instead of nebulizer during the outbreak of severe acute respiratory**

syndrome in Singapore. Khoo SM, Tan LK, Said N, Lim TK. *Respiratory Care*. 2009;54(7):855-60.

304. **Successful treatment of suspected organizing pneumonia in a patient with Middle East respiratory syndrome coronavirus infection: A case report.** Kim I, Lee JE, Kim KH, Lee S, Lee K, Mok JH. *Journal of Thoracic Disease*. 2016;8(10):E1190-E4.
305. **Atypical presentations of MERS-CoV infection in immunocompromised hosts.** Kim SH, Ko JH, Park GE, Cho SY, Ha YE, Kang JM, et al. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2017;23(11):769-73. <http://dx.doi.org/10.1016/j.jiac.2017.04.004>. Epub 2017 May 23.
306. **Severe acute respiratory syndrome: Providing care while minimizing personal risks.** Kissoon N. *Indian Pediatrics*. 2003;40(7):645-51.
307. **The threat of severe acute respiratory syndrome (SARS).** Kissoon N. *West Indian Medical Journal*. 2003;52(2):91-4.
308. **Current challenges in lower respiratory infections in children.** Klig JE. *Current Opinion in Pediatrics*. 2004;16(1):107-12.
309. **Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada.** Knowles SR, Phillips EJ, Dresser L, Matukas L. *Clinical Infectious Diseases*. 2003;37(8):1139-42.
310. **Mutational analysis of the estrogen receptor ligand-binding domain: influence of ligand structure and stereochemistry on transactivation.** Kohno H, Bocchinfuso WP, Gandini O, Curtis SW, Korach KS. *Journal of molecular endocrinology*. 1996;16(3):277-85. <http://dx.doi.org/10.1677/jme.0.0160277>.
311. **Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients.** Kong SL, Chui P, Lim B, Salto-Tellez M. *Virus Res*. 2009;145(2):260-9. <http://dx.doi.org/10.1016/j.virusres.2009.07.014>. Epub 2009 Jul 25.
312. **Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease.** Konrath EL, Passos Cdos S, Klein LC, Jr., Henriques AT. *The Journal of pharmacy and pharmacology*. 2013;65(12):1701-25. <http://dx.doi.org/10.1111/jphp.12090>. Epub 2013 Jun 20.
313. **Ribavirin in the treatment of SARS: A new trick for an old drug?** Koren G, King S, Knowles S, Phillips E. *Canadian Medical Association Journal*. 2003;168(10):1289-92.
314. **[SARS-CoV infection and pregnancy].** Ksiezakowska K, Laszczyk M, Wilczynski J, Nowakowska D. *Ginekologia polska*. 2008;79(1):47-50.
315. **Severe acute respiratory syndrome: Lessons and uncertainties.** Kullberg BJ, Voss A. *Netherlands Journal of Medicine*. 2003;61(7):235-7.
316. **Membrane estrogen receptors stimulate intracellular calcium release and progesterone synthesis in hypothalamic astrocytes.** Kuo J, Hamid N, Bondar G, Prossnitz ER, Micevych P. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2010;30(39):12950-7. <http://dx.doi.org/10.1523/JNEUROSCI.1158-10.2010>.
317. **Neurosteroids, trigger of the LH surge.** Kuo J, Micevych P. *The Journal of steroid biochemistry and molecular biology*. 2012;131(1):57-65. <http://dx.doi.org/10.1016/j.jsbmb.2012.01.008>. Epub 2012 Feb 2.
318. **Two cases of severe obstructive pneumonia associated with an HKU1-like coronavirus.** Kupfer B, Simon A, Jonassen CM, Viazov S, Ditt V, Tillmann RL, et al. *European journal of medical research*. 2007;12(3):134-8.

319. **MYRF is associated with encephalopathy with reversible myelin vacuolization.** Kurahashi H, Azuma Y, Masuda A, Okuno T, Nakahara E, Imamura T, et al. *Annals of Neurology*. 2018;83(1):98-106.
320. **Effective therapy with infliximab for clinically mild encephalitis/encephalopathy with a reversible splenic lesion in an infant with Kawasaki disease.** Kurokawa Y, Masuda H, Kobayashi T, Ono H, Kato H, Imadome KI, et al. *Japanese Journal of Clinical Immunology*. 2017;40(3):190-5.
321. **Tracheostomy in a patient with severe acute respiratory syndrome.** Kwan A, Fok WG, Law KI, Lam SH. *British Journal of Anaesthesia*. 2004;92(2):280-2.
322. **Severe Acute Respiratory Syndrome in a Hemodialysis Patient.** Kwan BCH, Leung CB, Szeto CC, Wang AYM, Li PKT. *American Journal of Kidney Diseases*. 2003;42(5):1069-74.
323. **Diarrhoea as the presenting sign in an adolescent suffering from severe acute respiratory syndrome.** Kwan YW, Leung CW, Chiu MC. *European Journal of Pediatrics*. 2005;164(4):227-30.
324. **Severe Acute Respiratory Syndrome: Developing a Research Response.** La Montagne JR, Simonsen L, Taylor RJ, Turnbull J. *Journal of Infectious Diseases*. 2004;189(4):634-41.
325. **Disinfection for prevention and control of infections on the threshold of the 21 century for the critically ill patient.** Lackner FX. *GMS Krankenhaushygiene interdisziplinär*. 2007;2(1):Doc12.
326. **Viral nephropathy.** Lai ASH, Lai KN. *Nature Clinical Practice Nephrology*. 2006;2(5):254-62.
327. **Severe acute respiratory syndrome: Quantitative assessment from chest radiographs with clinical and prognostic correlation.** Lai EKY, Deif H, LaMere EA, Pham DH, Wolff B, Ward S, et al. *American Journal of Roentgenology*. 2005;184(1):255-63.
328. **Clinical, laboratory, and radiologic manifestation of SARS.** Lai KN, Tsang KW, Seto WH, Ooi CGC. *Current Infectious Disease Reports*. 2004;6(3):213-9.
329. **Treatment of severe acute respiratory syndrome.** Lai ST. *European Journal of Clinical Microbiology and Infectious Diseases*. 2005;24(9):583-91.
330. **The lessons of SARS in Hong Kong.** Lai TST, Yu WC. *Clinical Medicine, Journal of the Royal College of Physicians of London*. 2010;10(1):50-3.
331. **Epi-sarsapogenin and epi-smilagenin: two saponins isolated from the rumen content of sheep intoxicated by *Brachiaria decumbens*.** Lajis NH, Abdullah AS, Salim SJ, Bremner JB, Khan MN. *Steroids*. 1993;58(8):387-9. [http://dx.doi.org/10.1016/0039-128x\(93\)90043-m](http://dx.doi.org/10.1016/0039-128x(93)90043-m).
332. **Severe acute respiratory syndrome: clinical and laboratory manifestations.** Lam CW, Chan MH, Wong CK. *The Clinical biochemist Reviews*. 2004;25(2):121-32.
333. **An Indolent Case of Severe Acute Respiratory Syndrome.** Lam MF, Ooi GC, Lam B, Ho JC, Seto WH, Ho PL, et al. *American Journal of Respiratory and Critical Care Medicine*. 2004;169(1):125-8.
334. **Epidemic viral pneumonia.** Lapinsky SE. *Current Opinion in Infectious Diseases*. 2010;23(2):139-44.
335. **Critical care lessons from severe acute respiratory syndrome.** Lapinsky SE, Granton JT. *Current opinion in critical care*. 2004;10(1):53-8. <http://dx.doi.org/10.1097/00075198-200402000-00009>.
336. **ICU management of severe acute respiratory syndrome.** Lapinsky SE, Hawryluck L. *Intensive Care Med*. 2003;29(6):870-5. <http://dx.doi.org/10.1007/s00134-003-1821-0>. Epub 2003 May 9.

337. **Outcome of coronavirus-associated severe acute respiratory syndrome using a standard treatment protocol.** Lau ACW, So LKY, Miu FPL, Yung RWH, Poon E, Cheung TMT, et al. *Respirology*. 2004;9(2):173-83.
338. **Effectiveness of ribavirin and corticosteroids for severe acute respiratory syndrome.** Lau EH, Cowling BJ, Muller MP, Ho LM, Tsang T, Lo SV, et al. *The American journal of medicine*. 2009;122(12):1150.e11-21. <http://dx.doi.org/10.1016/j.amjmed.2009.07.018>.
339. **Reduced bone mineral density in male Severe Acute Respiratory Syndrome (SARS) patients in Hong Kong.** Lau EMC, Chan FWK, Hui DSC, Wu AKL, Leung PC. *Bone*. 2005;37(3):420-4.
340. **The impact of severe acute respiratory syndrome on the physical profile and quality of life.** Lau HM, Lee EW, Wong CN, Ng GY, Jones AY, Hui DS. *Arch Phys Med Rehabil*. 2005;86(6):1134-40. <http://dx.doi.org/10.1016/j.apmr.2004.09.025>.
341. **A randomised controlled trial of the effectiveness of an exercise training program in patients recovering from severe acute respiratory syndrome.** Lau HM, Ng GY, Jones AY, Lee EW, Siu EH, Hui DS. *The Australian journal of physiotherapy*. 2005;51(4):213-9. [http://dx.doi.org/10.1016/s0004-9514\(05\)70002-7](http://dx.doi.org/10.1016/s0004-9514(05)70002-7).
342. **SARS: Future research and vaccine.** Lau YL. *Paediatric Respiratory Reviews*. 2004;5(4):300-3.
343. **Semisynthetic ursolic acid fluorolactone derivatives inhibit growth with induction of p21(waf1) and induce apoptosis with upregulation of NOXA and downregulation of c-FLIP in cancer cells.** Leal AS, Wang R, Salvador JA, Jing Y. *ChemMedChem*. 2012;7(9):1635-46. <http://dx.doi.org/10.1002/cmdc.201200282>. Epub 2012 Jul 16.
344. **Timosaponin AIII, a saponin isolated from *Anemarrhena asphodeloides*, ameliorates learning and memory deficits in mice.** Lee B, Jung K, Kim DH. *Pharmacology, biochemistry, and behavior*. 2009;93(2):121-7. <http://dx.doi.org/10.1016/j.pbb.2009.04.021>. Epub 2009 May 5.
345. **Inhibitory effects of steroidal timosaponins isolated from the rhizomes of *Anemarrhena asphodeloides* against passive cutaneous anaphylaxis reaction and pruritus.** Lee B, Trinh HT, Jung K, Han SJ, Kim DH. *Immunopharmacology and immunotoxicology*. 2010;32(3):357-63. <http://dx.doi.org/10.3109/08923970903383889>.
346. **Altered p38 mitogen-activated protein kinase expression in different leukocytes with increment of immunosuppressive mediators in patients with severe acute respiratory syndrome.** Lee CH, Chen RF, Liu JW, Yeh WT, Chang JC, Liu PM, et al. *Journal of Immunology*. 2004;172(12):7841-7.
347. **Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study.** Lee DT, Wing YK, Leung HC, Sung JJ, Ng YK, Yiu GC, et al. *Clin Infect Dis*. 2004;39(8):1247-9. <http://dx.doi.org/10.1086/424016>. Epub 2004 Sep 24.
348. **Annual and seasonal patterns in etiologies of pediatric community-acquired pneumonia due to respiratory viruses and *Mycoplasma pneumoniae* requiring hospitalization in South Korea.** Lee E, Kim CH, Lee YJ, Kim HB, Kim BS, Kim HY, et al. *BMC Infectious Diseases*. 2020;20(1).
349. **Surgical treatment of tracheoesophageal fistula in a patient with severe acute respiratory syndrome complicated with extensive pulmonary fibrosis.** Lee JM, Lee PL, Kuo SW, Hwang JJ, Lee YC. *Journal of the Formosan Medical Association = Taiwan yi zhi*. 2004;103(12):932-4.
350. **Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients.** Lee N, Allen Chan KC, Hui DS, Ng EKO, Wu A, Chiu RWK, et al. *Journal of Clinical Virology*. 2004;31(4):304-9.

351. **A major outbreak of severe acute respiratory syndrome in Hong Kong.** Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. *The New England journal of medicine*. 2003;348(20):1986-94. <http://dx.doi.org/10.1056/NEJMoa030685>. Epub 2003 Apr 7.
352. **Sharing the Roles: An Assessment of Japanese Medaka Estrogen Receptors in Vitellogenin Induction.** Lee Pow CS, Yost EE, Aday DD, Kullman SW. *Environmental science & technology*. 2016;50(16):8886-95. <http://dx.doi.org/10.1021/acs.est.6b01968>. Epub 2016 Jul 26.
353. **Is respiratory viral infection really an important trigger of asthma exacerbations in children?** Lee SL, Chiu SSS, Malik PJS, Chan KH, Wong HSW, Lau YL. *European Journal of Pediatrics*. 2011;170(10):1317-24.
354. **Microbial transformation of dihydrosarsapogenin with *Mycobacterium* sp.** Lee SS, Yan JL, Lin GY, Wang KC. *Journal of natural products*. 1998;61(2):275-8. <http://dx.doi.org/10.1021/np970392w>.
355. **2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity.** Leese MP, Leblond B, Smith A, Newman SP, Di Fiore A, De Simone G, et al. *Journal of medicinal chemistry*. 2006;49(26):7683-96. <http://dx.doi.org/10.1021/jm060705x>.
356. **Synthesis and biological evaluation of bufalin-3-yl nitrogen-containing-carbamate derivatives as anticancer agents.** Lei M, Xiao Z, Ma B, Chen Y, Liu M, Liu J, et al. *Steroids*. 2016;108:56-60. <http://dx.doi.org/10.1016/j.steroids.2016.01.011>. Epub 2016 Jan 28.
357. **Severe acute respiratory syndrome (SARS): Pointer from the American Thoracic Society.** Lemarié E. *Revue des Maladies Respiratoires*. 2003;20(5):6S67-6S72.
358. **Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003.** Leong HN, Ang B, Earnest A, Teoh C, Xu W, Leo YS. *Tropical medicine & international health : TM & IH*. 2004;9(8):923-7. <http://dx.doi.org/10.1111/j.1365-3156.2004.01281.x>.
359. **Hypocortisolism in survivors of severe acute respiratory syndrome (SARS).** Leow MK, Kwek DS, Ng AW, Ong KC, Kaw GJ, Lee LS. *Clinical endocrinology*. 2005;63(2):197-202. <http://dx.doi.org/10.1111/j.1365-2265.2005.02325.x>.
360. **Severe acute respiratory syndrome (SARS): The questions raised by the management of a patient in Besançon and Strasbourg.** Lesens O, Hustache-Mathieu L, Hansmann Y, Remy V, Hoen B, Christmann D. *Presse Medicale*. 2003;32(29):1359-64.
361. **[Severe acute respiratory syndrome (SARS). The questions raised by the management of a patient in Besançon and Strasbourg].** Lesens O, Hustache-Mathieu L, Hansmann Y, Remy V, Hoen B, Christmann D. *Presse medicale (Paris, France : 1983)*. 2003;32(29):1359-64.
362. **Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children.** Leung CW, Chiu WK. *Paediatric Respiratory Reviews*. 2004;5(4):275-88.
363. **The efficacy of Chinese medicine for SARS: A review of Chinese publications after the crisis.** Leung PC. *American Journal of Chinese Medicine*. 2007;35(4):575-81.
364. **Severe acute respiratory syndrome (SARS) in children: Epidemiology, presentation and management.** Leung TF, Wong GWK, Hon KLE, Fok TF. *Paediatric Respiratory Reviews*. 2003;4(4):334-9.
365. **Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series.** Leung TW, Wong KS, Hui AC, To KF, Lai ST, Ng WF, et al. *Arch Neurol*. 2005;62(7):1113-7. <http://dx.doi.org/10.1001/archneur.62.7.1113>.

366. **Clinical issues and research in respiratory failure from severe acute respiratory syndrome.** Levy MM, Baylor MS, Bernard GR, Fowler R, Franks TJ, Hayden FG, et al. *American Journal of Respiratory and Critical Care Medicine*. 2005;171(5):518-26.
367. **Oligodeoxynucleotides as probes for in situ hybridization with transmission electron microscopy to specifically localize phytoplasma in plant cells.** Lherminier J, Bonfiglioli RG, Daire X, Symons RH, Boudon-Padiou E. *Mol Cell Probes*. 1999;13(1):41-7. <http://dx.doi.org/10.1006/mcpr.1998.0213>.
368. **Long-term sequelae of SARS in children.** Li AM, Chan CHY, Chan DFY. *Paediatric Respiratory Reviews*. 2004;5(4):296-9.
369. **Severe acute respiratory syndrome: 'SARS' or 'not SARS'.** Li AM, Hon KLE, Cheng WT, Ng PC, Chan FY, Li CK, et al. *Journal of Paediatrics and Child Health*. 2004;40(1):63-5.
370. **Hepatic failure in a child with anti-epileptic hypersensitivity syndrome.** Li AM, Nelson EA, Hon EK, Cheng FW, Chan DF, Sin NC, et al. *J Paediatr Child Health*. 2005;41(4):218-20. <http://dx.doi.org/10.1111/j.1440-1754.2005.00591.x>.
371. **Severe acute respiratory syndrome (SARS) in neonates and children.** Li AM, Ng PC. *Archives of Disease in Childhood: Fetal and Neonatal Edition*. 2005;90(6):F461-F5.
372. **An overview of grayanane diterpenoids and their biological activities from the Ericaceae family in the last seven years.** Li CH, Zhang JY, Zhang XY, Li SH, Gao JM. *European journal of medicinal chemistry*. 2019;166:400-16. <http://dx.doi.org/10.1016/j.ejmech.2019.01.079>. Epub 2019 Feb 1.
373. **[Analysis and causation discussion of 185 severe acute respiratory syndrome dead cases].** Li CS, Pan SF. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue*. 2003;15(10):582-4.
374. **Novel nitric oxide-releasing spirolactone-type diterpenoid derivatives with in vitro synergistic anticancer activity as apoptosis inducer.** Li D, Han T, Tian K, Tang S, Xu S, Hu X, et al. *Bioorganic & medicinal chemistry letters*. 2016;26(17):4191-6. <http://dx.doi.org/10.1016/j.bmcl.2016.07.059>. Epub 2016 Jul 27.
375. **Association of RANTES with the replication of severe acute respiratory syndrome coronavirus in THP-1 cells.** Li D, Wu N, Yao H, Bader A, Brockmeyer NH, Altmeyer P. *European Journal of Medical Research*. 2005;10(3):117-20.
376. **[Quality Analysis and Evaluation of Anemarrhena asphodeloides Rhizome from Different Habitats].** Li GL, Yang J, Duan JA, Liu HB, Zhu ZH, Qian DW, et al. *Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials*. 2015;38(6):1148-52.
377. **Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle.** Li GM, Li YG, Yamate M, Li SM, Ikuta K. *Microbes Infect*. 2007;9(1):96-102. <http://dx.doi.org/10.1016/j.micinf.2006.10.015>. Epub 2006 Dec 8.
378. **[Clinical features of 77 patients with severe acute respiratory syndrome].** Li GQ, Zhang YH. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue*. 2003;15(7):404-7.
379. **Glucocorticoid-induced hyperglycemia in SARS patients: my experience.** Li GW. *Zhonghua yi xue za zhi*. 2003;83(12):1009-10.
380. **Rapid pulmonary fibrosis induced by acute lung injury via a lipopolysaccharide three-hit regimen.** Li H, Du S, Yang L, Chen Y, Huang W, Zhang R, et al. *Innate immunity*. 2009;15(3):143-54. <http://dx.doi.org/10.1177/1753425908101509>.

381. **Clinical observation on treatment of SARS with combination of chaihui droplet pill and huoxiang zhengqi droplet pill.** Li H, Lu CZ, Tang KC. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban. 2004;24(4):321-4.
382. **Clinical study on treatment of severe acute respiratory syndrome with integrative Chinese and Western medicine approach.** Li J, Li SD, Du N. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban. 2004;24(1):28-31.
383. **[Difference and significance of T-lymphocyte subsets in differential diagnosis between severe acute respiratory syndrome and common atypical pneumonia].** Li MH, Li XH, Li XW, Ma L, Yi W, Jiang YY, et al. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2004;18(2):137-41.
384. **[Retrospective analysis of the corticosteroids treatment on severe acute respiratory syndrome (SARS)].** Li N, Ma J, Nie L, Li H, Que C, Gao Z, et al. Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences. 2003;35:16-8.
385. **[Side effects of glucocorticosteroids in the management of 1291 patients of SARS].** Li N, Wang GF, Wu YF, Xie GQ, Xiao F, Chen BW, et al. Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences. 2004;36(5):519-24.
386. **Severe Acute Respiratory Syndrome (SARS) and the GDP. Part II: Implications for GDPs.** Li RWK, Leung KWC, Sun FCS, Samaranayake LP. British Dental Journal. 2004;197(3):130-4.
387. **Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS.** Li S, Wang R, Zhang Y, Zhang X, Layon AJ, Li Y, et al. The American journal of Chinese medicine. 2006;34(6):937-47. <http://dx.doi.org/10.1142/S0192415X06004417>.
388. **Left Ventricular Performance in Patients With Severe Acute Respiratory Syndrome: A 30-Day Echocardiographic Follow-Up Study.** Li SSL, Cheng CW, Fu CL, Chan YH, Lee MP, Chan JWM, et al. Circulation. 2003;108(15):1798-803.
389. **The structure–activity relationship (SAR) for phthalate-mediated developmental and reproductive toxicity in males.** Li X, Mo J, Zhu Q, Ni C, Wang Y, Li H, et al. Chemosphere. 2019;223:504-13.
390. **The structure-activity relationship (SAR) for phthalate-mediated developmental and reproductive toxicity in males.** Li X, Mo J, Zhu Q, Ni C, Wang Y, Li H, et al. Chemosphere. 2019;223:504-13. <http://dx.doi.org/10.1016/j.chemosphere.2019.02.090>. Epub 2019 Feb 15.
391. **[Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report].** Li XW, Jiang RM, Guo JZ. Zhonghua nei ke za zhi. 2003;42(6):378-81.
392. **[Clinical analysis of SARS: 27 cases report].** Li XW, Jiang RM, Guo JZ, Wang QY. Zhonghua yi xue za zhi. 2003;83(11):910-2.
393. **[Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence].** Li YM, Wang SX, Gao HS, Wang JG, Wei CS, Chen LM, et al. Zhonghua yi xue za zhi. 2004;84(16):1348-53.
394. **Clinical research of correlation between osteonecrosis and steroid.** Li ZR, Sun W, Qu H, Zhou YX, Dou BX, Shi ZC, et al. Zhonghua wai ke za zhi [Chinese journal of surgery]. 2005;43(16):1048-53.

395. **[Clinical analysis of pediatric SARS cases in Beijing]**. Li ZZ, Shen KL, Wei XM, Wang HL, Lu J, Tian H, et al. *Zhonghua Er Ke Za Zhi*. 2003;41(8):574-7.
396. **Characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients**. Lien TC, Sung CS, Lee CH, Kao HK, Huang YC, Liu CY, et al. *J Crit Care*. 2008;23(4):557-64. <http://dx.doi.org/10.1016/j.jcrc.2007.05.004>.
397. **Plagues in the ICU: A Brief History of Community-Acquired Epidemic and Endemic Transmissible Infections Leading to Intensive Care Admission**. Light RB. *Critical Care Clinics*. 2009;25(1):67-81.
398. **Effect of sarsaponin on ruminal fermentation with particular reference to methane production in vitro**. Lila ZA, Mohammed N, Kanda S, Kamada T, Itabashi H. *Journal of dairy science*. 2003;86(10):3330-6. [http://dx.doi.org/10.3168/jds.S0022-0302\(03\)73935-6](http://dx.doi.org/10.3168/jds.S0022-0302(03)73935-6).
399. **Timosaponin AIII and its metabolite sarsapogenin ameliorate colitis in mice by inhibiting NF-kappaB and MAPK activation and restoring Th17/Treg cell balance**. Lim SM, Jeong JJ, Kang GD, Kim KA, Choi HS, Kim DH. *International immunopharmacology*. 2015;25(2):493-503. <http://dx.doi.org/10.1016/j.intimp.2015.02.016>. Epub 2015 Feb 16.
400. **Hospital management of adults with severe acute respiratory syndrome (SARS) if SARS re-emerges - Updated 10 February 2004**. Lim WS, Anderson SR, Read RC. *Journal of Infection*. 2004;49(1):1-7.
401. **Differential ligand binding affinities of human estrogen receptor-alpha isoforms**. Lin AH, Li RW, Ho EY, Leung GP, Leung SW, Vanhoutte PM, et al. *PLoS One*. 2013;8(4):e63199. <http://dx.doi.org/10.1371/journal.pone.0063199>. Print 2013.
402. **Clinical observation on 103 patients of severe acute respiratory syndrome treated by integrative traditional Chinese and Western Medicine**. Lin L, Han Y, Yang ZM. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban*. 2003;23(6):409-13.
403. **Treating severe acute respiratory syndrome with integrated Chinese and Western medicine - A report on 103 hospitalised cases at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, China**. Lin L, He DP, Han Y, Xu JY, Lin ZX. *Journal of Chinese Medicine*. 2003(72):5-10.
404. **Applying integrative Chinese and western medicine in fighting SARS**. Lin L, Rong-bing W, Yong-tao Z, Guang-hua T. *Chinese Journal of Integrative Medicine*. 2003;9(3):162-8.
405. **A retrospective study on clinical features of and treatment methods for 77 severe cases of SARS**. Lin L, Xu YJ, He DP, Han Y, Tang GH, Yang ZM, et al. *The American journal of Chinese medicine*. 2003;31(6):821-39. <http://dx.doi.org/10.1142/S0192415X03001521>.
406. **Mild encephalitis/encephalopathy with a reversible splenic lesion in children**. Liptai Z, Ivady B, Barsi P, Varallyay G, Rudas G, Fogarasi A. *Ideggyogyaszati szemle*. 2013;66(1):67-71.
407. **Effect of glucocorticoid with traditional Chinese medicine in severe acute respiratory syndrome (SARS)**. Liu BY, He LY, Liang ZW, Tong XY, Hu JQ, Jiao Q, et al. *Zhongguo Zhongyao Zazhi*. 2005;30(23):1874-7.
408. **[Effect of glucocorticoid with traditional Chinese medicine in severe acute aespriatory syndrome (SARS)]**. Liu BY, He LY, Liang ZW, Tong XY, Hu JQ, Jiao Q, et al. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica*. 2005;30(23):1874-7.
409. **Clinical and laboratory features of severe acute respiratory syndrome vis-à-vis onset of fever**. Liu CL, Lu YT, Peng MJ, Chen PJ, Lin RL, Wu CL, et al. *Chest*. 2004;126(2):509-17.

410. **Clinical characteristics, management and prognostic factors in patients with probable severe acute respiratory syndrome (SARS) in a SARS center in Taiwan.** Liu CY, Huang LJ, Lai CH, Chen HP, Chen TL, Fung CP, et al. *Journal of the Chinese Medical Association* : JCMA. 2005;68(3):110-7.
[http://dx.doi.org/10.1016/S1726-4901\(09\)70231-X](http://dx.doi.org/10.1016/S1726-4901(09)70231-X).
411. **Synthesis, preliminary structure-activity relationships, and in vitro biological evaluation of 6-aryl-3-amino-thieno[2,3-b]pyridine derivatives as potential anti-inflammatory agents.** Liu H, Li Y, Wang XY, Wang B, He HY, Liu JY, et al. *Bioorganic & medicinal chemistry letters*. 2013;23(8):2349-52.
<http://dx.doi.org/10.1016/j.bmcl.2013.02.059>. Epub 2013 Feb 24.
412. **Major advances in respiratory medicine in China.** Liu HJ, Shi HZ. *Chinese Medical Journal*. 2009;122(17):2054-60.
413. **Chinese herbal medicine for severe acute respiratory syndrome: A systematic review and meta-analysis.** Liu J, Manheimer E, Shi Y, Gluud C. *Journal of Alternative and Complementary Medicine*. 2004;10(6):1041-51.
414. **Systematic review and meta-analysis on the integrative traditional Chinese and Western medicine in treating SARS.** Liu JP, Manheimer E, Shi Y. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban*. 2005;25(12):1082-8.
415. **Roles of substance P receptors in human colon circular muscle: alterations in diverticular disease.** Liu L, Shang F, Markus I, Burcher E. *The Journal of pharmacology and experimental therapeutics*. 2002;302(2):627-35.
<http://dx.doi.org/10.1124/jpet.102.034702>.
416. **Determination of ruscogenin in crude Chinese medicines and biological samples by immunoassay.** Liu N, Wen X, Liu J, Liang M, Zeng H, Lin Y, et al. *Analytical and bioanalytical chemistry*. 2006;386(6):1727-33.
<http://dx.doi.org/10.1007/s00216-006-0767-9>. Epub 2006 Sep 7.
417. **Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome.** Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, et al. *Journal of Infectious Diseases*. 2006;193(6):792-5.
418. **Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS).** Liu X, Zhang M, He L, Li Y. *Cochrane database of systematic reviews (Online)*. 2012;10:CD004882.
419. **[Management of critical severe acute respiratory syndrome and risk factors for death].** Liu XQ, Chen SB, He GQ, Li YM, He WQ, Chen RC, et al. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases*. 2003;26(6):329-33.
420. **[Determination of sarsasapogenin in Anemarrhena asphodeloides Bunge by GC].** Liu Y, Chen W, Qiao C, Zhao N. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica*. 1999;24(9):554-5, 75.
421. **Protective effects of sarsasapogenin against early stage of diabetic nephropathy in rats.** Liu YW, Hao YC, Chen YJ, Yin SY, Zhang MY, Kong L, et al. *Phytotherapy research : PTR*. 2018;32(8):1574-82.
<http://dx.doi.org/10.1002/ptr.6088>. Epub 2018 Apr 23.
422. **[Clinical features and therapy of 106 cases of severe acute respiratory syndrome].** Liu ZY, Li TS, Wang Z, Xu ZJ, Wang HL, Yu Y, et al. *Zhonghua nei ke za zhi*. 2003;42(6):373-7.
423. **Ovine metabolism of lithogenic sapogenins. Synthesis of [2,2,4,4-(2)h(4)]sarsasapogenone,**

[2,2,4,4-(2)h(4)]sarsasapogenin, and [2,2,4,4-(2)h(4)]episarsasapogenin and evaluation of deuterium retention in a sheep-dosing trial. Loader JI, Wilkins AL, Flaoyen A, Ryste E, Hove K. *Journal of agricultural and food chemistry*. 2003;51(9):2641-5. <http://dx.doi.org/10.1021/jf026075z>.

424. **Clinical recommendations from an observational study on MERS: Glucocorticoids was benefit in treating SARS patients.** Long Y, Xu Y, Wang B, Zhang L, Jia D, Xue F, et al. *International Journal of Clinical and Experimental Medicine*. 2016;9(5):8865-73.

425. **Newly Recognized Causes of Acute Lung Injury: Transfusion of Blood Products, Severe Acute Respiratory Syndrome, and Avian Influenza.** Looney MR. *Clinics in Chest Medicine*. 2006;27(4):591-600.

426. **Nursing care of patients with severe acute respiratory syndrome in the intensive care unit: Case reports in Hong Kong.** Lopez V, Chan KS, Wong YC. *International Journal of Nursing Studies*. 2004;41(3):263-72.

427. **Regioselective cleavage of 22-oxo-23-spiroketals. Novel cholestanic frameworks with pyranone and cyclopentenone E rings on the side chain.** Lopez Y, Rodriguez L, del Rio RE, Farfan N, Morzycki JW, Santillan R. *Steroids*. 2012;77(5):534-41. <http://dx.doi.org/10.1016/j.steroids.2012.01.018>. Epub 2012 Feb 8.

428. **New bisfuran derivative from sarsasapogenin. An X-ray and NMR analysis.** Lopez Y, Santillan R, Farfan N. *Steroids*. 2006;71(1):12-7. <http://dx.doi.org/10.1016/j.steroids.2005.07.009>. Epub 2005 Sep 30.

429. **Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome: A Preliminary Study.** Loutfy MR, Blatt LM, Siminovitsh KA, Ward S, Wolff B, Lho H, et al. *Journal of the American Medical Association*. 2003;290(24):3222-8.

430. **Anti-inflammatory effect of Houltuynia cordata injection.** Lu HM, Liang YZ, Yi LZ, Wu XJ. *J Ethnopharmacol*. 2006;104(1):245-9. <http://dx.doi.org/10.1016/j.jep.2005.09.012>. Epub 2005 Oct 5.

431. **Influence of factors on production of IgG antibody in SARS patients.** Lu HY, Huo N, Wang GF, Li HC, Nie LG, Que CL, et al. *World Chinese Journal of Digestology*. 2004;12(3):723-5.

432. **Preliminary analysis of treatment in 32 patients with critical severe acute respiratory syndrome.** Lu W, Zhang H, Wang F, Wang S, Wu X, Zhang N, et al. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue*. 2003;15(8):492-4.

433. **Adjuvant corticosteroid therapy for critically ill patients with COVID-19.** Lu X, Chen T, Wang Y, Wang J, Zhang B, Li Y, et al. *medRxiv*. 2020.

434. **Virus-induced acute respiratory distress syndrome: Epidemiology, management and outcome.** Luyt CT, Combes A, Trouillet JL, Nieszkowska A, Chastre J. *Presse Medicale*. 2011;40(12):e561-e8.

435. **Avascular osteonecrosis after treatment of SARS: a 3-year longitudinal study.** Lv H, de Vlas SJ, Liu W, Wang TB, Cao ZY, Li CP, et al. *Tropical medicine & international health : TM & IH*. 2009;14:79-84. <http://dx.doi.org/10.1111/j.1365-3156.2008.02187.x>. Epub 2009 Jun 5.

436. **Effects of gadolinium chloride on slowly adapting and rapidly adapting receptors of the rabbit lung.** Ma AA, Ravi K, Bravo EM, Kappagoda CT. *Respiratory physiology & neurobiology*. 2004;141(2):125-35. <http://dx.doi.org/10.1016/j.resp.2004.04.008>.

437. **Synthesis and structure-activity relationships study of cytotoxic bufalin 3-nitrogen-containing-ester derivatives.** Ma B, Xiao ZY, Chen YJ, Lei M, Meng YH, Guo DA, et al. *Steroids*. 2013;78(5):508-12. <http://dx.doi.org/10.1016/j.steroids.2013.02.007>. Epub 2013 Feb 26.

438. **Effect of sarsasapogenin and its derivatives on the stimulus coupled responses of human neutrophils.**

- Ma D, Zhang J, Sugahara K, Sagara Y, Kodama H. Clinica chimica acta; international journal of clinical chemistry. 2001;314(1):107-12. [http://dx.doi.org/10.1016/s0009-8981\(01\)00638-6](http://dx.doi.org/10.1016/s0009-8981(01)00638-6).
439. **[Dynamic observation of the features of chest radiograph in SARS patients]**. Ma J, Li N, Que C, Li H, Nie L, Wang G, et al. Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences. 2003;35:38-40.
440. **[Pharmaceutical screening of the effective fraction from Smilax for treatment of chronic pelvic inflammatory disease]**. Ma Y, Luo Y, Song L, Qin F, Hou L. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2013;33(1):145-9.
441. **Three men, a paint brush and a coronavirus**. MacConnachie AA, Collins TC, Seaton RA, Kennedy DH. International Journal of STD and AIDS. 2007;18(2):132-3.
442. **Effect of feeding Sarsaponin in cattle and swine diets**. Mader TL, Brumm MC. Journal of animal science. 1987;65(1):9-15. <http://dx.doi.org/10.2527/jas1987.6519>.
443. **Host-directed therapies for antimicrobial resistant respiratory tract infections**. Maeurer M, Rao M, Zumla A. Current Opinion in Pulmonary Medicine. 2016;22(3):203-11.
444. **Decoding the enigma of antiviral crisis: Does one target molecule regulate all?** Mahmud-Al-Rafat A, Majumder A, Taufiqur Rahman KM, Mahedi Hasan AM, Didarul Islam KM, Taylor-Robinson AW, et al. Cytokine. 2019;115:13-23.
445. **Risk factors for chronic post-traumatic stress disorder (PTSD) in SARS survivors**. Mak IW, Chu CM, Pan PC, Yiu MG, Ho SC, Chan VL. Gen Hosp Psychiatry. 2010;32(6):590-8. <http://dx.doi.org/10.1016/j.genhosppsy.2010.07.007>. Epub 2010 Sep 15.
446. **Severe acute respiratory distress syndrome (SARS): A critical care perspective**. Manocha S, Walley KR, Russell JA. Critical Care Medicine. 2003;31(11):2684-92.
447. **Interfering with HuR-RNA Interaction: Design, Synthesis and Biological Characterization of Tanshinone Mimics as Novel, Effective HuR Inhibitors**. Manzoni L, Zucal C, Maio DD, D'Agostino VG, Thongon N, Bonomo I, et al. Journal of medicinal chemistry. 2018;61(4):1483-98. <http://dx.doi.org/10.1021/acs.jmedchem.7b01176>. Epub 2018 Jan 31.
448. **Membrane-bound estrogen receptor alpha initiated signaling is dynamin dependent in breast cancer cells**. Marczell I, Balogh P, Nyiro G, Kiss AL, Kovacs B, Bekesi G, et al. European journal of medical research. 2018;23(1):31. <http://dx.doi.org/10.1186/s40001-018-0328-7>.
449. **Considerations on the treatment of Severe Acute Respiratory Syndrome (SARS)**. Marraro G. Acta Anaesthesiologica Italica / Anaesthesia and Intensive Care in Italy. 2003;54(2):136-47.
450. **Comparison of mild encephalopathy with reversible splenic lesion with and without acute focal bacterial nephritis**. Maruyama Y, Sato M, Inaba Y, Fukuyama T. Brain Dev. 2020;42(1):56-63. <http://dx.doi.org/10.1016/j.braindev.2019.08.008>. Epub 2019 Oct 4.
451. **Day-to-day variations in salivary cortisol measurements**. Matsuda S, Yamaguchi T, Okada K, Gotouda A, Mikami S. Journal of Prosthodontic Research. 2012;56(1):37-41.
452. **The inhibitory effect of ouabain on the response of slowly adapting pulmonary stretch receptors to hyperinflation in the rabbit**. Matsumoto S, Ikeda M, Yoshida S, Nishikawa T, Itoh Y, Fujimi Y, et al. Life sciences. 2005;78(1):112-20. <http://dx.doi.org/10.1016/j.lfs.2005.04.036>. Epub 2005 Aug 22.
453. **Effect of ouabain on the afterhyperpolarization of slowly adapting pulmonary stretch receptors in the**

- rat lung.** Matsumoto S, Saiki C, Yoshida S, Takeda M, Kumagai Y. *Brain research*. 2006;1107(1):131-9. <http://dx.doi.org/10.1016/j.brainres.2006.06.015>. Epub 2006 Jul 7.
454. **Effects of ouabain and flecainide on CO(2)-induced slowly adapting pulmonary stretch receptor inhibition in the rabbit.** Matsumoto S, Takahashi T, Tanimoto T, Saiki C, Takeda M. *Life sciences*. 2000;66(5):441-8. [http://dx.doi.org/10.1016/s0024-3205\(99\)00610-4](http://dx.doi.org/10.1016/s0024-3205(99)00610-4).
455. **Excitatory mechanism of veratridine on slowly adapting pulmonary stretch receptors in anesthetized rabbits.** Matsumoto S, Takahashi T, Tanimoto T, Saiki C, Takeda M, Ojima K. *Life sciences*. 1998;63(16):1431-7. [http://dx.doi.org/10.1016/s0024-3205\(98\)00410-x](http://dx.doi.org/10.1016/s0024-3205(98)00410-x).
456. **The immediate psychological and occupational impact of the 2003 SARS outbreak in a teaching hospital.** Maunder R, Hunter J, Vincent L, Bennett J, Peladeau N, Leszcz M, et al. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2003;168(10):1245-51.
457. **No. 225-Management Guidelines for Obstetric Patients and Neonates Born to Mothers With Suspected or Probable Severe Acute Respiratory Syndrome (SARS).** Maxwell C, McGeer A, Tai KFY, Sermer M. *Journal of Obstetrics and Gynaecology Canada*. 2017;39(8):e130-e7.
458. **Severe Acute Respiratory Syndrome (SARS): A brief overview.** Mazzulli T. *Journal of Clinical Ligand Assay*. 2004;27(1):56-7.
459. **Severe acute respiratory syndrome-associated coronavirus in lung tissue.** Mazzulli T, Farcas GA, Poutanen SM, Willey BM, Low DE, Butany J, et al. *Emerg Infect Dis*. 2004;10(1):20-4. <http://dx.doi.org/10.3201/eid1001.030404>.
460. **Severe acute respiratory syndrome: Overview with an emphasis on the Toronto experience.** Mazzulli T, Kain K, Butany J. *Archives of Pathology and Laboratory Medicine*. 2004;128(12):1346-50.
461. **Family cluster of middle east respiratory syndrome coronavirus infections.** Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeh AA, Stephens GM. *New England Journal of Medicine*. 2013;368(26):2487-94.
462. **Use of glucocorticoid in treatment of severe acute respiratory syndrome cases.** Meng QH, Dong PL, Guo YB, Zhang K, Liang LC, Hou W, et al. *Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]*. 2003;37(4):233-5.
463. **[Clinical features of severe acute respiratory syndrome in forty-one confirmed health care workers].** Meng QH, Zhao CH, Dong PL, Hu ZJ, Hou W, Zhang K, et al. *Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]*. 2003;37(4):236-9.
464. **2-Phenylimidazo[1,2-a]pyridine-containing ligands of the 18-kDa translocator protein (TSPO) behave as agonists and antagonists of steroidogenesis in a mouse leydig tumor cell line.** Midzak A, Denora N, Laquintana V, Cutrignelli A, Lopodota A, Franco M, et al. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*. 2015;76:231-7. <http://dx.doi.org/10.1016/j.ejps.2015.05.021>. Epub 2015 May 19.
465. **The emergence of the Middle East Respiratory Syndrome coronavirus.** Milne-Price S, Miazgowicz KL, Munster VJ. *Pathogens and Disease*. 2014;71(2):121-36.
466. **Role of Ca2+ in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle.** Mirza KA, Tisdale MJ. *Cellular signalling*. 2012;24(11):2118-22. <http://dx.doi.org/10.1016/j.cellsig.2012.07.016>. Epub 2012 Jul 20.
467. **High dose intravenous methylprednisolone in the treatment of severe acute respiratory syndrome.** Mishra S, Lee WM, Bressler B, Juvet SC, Hadjiliadis D. *Canadian Respiratory Journal*. 2004;11(4):311-2.

468. **A review of treatment modalities for Middle East Respiratory Syndrome.** Mo Y, Fisher D. *Journal of Antimicrobial Chemotherapy*. 2016;71(12):3340-50.
469. **Lupus pneumonitis or severe acute respiratory syndrome?** Mok CC, Ying KY. *Lupus*. 2004;13(7):549-53.
470. **A never ending and new story: Meningitis and SARS.** Møller K, Benfield T. *Ugeskrift for Laeger*. 2004;166(12):1108.
471. **Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy.** Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA. *International Journal of Infectious Diseases*. 2013;17(10):e792-e8.
472. **Sarsasapogenin Increases Melanin Synthesis via Induction of Tyrosinase and Microphthalmia-Associated Transcription Factor Expression in Melan-a Cells.** Moon E, Kim AJ, Kim SY. *Biomolecules & therapeutics*. 2012;20(3):340-5. <http://dx.doi.org/10.4062/biomolther.2012.20.3.340>.
473. **High production of interleukin-10 and interferon- γ in influenza-associated MERS in the early phase.** Morichi S, Kawashima H, Ioi H, Yamanaka G, Kashiwagi Y, Hoshika A. *Pediatrics International*. 2012;54(4):536-8.
474. **Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome.** Muller MP, Dresser L, Raboud J, McGeer A, Rea E, Richardson SE, et al. *Pharmacotherapy*. 2007;27(4):494-503. <http://dx.doi.org/10.1592/phco.27.4.494>.
475. **Severe acute respiratory syndrome (SARS) coronavirus.** Muller MP, McGeer A. *Seminars in Respiratory and Critical Care Medicine*. 2007;28(2):201-12.
476. **Clinical Trials and Novel Pathogens: Lessons Learned from SARS.** Muller MP, McGeer A, Straus SE, Hawryluck L, Gold WL. *Emerging Infectious Diseases*. 2004;10(3):389-94.
477. **Formulation and evaluation of polyherbal antipsoriatic cream.** Mundada AS, Mahajan MS, Gangurde HH, Borkar VS, Gulecha VS, Khandare RA. *Pharmacologyonline*. 2009;2:1185-91.
478. **[Suspected adverse drug reactions in 2004].** Muntener CR, Gassner B, Demuth DC, Althaus FR, Zwahlen R. *Schweizer Archiv für Tierheilkunde*. 2005;147(7):304-10. <http://dx.doi.org/10.1024/0036-7281.147.7.304>.
479. **Activation of a Gq-coupled membrane estrogen receptor rapidly attenuates alpha2-adrenoceptor-induced antinociception via an ERK I/II-dependent, non-genomic mechanism in the female rat.** Nag S, Mokha SS. *Neuroscience*. 2014;267:122-34. <http://dx.doi.org/10.1016/j.neuroscience.2014.02.040>. Epub 2014 Mar 6.
480. **Acute encephalopathy with callosal, Subcortical and thalamic lesions.** Nakano Y, Monden Y, Mizuguchi M, Nagashima M, Koike Y, Gunji Y, et al. *Neurology Asia*. 2015;20(1):85-9.
481. **Effect of estrogens on the interferon-gamma producing cell population of mouse splenocytes.** Nakaya M, Tachibana H, Yamada K. *Bioscience, biotechnology, and biochemistry*. 2006;70(1):47-53. <http://dx.doi.org/10.1271/bbb.70.47>.
482. **Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1.** Natarajan P, Forte TM, Chu B, Phillips MC, Oram JF, Bielicki JK. *The Journal of biological chemistry*. 2004;279(23):24044-52. <http://dx.doi.org/10.1074/jbc.M400561200>. Epub 2004 Mar 29.
483. **Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development.** Navas-Martín S, Weiss SR. *Journal of*

NeuroVirology. 2004;10(2):75-85.

484. **Chemical constituents of Asparagus.** Negi JS, Singh P, Joshi GP, Rawat MS, Bisht VK. *Pharmacognosy reviews*. 2010;4(8):215-20. <http://dx.doi.org/10.4103/0973-7847.70921>.
485. **Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors.** Ng CK, Chan JWM, Kwan TL, To TS, Chan YH, Ng FYY, et al. *Thorax*. 2004;59(10):889-91.
486. **Severe acute respiratory syndrome coronavirus infection in children.** Ng DK, Lau WF, Chan KK, Pau BC, Lam YY, Chan EY, et al. *Pediatrics International*. 2005;47(4):452-5.
487. **Inflammatory cytokine profile in children with severe acute respiratory syndrome.** Ng PC, Lam CW, Li AM, Wong CK, Cheng FW, Leung TF, et al. *Pediatrics*. 2004;113(1):e7-14. <http://dx.doi.org/10.1542/peds.113.1.e7>.
488. **Chemokine response in children with SARS.** Ng PC, Lam CWK, Li AM, Wong CK, Leung TF, Cheng FWT, et al. *Archives of Disease in Childhood*. 2005;90(4):422-3.
489. **SARS in newborns and children.** Ng PC, Leung C, Chiu WK, Wong SF, Hon EKL. *Biology of the Neonate*. 2004;85(4):293-8.
490. **Mitochondrial ROS burst as an early sign in sarsapogenin-induced apoptosis in HepG2 cells.** Ni Y, Gong XG, Lu M, Chen HM, Wang Y. *Cell biology international*. 2008;32(3):337-43. <http://dx.doi.org/10.1016/j.cellbi.2007.12.004>. Epub 2008 Jan 9.
491. **[Severe acute respiratory syndrome: the first transmissible disease of the 21st century].** Nicastrì E, Petrosillo N, Macri G, Ippolito G. *Recenti progressi in medicina*. 2003;94(7):295-303.
492. **Avian influenza: Update on pathogenesis and laboratory diagnosis.** Nicholls JM, Peiris JSM. *Respirology*. 2008;13:S14-S8.
493. **Radiologic manifestations of severe acute respiratory syndrome.** Nicolaou S, Al-Nakshabandi NA, Müller NL. *New England Journal of Medicine*. 2003;348(20):2006.
494. **[Clinical features and management of recurrence of severe acute respiratory syndrome].** Nie L, Li H, Que C, Wang G, Ma J, Li N, et al. *Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences*. 2003;35(5):553-5.
495. **Current status of severe acute respiratory syndrome in China.** Nie QH, Lou XD, Zhang JZ, Su Q. *World Journal of Gastroenterology*. 2003;9(8):1635-45.
496. **Advances in clinical diagnosis and treatment of severe acute respiratory syndrome.** Nie QH, Luo XD, Hui WL. *World J Gastroenterol*. 2003;9(6):1139-43. <http://dx.doi.org/10.3748/wjg.v9.i6.1139>.
497. **Current status of severe acute respiratory syndrome in China.** Nie QH, Luo XD, Zhang JZ, Su Q. *World J Gastroenterol*. 2003;9(8):1635-45. <http://dx.doi.org/10.3748/wjg.v9.i8.1635>.
498. **Steroid Alkaloids from *Holarrhena africana* with Strong Activity against *Trypanosoma brucei rhodesiense*.** Nnadi CO, Nwodo NJ, Kaiser M, Brun R, Schmidt TJ. *Molecules (Basel, Switzerland)*. 2017;22(7). <http://dx.doi.org/10.3390/molecules22071129>.
499. **Infectious diseases. Battling SARS on the frontlines.** Normile D. *Science*. 2003;300(5620):714-5. <http://dx.doi.org/10.1126/science.300.5620.714>.
500. **The use of corticosteroids in SARS.** Oba Y. *The New England journal of medicine*. 2003;348(20):2034-5;

author reply -5. <http://dx.doi.org/10.1056/NEJM200305153482017>.

501. **Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein.** Obitsu S, Ahmed N, Nishitsuji H, Hasegawa A, Nakahama K, Morita I, et al. Arch Virol. 2009;154(9):1457-64. <http://dx.doi.org/10.1007/s00705-009-0472-z>. Epub 2009 Aug 14.
502. **Middle east respiratory syndrome: What we learned from the 2015 outbreak in the republic of Korea.** Oh MD, Park WB, Park SW, Choe PG, Bang JH, Song KH, et al. Korean Journal of Internal Medicine. 2018;33(2):233-46.
503. **Singapore's experience of SARS.** Oh V, Lim TK. Clinical Medicine. 2003;3(5):448-51.
504. **Clinically mild encephalitis/encephalopathy with a reversible splenic lesion associated with febrile urinary tract infection.** Okamoto T, Sato Y, Yamazaki T, Hayashi A. Eur J Pediatr. 2014;173(4):533-6. <http://dx.doi.org/10.1007/s00431-013-2199-9>. Epub 2013 Nov 13.
505. **Severe Acute Respiratory Syndrome: Radiographic Evaluation and Clinical Outcome Measures.** Ooi CGC, Khong PL, Ho JCM, Lam B, Wong WM, Yiu WC, et al. Radiology. 2003;229(2):500-6.
506. **Severe Acute Respiratory Syndrome: Relationship between Radiologic and Clinical Parameters.** Ooi CGC, Khong PL, Lam B, Ho JCM, Yiu WC, Wong WM, et al. Radiology. 2003;229(2):492-9.
507. **Structure-DPPH* scavenging activity relationships: parallel study of catechol and guaiacol acid derivatives.** Ordoudi SA, Tsimidou MZ, Vafiadis AP, Bakalbassis EG. Journal of agricultural and food chemistry. 2006;54(16):5763-8. <http://dx.doi.org/10.1021/jf060132x>.
508. **Ranking of concern, based on environmental indexes, for pharmaceutical and personal care products: an application to the Spanish case.** Ortiz de Garcia S, Pinto GP, Garcia-Encina PA, Irusta Mata RI. Journal of environmental management. 2013;129:384-97. <http://dx.doi.org/10.1016/j.jenvman.2013.06.035>. Epub 2013 Aug 28.
509. **[Studies on IgG antibodies of SARS patients].** Ou WN, Xie Y, Ling W, Li P, Feng L, Xu DZ. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2004;18(1):51-3.
510. **New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus.** Oxford JS, Balasingam S, Chan C, Catchpole A, Lambkin R. Antiviral chemistry & chemotherapy. 2005;16(1):13-21. <http://dx.doi.org/10.1177/095632020501600102>.
511. **Severe acute respiratory syndrome coronavirus 3a protein activates the mitochondrial death pathway through p38 MAP kinase activation.** Padhan K, Minakshi R, Towheed MAB, Jameel S. The Journal of general virology. 2008;89:1960-9. <http://dx.doi.org/10.1099/vir.0.83665-0>.
512. **Synthesis and SAR study of novel sarsasapogenin derivatives as potent neuroprotective agents and NO production inhibitors.** Pan H, Van Khang P, Dong D, Wang R, Ma L. Bioorganic & medicinal chemistry letters. 2017;27(3):662-5. <http://dx.doi.org/10.1016/j.bmcl.2016.11.070>. Epub 2016 Nov 24.
513. **Mild encephalitis/encephalopathy with a reversible splenic lesion: five cases and a literature review.** Pan JJ, Zhao YY, Lu C, Hu YH, Yang Y. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2015;36(11):2043-51. <http://dx.doi.org/10.1007/s10072-015-2302-2>. Epub 2015 Jul 1.
514. **Sudden worsening after subdural haematoma surgery: Will there be a corpus callosum injury?** Panciani PP, Roca E, Lodoli G, Fontanella MM. BMJ Case Reports. 2014.
515. **Lymphopenia in SARS.** Panesar NS. Lancet. 2003;361(9373):1985.

[http://dx.doi.org/10.1016/S0140-6736\(03\)13557-X](http://dx.doi.org/10.1016/S0140-6736(03)13557-X).

516. **What caused lymphopenia in SARS and how reliable is the lymphokine status in glucocorticoid-treated patients?** Panesar NS. *Med Hypotheses*. 2008;71(2):298-301. <http://dx.doi.org/10.1016/j.mehy.2008.03.019>. Epub 2008 Apr 29.
517. **Lymphopenia and neutrophilia in SARS are related to the prevailing serum cortisol.** Panesar NS, Lam CW, Chan MH, Wong CK, Sung JJ. *European journal of clinical investigation*. 2004;34(5):382-4. <http://dx.doi.org/10.1111/j.1365-2362.2004.01347.x>.
518. **Estrogen signaling characteristics of Atlantic croaker G protein-coupled receptor 30 (GPR30) and evidence it is involved in maintenance of oocyte meiotic arrest.** Pang Y, Dong J, Thomas P. *Endocrinology*. 2008;149(7):3410-26. <http://dx.doi.org/10.1210/en.2007-1663>. Epub 2008 Apr 17.
519. **Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.** Park JY, Kim JH, Kim YM, Jeong HJ, Kim DW, Park KH, et al. *Bioorganic & medicinal chemistry*. 2012;20(19):5928-35. <http://dx.doi.org/10.1016/j.bmc.2012.07.038>. Epub 2012 Aug 2.
520. **Prognostic Significance of the Radiographic Pattern of Disease in Patients with Severe Acute Respiratory Syndrome.** Paul NS, Chung T, Konen E, Roberts HC, Rao TNA, Gold WL, et al. *American Journal of Roentgenology*. 2004;182(2):493-8.
521. **Hydroxylation of steroids by Fusarium oxysporum, Exophiala jeanselmei and Ceratocystis paradoxa.** Peart PC, McCook KP, Russell FA, Reynolds WF, Reese PB. *Steroids*. 2011;76(12):1317-30. <http://dx.doi.org/10.1016/j.steroids.2011.06.010>. Epub 2011 Jul 7.
522. **Lack of SARS Transmission and U.S. SARS Case-Patient.** Peck AJ, Newbern EC, Feikin DR, Isakbaeva ET, Park BJ, Fehr JT, et al. *Emerging Infectious Diseases*. 2004;10(2):217-24.
523. **Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.** Peduto A, Scuotto M, Krauth V, Roviezzo F, Rossi A, Temml V, et al. *European journal of medicinal chemistry*. 2017;127:715-26. <http://dx.doi.org/10.1016/j.ejmech.2016.10.046>. Epub 2016 Oct 22.
524. **Development and validation of a UPLC-MS/MS method for determination of Sarsasapogenin-AA22 in rat plasma and its application to a pharmacokinetic study.** Pei L, Ge S, Ye Y, Jiang Z, Liang X, Zhao W, et al. *Biomedical chromatography : BMC*. 2018;32(10):e4295. <http://dx.doi.org/10.1002/bmc.4295>. Epub 2018 Jun 21.
525. **A validated UPLC-MS/MS method for quantitative determination of a potent neuroprotective agent Sarsasapogenin-AA13 in rat plasma: Application to pharmacokinetic studies.** Pei L, Ye Y, Zhao W, Ye Q, Ge S, Jiang ZW, et al. *Biomedical chromatography : BMC*. 2020;34(3):e4775. <http://dx.doi.org/10.1002/bmc.4775>. Epub 2020 Jan 17.
526. **Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study.** Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, et al. *Lancet*. 2003;361(9371):1767-72.
527. **Advanced oxidation protein products induce monocyte chemoattractant protein-1 expression via p38 mitogen-activated protein kinase activation in rat vascular smooth muscle cells.** Peng KF, Wu XF, Zhao HW, Sun Y. *Chin Med J (Engl)*. 2006;119(13):1088-93.
528. **Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases.** Poissy J, Goffard A, Parmentier-Decrucq E, Favory R, Kauh M, Kipnis E, et al. *Journal of Clinical Virology*. 2014;61(2):275-8.
529. **Saliva collection method affects predictability of serum cortisol.** Poll EM, Kreitschmann-Andermahr I,

- Langejuergen Y, Stanzel S, Gilsbach JM, Gressner A, et al. *Clinica chimica acta; international journal of clinical chemistry*. 2007;382(1):15-9. <http://dx.doi.org/10.1016/j.cca.2007.03.009>. Epub 2007 Mar 19.
530. **Serial analysis of plasma proteomic signatures in pediatric patients with severe acute respiratory syndrome and correlation with viral load.** Poon TCW, Chan KCA, Ng PC, Chiu RWK, Ang IL, Tong YK, et al. *Clinical Chemistry*. 2004;50(8):1452-5.
531. **Severe acute respiratory infections in the postpandemic era of H1N1.** Poulakou G, Perez M, Rello J. *Current opinion in critical care*. 2012;18(5):441-50. <http://dx.doi.org/10.1097/MCC.0b013e32835605f2>.
532. **Influence of sarsaponin on growth, feed and nitrogen utilization in growing male rats fed diets with added urea or protein.** Preston RL, Bartle SJ, May T, Goodall SR. *Journal of animal science*. 1987;65(2):481-7. <http://dx.doi.org/10.2527/jas1987.652481x>.
533. **N,N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor.** Primofiore G, Da Settimo F, Taliani S, Simorini F, Patrizi MP, Novellino E, et al. *Journal of medicinal chemistry*. 2004;47(7):1852-5. <http://dx.doi.org/10.1021/jm030973k>.
534. **Structural diversity of neurotogenic substances and their application perspective.** Qi J, Luo Y, Gao L. *Mini reviews in medicinal chemistry*. 2011;11(8):658-77. <http://dx.doi.org/10.2174/138955711796268796>.
535. **Clinical controlled study of integrative Chinese and western medicine in treating 49 cases of SARS.** Qiang J, Biao W, Rui-lin Z, Bao-guo W, Li-min F, Hai-jian W, et al. *Chinese Journal of Integrative Medicine*. 2003;9(3):175-80.
536. **A review of candidate therapies for middle east respiratory syndrome from a molecular perspective.** Rabaan AA, Alahmed SH, Bazzi AM, Alhani HM. *Journal of Medical Microbiology*. 2017;66(9):1261-74.
537. **Development in lipid drugs.** Raulin J. *Mini reviews in medicinal chemistry*. 2005;5(5):489-98. <http://dx.doi.org/10.2174/1389557053765574>.
538. **Structure-activity relationships of cytotoxic cholesterol-modified DNA duplexes.** Reed MW, Lukhtanov EA, Gorn VV, Lucas DD, Zhou JH, Pai SB, et al. *Journal of medicinal chemistry*. 1995;38(22):4587-96. <http://dx.doi.org/10.1021/jm00022a025>.
539. **Clinical study on treatment of severe acute respiratory syndrome by integrative Chinese and Western medicine.** Ren AM, Zhang SW, Wang BE. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban*. 2004;24(2):112-4.
540. **Antidepressant activity of sarsapogenin from *Anemarrhena asphodeloides* Bunge (Liliaceae).** Ren LX, Luo YF, Li X, Wu YL. *Die Pharmazie*. 2007;62(1):78-9.
541. **Antidepressant-like effects of sarsapogenin from *Anemarrhena asphodeloides* BUNGE (Liliaceae).** Ren LX, Luo YF, Li X, Zuo DY, Wu YL. *Biological & pharmaceutical bulletin*. 2006;29(11):2304-6. <http://dx.doi.org/10.1248/bpb.29.2304>.
542. **The use of proteomics in the discovery of serum biomarkers from patients with severe acute respiratory syndrome.** Ren Y, He QY, Fan J, Jones B, Zhou Y, Xie Y, et al. *Proteomics*. 2004;4(11):3477-84.
543. **Host factors and disease severity in two patients with SARS.** Rickerts V, Brodt HR, Schneider B, Weidmann E, Kai UC. *LaboratoriumsMedizin*. 2006;30(1):18-22.
544. **[Clinical presentation and management of the severe acute respiratory syndrome (SARS)].** Rickerts V,

- Wolf T, Rottmann C, Preiser W, Drosten C, Jakobi V, et al. Deutsche medizinische Wochenschrift (1946). 2003;128(20):1109-14. <http://dx.doi.org/10.1055/s-2003-39253>.
545. **Viral lung infections and the potential for a human pandemic.** Roberts H, Lim WS. *Medicine*. 2008;36(6):291-4.
546. **Revisiting 23-iodospirostanes. New facts and full characterization.** Ruiz-Perez KM, Romero-Avila M, Flores-Perez B, Flores-Alamo M, Moreno-Esparza R, Iglesias-Arteaga MA. *Steroids*. 2009;74(12):996-1002. <http://dx.doi.org/10.1016/j.steroids.2009.07.008>. Epub 2009 Jul 29.
547. **SARS: Would You Be Ready?** Sadigh M, Aronin SI. *Consultant*. 2003;43(14):1716-23.
548. **Evaluation of estrogen and G protein-coupled estrogen receptor 1 (GPER) levels in drug-naive patients with attention deficit hyperactivity disorder (ADHD).** Sahin N, Altun H, Kurutas EB, Findikli E. *Bosnian journal of basic medical sciences*. 2018;18(2):126-31. <http://dx.doi.org/10.17305/bjbms.2018.2942>.
549. **Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.** Saijo M, Morikawa S, Fukushi S, Mizutani T, Hasegawa H, Nagata N, et al. *Antiviral Res*. 2005;66(2):159-63. <http://dx.doi.org/10.1016/j.antiviral.2005.01.003>. Epub 2005 Feb 19.
550. **The reactions of beta- and alpha-pyranose peracetates with PCI5, and utilization of the products to construct sarsasapogenin glycosides.** Saito S, Ichinose K, Sasaki Y, Sumita S. *Chemical & pharmaceutical bulletin*. 1992;40(12):3261-8. <http://dx.doi.org/10.1248/cpb.40.3261>.
551. **SARS: Epidemiology, clinical presentation, management, and infection control measures.** Sampathkumar P, Temesgen Z, Smith TF, Thompson RL. *Mayo Clinic Proceedings*. 2003;78(7):882-9.
552. **Regioselective cleavage of rings E and F in sarsasapogenin.** Sandoval-Ramirez J, Meza-Reyes S, del Rio RE, Hernandez-Linares G, Suarez-Rojas A, Rincon S, et al. *Steroids*. 2003;68(2):199-204. [http://dx.doi.org/10.1016/s0039-128x\(02\)00170-8](http://dx.doi.org/10.1016/s0039-128x(02)00170-8).
553. **Activation of membrane-associated estrogen receptors decreases food and water intake in ovariectomized rats.** Santollo J, Marshall A, Daniels D. *Endocrinology*. 2013;154(1):320-9. <http://dx.doi.org/10.1210/en.2012-1858>. Epub 2012 Nov 26.
554. **Beyond tribulus (Tribulus terrestris L.): The effects of phytotherapics on testosterone, sperm and prostate parameters.** Santos HO, Howell S, Teixeira FJ. *J Ethnopharmacol*. 2019;235:392-405. <http://dx.doi.org/10.1016/j.jep.2019.02.033>. Epub 2019 Feb 18.
555. **Mild encephalitis/encephalopathy with a reversible splenic lesion: Evaluation by diffusion tensor imaging.** Satoru O, Imai H, Ishikawa E, Matsushita A, Yamamoto T, Nozue H, et al. *Neurologia Medico-Chirurgica*. 2010;50(12):1118-22.
556. **Postinjury Inflammation and Organ Dysfunction.** Sauaia A, Moore FA, Moore EE. *Critical Care Clinics*. 2017;33(1):167-91.
557. **Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza.** Savarino A. *Journal of Clinical Virology*. 2005;34(3):170-8.
558. **Potential therapies for coronaviruses.** Savarino A, Bounavoglia C, Norelli S, Di Trani L, Cassone A. *Expert Opinion on Therapeutic Patents*. 2006;16(9):1269-88.
559. **Illness in intensive care staff after brief exposure to severe acute respiratory syndrome.** Scales DC, Green K, Chan AK, Poutanen SM, Foster D, Nowak K, et al. *Emerging Infectious Diseases*. 2003;9(10):1205-10.

560. **A dynamic network of estrogen receptors in murine lymphocytes: fine-tuning the immune response.** Schneider AE, Karpati E, Schuszter K, Toth EA, Kiss E, Kulcsar M, et al. *Journal of leukocyte biology*. 2014;96(5):857-72. <http://dx.doi.org/10.1189/jlb.2A0214-080RR>. Epub 2014 Jul 28.
561. **Influence of separator gel in Sarstedt S-Monovette® serum tubes on various therapeutic drugs, hormones, and proteins.** Schouwers S, Brandt I, Willemse J, Van Regenmortel N, Uyttenbroeck W, Wauters A, et al. *Clinica Chimica Acta*. 2012;413(1):100-4.
562. **Community acquired pneumonia in the tropics.** Scrimini S, Junemann A, Luna CM. *Current Opinion in Pulmonary Medicine*. 2007;13(3):170-6.
563. **Effect of Quillaja saponaria saponins and Yucca schidigera plant extract on growth of Escherichia coli.** Sen S, Makkar HP, Muetzel S, Becker K. *Letters in applied microbiology*. 1998;27(1):35-8. <http://dx.doi.org/10.1046/j.1472-765x.1998.00379.x>.
564. **Estrogen Receptor beta Activation Rapidly Modulates Male Sexual Motivation through the Transactivation of Metabotropic Glutamate Receptor 1a.** Serebinski AL, Balthazart J, Ball GF, Cornil CA. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2015;35(38):13110-23. <http://dx.doi.org/10.1523/JNEUROSCI.2056-15.2015>.
565. **Pulmonary diseases and corticosteroids.** Sethi GR, Singhal KK. *Indian Journal of Pediatrics*. 2008;75(10):1045-56.
566. **Successful recovery of MERS CoV pneumonia in a patient with acquired immunodeficiency syndrome: a case report.** Shalhoub S, AlZahrani A, Simhairi R, Mushtaq A. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2015;62:69-71. <http://dx.doi.org/10.1016/j.jcv.2014.11.030>. Epub 2014 Nov 29.
567. **Evaluation of mild encephalitis/encephalopathy with a reversible splenic lesion (MERS) by diffusion-weighted and diffusion tensor imaging.** Shankar B, Narayanan R, Muralitharan P, Ulaganathan B. *BMJ Case Reports*. 2014.
568. **Transient elevation of cerebrospinal fluid protein in a patient of mild encephalitis with reversible lesion in the splenium: a case report.** Sharma B, Handa R, Nagpal K, Prakash S, Panagariya A. *The Malaysian journal of medical sciences : MJMS*. 2014;21(3):94-7.
569. **Evidence of a tendency to self-association of the transmembrane domain of ErbB-2 in fluid phospholipid bilayers.** Sharpe S, Barber KR, Grant CW. *Biochemistry*. 2002;41(7):2341-52. <http://dx.doi.org/10.1021/bi011340f>.
570. **Infants born to mothers with severe acute respiratory syndrome.** Shek CC, Ng PC, Fung GP, Cheng FW, Chan PK, Peiris MJ, et al. *Pediatrics*. 2003;112(4):e254. <http://dx.doi.org/10.1542/peds.112.4.e254>.
571. **Report on the investigation of lower extremity osteonecrosis with magnetic resonance imaging in recovered severe acute respiratory syndrome in Guangzhou.** Shen J, Liang BL, Zeng QS, Chen JY, Liu QY, Chen RC, et al. *Zhonghua yi xue za zhi*. 2004;84(21):1814-7.
572. **[Investigation of proximal femoral marrow with magnetic resonance imaging in recovered patients with severe acute respiratory syndrome].** Shen J, Liang BL, Zeng QS, Chen JY, Liu QY, Chen RC, et al. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases*. 2006;29(3):189-93.
573. **Sarsapogenin induces apoptosis via the reactive oxygen species-mediated mitochondrial pathway**

and ER stress pathway in HeLa cells. Shen S, Zhang Y, Zhang R, Gong X. *Biochem Biophys Res Commun.* 2013;441(2):519-24.

574. **The effects of disease severity, use of corticosteroids and social factors on neuropsychiatric complaints in severe acute respiratory syndrome (SARS) patients at acute and convalescent phases.** Sheng B, Cheng SK, Lau KK, Li HL, Chan EL. *European psychiatry : the journal of the Association of European Psychiatrists.* 2005;20(3):236-42. <http://dx.doi.org/10.1016/j.eurpsy.2004.06.023>.

575. **Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome.** Sheng WH, Chiang BL, Chang SC, Ho HN, Wang JT, Chen YC, et al. *Journal of the Formosan Medical Association.* 2005;104(10):715-23.

576. **Severe acute respiratory syndrome: Emergence of a new pandemic.** Sheth A, Romanelli F. *Journal of Pharmacy Practice.* 2005;18(1):63-70.

577. **Mild encephalitis/encephalopathy with a reversible splenic lesion secondary to encephalitis complicated by hyponatremia: A case report and literature review.** Shi BC, Li J, Jiang JW, Li MX, Zhang J, Shang XL. *Medicine (United States).* 2019;98(47).

578. **Inhibitory constituents from the aerial parts of *Polygala tenuifolia* on LPS-induced NO production in BV2 microglia cells.** Shi TX, Wang S, Zeng KW, Tu PF, Jiang Y. *Bioorganic & medicinal chemistry letters.* 2013;23(21):5904-8. <http://dx.doi.org/10.1016/j.bmcl.2013.08.085>. Epub 2013 Aug 30.

579. **Synthesis and biological evaluation of new steroidal pyridines as potential anti-prostate cancer agents.** Shi YK, Wang B, Shi XL, Zhao YD, Yu B, Liu HM. *European journal of medicinal chemistry.* 2018;145:11-22. <http://dx.doi.org/10.1016/j.ejmech.2017.12.094>. Epub 2018 Jan 2.

580. **Rat growth-hormone release stimulators from fenugreek seeds.** Shim SH, Lee EJ, Kim JS, Kang SS, Ha H, Lee HY, et al. *Chemistry & biodiversity.* 2008;5(9):1753-61. <http://dx.doi.org/10.1002/cbdv.200890164>.

581. **A case of *Staphylococcus aureus* meningitis associated with cryoglobulin-related renal failure and clinically mild encephalitis/encephalopathy with a reversible splenic lesion.** Shimozono K, Korenaga H, Mawatari R, Tsukishima N. *Rinsho shinkeigaku = Clinical neurology.* 2016;56(5):318-22. <http://dx.doi.org/10.5692/clinicalneurol.cn-000824>. Epub 2016 Apr 28.

582. **Therapeutic potentials of *Houttuynia cordata* Thunb. against inflammation and oxidative stress: A review.** Shingnaisui K, Dey T, Manna P, Kalita J. *J Ethnopharmacol.* 2018;220:35-43. <http://dx.doi.org/10.1016/j.jep.2018.03.038>. Epub 2018 Mar 30.

583. **Urgent search for safe and effective treatments of severe acute respiratory syndrome: is melatonin a promising candidate drug?** Shiu SY, Reiter RJ, Tan DX, Pang SF. *Journal of pineal research.* 2003;35(1):69-70. <http://dx.doi.org/10.1034/j.1600-079x.2003.00068.x>.

584. **A novel sarsasapogenin glycoside from *Asparagus racemosus* elicits protective immune responses against HBsAg.** Sidiq T, Khajuria A, Suden P, Singh S, Satti NK, Suri KA, et al. *Immunology letters.* 2011;135(1):129-35. <http://dx.doi.org/10.1016/j.imlet.2010.10.013>. Epub 2010 Oct 28.

585. **Acrylic/cyclodextrin hydrogels with enhanced drug loading and sustained release capability.** Siemoneit U, Schmitt C, Alvarez-Lorenzo C, Luzardo A, Otero-Espinar F, Concheiro A, et al. *International Journal of Pharmaceutics.* 2006;312(1):66-74.

586. **Severe acute respiratory syndrome complicated by spontaneous pneumothorax.** Sihoe ADL, Wong RHL, Lee ATH, Lau LS, Leung NYY, Law KI, et al. *Chest.* 2004;125(6):2345-51.

587. **Medicinal chemistry of indolylglyoxylamide TSPO high affinity ligands with anxiolytic-like effects.** Simorini F, Marini AM, Taliani S, la Motta C, Salerno S, Pugliesi I, et al. *Current Topics in Medicinal Chemistry*. 2012;12(4):333-51.
588. **A review on medicinal properties of *Ichnocarpus frutescens*.** Singh N, Tamizh Mani T, Prakash D, Singh P. *Indian Journal of Novel Drug Delivery*. 2012;4(1):24-7.
589. **Determination of Bioactive Compounds of Fenugreek (*Trigonella foenum-graecum*) Seeds Using LC-MS Techniques.** Singh P, Bajpai V, Gond V, Kumar A, Tadigoppula N, Kumar B. *Methods Mol Biol*. 2020;2107:377-93. http://dx.doi.org/10.1007/978-1-0716-0235-5_21.
590. **New substituted C-19-andrographolide analogues with potent cytotoxic activities.** Sirion U, Kasemsook S, Suksen K, Piyachaturawat P, Suksamrarn A, Saeeng R. *Bioorganic & medicinal chemistry letters*. 2012;22(1):49-52. <http://dx.doi.org/10.1016/j.bmcl.2011.11.085>. Epub 2011 Nov 28.
591. **Severe acute respiratory syndrome (SARS): a year in review.** Skowronski DM, Astell C, Brunham RC, Low DE, Petric M, Roper RL, et al. *Annual review of medicine*. 2005;56:357-81. <http://dx.doi.org/10.1146/annurev.med.56.091103.134135>.
592. **Severe acute respiratory syndrome (SARS): Update on a moving target.** Smith FW. *Cleveland Clinic Journal of Medicine*. 2003;70(5):413-6.
593. **Exacerbated innate host response to SARS-CoV in aged non-human primates.** Smits SL, de Lang A, van den Brand JM, Leijten LM, van IWF, Eijkemans MJ, et al. *PLoS Pathog*. 2010;6(2):e1000756. <http://dx.doi.org/10.1371/journal.ppat.1000756>.
594. **Novel and re-emerging respiratory infections.** Snell NJC. *Expert Review of Anti-Infective Therapy*. 2004;2(3):405-12.
595. **Development of a standard treatment protocol for severe acute respiratory syndrome.** So LKY, Lau ACW, Yam LYC, Cheung TMT, Poon E, Yung RWH, et al. *Lancet*. 2003;361(9369):1615-7.
596. **Quantitative structure-activity relationship studies of progesterone receptor binding steroids.** So SS, van Helden SP, van Geerestein VJ, Karplus M. *Journal of chemical information and computer sciences*. 2000;40(3):762-72. <http://dx.doi.org/10.1021/ci990130v>.
597. **Rabies encephalitis and extra-neural manifestations in a patient bitten by a domestic cat.** Soler-Rangel S, Jiménez-Restrepo N, Nariño D, Rosselli D. *Revista do Instituto de Medicina Tropical de Sao Paulo*. 2020;62.
598. **Structure-activity relationships of 3-O-beta-chacotriosyl ursolic acid derivatives as novel H5N1 entry inhibitors.** Song G, Shen X, Li S, Li Y, Liu Y, Zheng Y, et al. *European journal of medicinal chemistry*. 2015;93:431-42. <http://dx.doi.org/10.1016/j.ejmech.2015.02.029>. Epub 2015 Feb 20.
599. **[Investigation on the technology of processing *Anemarrhena asphodeloides* Bge. without hair by water].** Song S, Lu TL, Ji D. *Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials*. 2007;30(3):335-8.
600. **[Comparison of serum biochemical features between SARS and other viral pneumonias].** Song SZ, Liu HY, Shen H, Yuan B, Dong ZN, Jia XW, et al. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiu yixue*. 2004;16(11):664-6.
601. **Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.** Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KKS, et al. *Clinical Microbiology and Infection*. 2004;10(7):676-8.

602. **New and emerging infectious diseases.** Spicuzza L, Spicuzza A, La Rosa M, Polosa R, Di Maria G. Allergy and asthma proceedings. 2007;28(1):28-34. <http://dx.doi.org/10.2500/aap.2007.28.2870>.
603. **SARS clinical features, United States, 2003.** Srikantiah P, Charles MD, Reagan S, Clark TA, Pletz MWR, Patel PR, et al. Emerging Infectious Diseases. 2005;11(1):135-8.
604. **Effect of immobilization and concurrent exposure to a pulse-modulated microwave field on core body temperature, plasma ACTH and corticosteroid, and brain ornithine decarboxylase, Fos and Jun mRNA.** Stagg RB, Hawel LH, 3rd, Pastorian K, Cain C, Adey WR, Byus CV. Radiat Res. 2001;155(4):584-92. [http://dx.doi.org/10.1667/0033-7587\(2001\)155\[0584:eoiace\]2.0.co;2](http://dx.doi.org/10.1667/0033-7587(2001)155[0584:eoiace]2.0.co;2).
605. **SARS: Systematic review of treatment effects.** Stockman LJ, Bellamy R, Garner P. PLoS Medicine. 2006;3(9):1525-31.
606. **Severe acute respiratory syndrome in children.** Stockman LJ, Massoudi MS, Helfand R, Erdman D, Siwek AM, Anderson LJ, et al. Pediatric Infectious Disease Journal. 2007;26(1):68-74.
607. **[ON THE ISSUE OF SELECTION OF COAGULANTS UNDER ADP-INDUCED IMPEDANCE TEST OF AGGREGATION OF THROMBOCYTES IN PATIENTS WITH CHRONIC MYELO-PROLIFERATIVE TUMORS].** Stolyar MA, Ivashin DS, Olkhovsky IA. Klinicheskaia laboratornaia diagnostika. 2017;62(3):156-60.
608. **Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates.** Straarup EM, Fisker N, Hedtjarn M, Lindholm MW, Rosenbohm C, Aarup V, et al. Nucleic Acids Res. 2010;38(20):7100-11. <http://dx.doi.org/10.1093/nar/gkq457>. Epub 2010 Jul 8.
609. **Viral rewiring of cellular lipid metabolism to create membranous replication compartments.** Strating JR, van Kuppeveld FJ. Current opinion in cell biology. 2017;47:24-33. <http://dx.doi.org/10.1016/j.ceb.2017.02.005>. Epub 2017 Feb 24.
610. **Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose.** Stretz E, Oppel EM, R awer HC, Chatelain R, Mastnik S, Przybilla B, et al. Clinical and Experimental Allergy. 2017;47(12):1631-9.
611. **Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha.** Stroher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, et al. The Journal of infectious diseases. 2004;189(7):1164-7. <http://dx.doi.org/10.1086/382597>. Epub 2004 Mar 12.
612. **Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- .** Str oher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, et al. Journal of Infectious Diseases. 2004;189(7):1164-7.
613. **Microbial biotransformation of bioactive and clinically useful steroids and some salient features of steroids and biotransformation.** Sultana N. Steroids. 2018;136:76-92. <http://dx.doi.org/10.1016/j.steroids.2018.01.007>. Epub 2018 Jan 31.
614. **Treatment of severe acute respiratory syndrome in health-care workers.** Sun HY, Fang CT, Wang JT, Chen YC, Chang SC. Lancet. 2003;362(9400):2025-6. [http://dx.doi.org/10.1016/S0140-6736\(03\)15036-2](http://dx.doi.org/10.1016/S0140-6736(03)15036-2).
615. **Osteonecrosis in patients after severe acute respiratory syndrome (SARS): Possible role of anticardiolipin antibodies.** Sun W, Wang BL, Liu BL, Zhao FC, Shi ZC, Guo WS, et al. Journal of Clinical Rheumatology. 2010;16(2):61-3.
616. **[TLC-densitometric determination of sarsasapogenin in Anemarrhena asphodeloides Bge].** Sun WJ, Sha ZF, Yang CG. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

1989;14(9):546-8, 75.

617. **Metabolites characterization of timosaponin AIII in vivo and in vitro by using liquid chromatography-mass spectrometry.** Sun Y, Liu L, Peng Y, Liu B, Lin D, Li L, et al. *Journal of chromatography B, Analytical technologies in the biomedical and life sciences.* 2015;997:236-43. <http://dx.doi.org/10.1016/j.jchromb.2015.06.015>. Epub 2015 Jun 19.
618. **Severe acute respiratory syndrome: Report of treatment and outcome after a major outbreak.** Sung JY, Wu A, Joynt GM, Yuen KY, Lee N, Chan PKS, et al. *Thorax.* 2004;59(5):414-20.
619. **Identification of "sarsasapogenin-aglyconed" timosaponins as novel Abeta-lowering modulators of amyloid precursor protein processing.** Sy LK, Lok CN, Wang JY, Liu Y, Cheng L, Wan PK, et al. *Chemical science.* 2016;7(5):3206-14. <http://dx.doi.org/10.1039/c5sc02377g>. Epub 2016 Jan 22.
620. **Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships.** Tachibana K, Imaoka I, Yoshino H, Emura T, Kodama H, Furuta Y, et al. *Bioorganic & medicinal chemistry.* 2007;15(1):174-85. <http://dx.doi.org/10.1016/j.bmc.2006.09.072>. Epub 2006 Oct 4.
621. **[Possibility of using saliva for therapeutic monitoring of digoxin].** Tadeusiak W, Marcinowska-Suchowierska E, Podlesny J, Andrzejewski A. *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.* 1997;2(8):116-9.
622. **SARS: How to manage future outbreaks?** Tai DYH. *Annals of the Academy of Medicine Singapore.* 2006;35(5):368-73.
623. **Pharmacologic treatment of SARS: Current knowledge and recommendations.** Tai DYH. *Annals of the Academy of Medicine Singapore.* 2007;36(6):438-43.
624. **Two newly proposed infectious encephalitis/encephalopathy syndromes.** Takanashi Ji. *Brain and Development.* 2009;31(7):521-8.
625. **Kawasaki disease complicated by mild encephalopathy with a reversible splenic lesion (MERS).** Takanashi Ji, Shirai K, Sugawara Y, Okamoto Y, Obonai T, Terada H. *Journal of the Neurological Sciences.* 2012;315(1):167-9.
626. **Doxycycline-induced hypoglycaemia.** Tan CH, Shelley C, Harman KE. *Clinical and Experimental Dermatology.* 2016;41(1):43-4.
627. **Radiographic features of a case of severe acute respiratory syndrome with fatal outcome.** Tan DYL, Kaw GJL, Tsou IYY, Wansaicheong GKL, Green JA, Tai DYH, et al. *Annals of the Academy of Medicine Singapore.* 2003;32(4):542-6.
628. **Atypical SARS and Escherichia coli Bacteremia.** Tan TT, Tan BH, Kurup A, Oon LLE, Heng D, Thoe SYS, et al. *Emerging Infectious Diseases.* 2004;10(2):349-52.
629. **Severe acute respiratory syndrome in haemodialysis patients: A report of two cases.** Tang HL, Cheuk A, Chu KH, Lee W, Wong SH, Cheng YL, et al. *Nephrology Dialysis Transplantation.* 2003;18(10):2178-81.
630. **Structure Diversity, Synthesis, and Biological Activity of Cyathane Diterpenoids in Higher Fungi.** Tang HY, Yin X, Zhang CC, Jia Q, Gao JM. *Curr Med Chem.* 2015;22(19):2375-91. <http://dx.doi.org/10.2174/0929867322666150521091333>.
631. **Severe acute respiratory syndrome (SARS) in intensive care units (ICUs): limiting the risk to healthcare workers.** Tang JW, Chan RCW. *Current anaesthesia and critical care.* 2004;15(3):143-55.

<http://dx.doi.org/10.1016/j.cacc.2004.05.003>. Epub 2004 Jun 26.

632. **Quantitative temporal-spatial distribution of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV) in post-mortem tissues.** Tang JW, To KF, Lo AWI, Sung JY, Ng HK, Chan PKS. *Journal of Medical Virology*. 2007;79(9):1245-53.
633. **Synthesis and biological activity of 4-substituted benzoxazolone derivatives as a new class of sEH inhibitors with high anti-inflammatory activity in vivo.** Tang L, Ma WH, Ma YL, Ban SR, Feng XE, Li QS. *Bioorganic & medicinal chemistry letters*. 2013;23(8):2380-3. <http://dx.doi.org/10.1016/j.bmcl.2013.02.048>. Epub 2013 Feb 19.
634. **UPLC-QTOF-MS identification of metabolites in rat biosamples after oral administration of Dioscorea saponins: a comparative study.** Tang YN, Pang YX, He XC, Zhang YZ, Zhang JY, Zhao ZZ, et al. *J Ethnopharmacol*. 2015;165:127-40. <http://dx.doi.org/10.1016/j.jep.2015.02.017>. Epub 2015 Feb 16.
635. **Microdetermination of diosgenin from fenugreek (*Trigonella foenum-graecum*) seeds.** Taylor WG, Elder JL, Chang PR, Richards KW. *Journal of agricultural and food chemistry*. 2000;48(11):5206-10. <http://dx.doi.org/10.1021/jf000467t>.
636. **Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells.** Thomas P, Pang Y, Filardo EJ, Dong J. *Endocrinology*. 2005;146(2):624-32. <http://dx.doi.org/10.1210/en.2004-1064>. Epub 2004 Nov 11.
637. **Influenza, respiratory syncytial virus and SARS.** Thompson C, Zambon M. *Medicine*. 2009;37(12):679-85.
638. **Fibromyalgia after severe acute respiratory syndrome: A case report.** Tian XP, Zeng XF, Xu WB. *Chinese Medical Journal*. 2006;119(10):875-7.
639. **Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues.** Tidd DM, Hawley P, Warenus HM, Gibson I. *Anti-Cancer Drug Design*. 1988;3(2):117-27.
640. **[Xanthoma disseminatum with marked mucocutaneous involvement].** Tietge UJ, Maschek H, Schneider A, Gawehn AE, Wagner S, Manns MP, et al. *Deutsche medizinische Wochenschrift (1946)*. 1998;123(45):1337-42. <http://dx.doi.org/10.1055/s-2007-1024184>.
641. **Severe acute respiratory syndrome (SARS) in Hong Kong: patients' experiences.** Tiwari A, Chan S, Wong A, Tai J, Cheng K, Chan J, et al. *Nursing outlook*. 2003;51(5):212-9. <http://dx.doi.org/10.1016/j.outlook.2003.07.002>.
642. **Spirostanols obtained by cyclization of pseudosaponin derivatives and comparison of anti-platelet agglutination activities of spirostanol glycosides.** Tobarí A, Teshima M, Koyanagi J, Kawase M, Miyamae H, Yoza K, et al. *European journal of medicinal chemistry*. 2000;35(5):511-27. [http://dx.doi.org/10.1016/s0223-5234\(00\)00151-3](http://dx.doi.org/10.1016/s0223-5234(00)00151-3).
643. **TNF- α inhibition for potential therapeutic modulation of SARS coronavirus infection.** Tobinick E. *Current Medical Research and Opinion*. 2004;20(1):39-40.
644. **TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection.** Tobinick E. *Curr Med Res Opin*. 2004;20(1):39-40. <http://dx.doi.org/10.1185/030079903125002757>.
645. **The usefulness of mobile insulator sheets for the optimisation of deep heating area for regional hyperthermia using a capacitively coupled heating method: phantom, simulation and clinical prospective studies.** Tomura K, Ohguri T, Mulder HT, Murakami M, Nakahara S, Yahara K, et al. *International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group*. 2018;34(7):1092-103. <http://dx.doi.org/10.1080/02656736.2017.1402130>. Epub 2017 Nov 20.
646. **TCM treatment of infectious atypical pneumonia--a report of 16 cases.** Tong X, Li A, Zhang Z, Duan J,

- Chen X, Hua C, et al. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan. 2004;24(4):266-9.
647. **TCM treatment of infectious atypical pneumonia - A report of 16 cases.** Tong X, Li A, Zhang Z, Duan J, Chen X, Hua C, et al. Journal of Traditional Chinese Medicine. 2004;24(4):266-9.
648. **The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.** Tran QTN, Wong WSF, Chai CLL. European journal of medicinal chemistry. 2019;174:33-44. <http://dx.doi.org/10.1016/j.ejmech.2019.04.023>. Epub 2019 Apr 16.
649. **SARS-Cov: 1. The virus.** Tratner I. Medecine/Sciences. 2003;19(8):885-91.
650. **Tomatidine, a natural steroidal alkaloid shows antiviral activity towards chikungunya virus in vitro.** Troost B, Mulder LM, Diosa-Toro M, van de Pol D, Rodenhuis-Zybert IA, Smit JM. Sci Rep. 2020;10(1):6364. <http://dx.doi.org/10.1038/s41598-020-63397-7>.
651. **Structure-function relationship for saponin effects on cell cycle arrest and apoptosis in the human 1547 osteosarcoma cells: a molecular modelling approach of natural molecules structurally close to diosgenin.** Trouillas P, Corbiere C, Liagre B, Duroux JL, Beneytout JL. Bioorganic & medicinal chemistry. 2005;13(4):1141-9. <http://dx.doi.org/10.1016/j.bmc.2004.11.031>.
652. **Neurological manifestations in severe acute respiratory syndrome.** Tsai LK, Hsieh ST, Chang YC. Acta Neurologica Taiwanica. 2005;14(3):113-9.
653. **Neuromuscular disorders in severe acute respiratory syndrome.** Tsai LK, Hsieh ST, Chao CC, Chen YC, Lin YH, Chang SC, et al. Archives of Neurology. 2004;61(11):1669-73.
654. **Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment.** Tsang K, Seto WH. Current opinion in investigational drugs (London, England : 2000). 2004;5(2):179-85.
655. **SARS: pharmacotherapy.** Tsang K, Zhong NS. Respiriology. 2003;8:S25-30. <http://dx.doi.org/10.1046/j.1440-1843.2003.00525.x>.
656. **Respiratory infections unique to Asia.** Tsang KW, File Jr TM. Respiriology. 2008;13(7):937-49.
657. **A cluster of cases of severe acute respiratory syndrome in Hong Kong.** Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. The New England journal of medicine. 2003;348(20):1977-85. <http://dx.doi.org/10.1056/NEJMoa030666>. Epub 2003 Mar 31.
658. **Severe acute respiratory syndrome (SARS) in Hong Kong.** Tsang KW, Mok TY, Wong PC, Ooi GC. Respiriology. 2003;8(3):259-65.
659. **Diagnosis and pharmacotherapy of severe acute respiratory syndrome: What have we learn?** Tsang KWT, Ooi GC, Ho PL. European Respiratory Journal. 2004;24(6):1025-32.
660. **[Steroid saponins with more than 1 sugar chain. II. Sarsaparilloside, a bisdesmosidic 22-hydroxy-furanostanol saponin].** Tschesche R, Ludke G, Wulff G. Chemische Berichte. 1969;102(4):1253-69. <http://dx.doi.org/10.1002/cber.19691020417>.
661. **Severe acute respiratory syndrome: clinical outcome and prognostic correlates.** Tsui PT, Kwok ML, Yuen H, Lai ST. Emerg Infect Dis. 2003;9(9):1064-9. <http://dx.doi.org/10.3201/eid0909.030362>.
662. **Two cases of MERS associated with Legionnaires' Disease.** Tsunemi Y, Takano T, Sato N, Yoritaka A, Hiramatsu M, Yoritaka A, et al. Japanese Journal of Clinical Radiology. 2014;59(1):202-9.

663. **Systematic studies on the paracellular permeation of model permeants and oligonucleotides in the rat small intestine with chenodeoxycholate as enhancer.** Tsutsumi K, Li SK, Hymas RV, Teng CL, Tillman LG, Hardee GE, et al. *Journal of pharmaceutical sciences*. 2008;97(1):350-67. <http://dx.doi.org/10.1002/jps.21093>.
664. **Investigation of spectrophotometrically determined substances in Yucca extract by GC/MS, TLC and on-column injection GC.** Uematsu Y, Hirata K, Suzuki K, Iida K, Kamata K. *Shokuhin eiseigaku zasshi Journal of the Food Hygienic Society of Japan*. 2004;45(3):141-5. <http://dx.doi.org/10.3358/shokueishi.45.141>.
665. **Identification of cytotoxic constituents of *Narthecium ossifragum* using bioassay-guided fractionation.** Uhlig S, Wisloff H, Petersen D. *Journal of agricultural and food chemistry*. 2007;55(15):6018-26. <http://dx.doi.org/10.1021/jf070776k>. Epub 2007 Jun 29.
666. **Effect of steroidal saponins on ruminal fermentation and on production of lactating dairy cows.** Valdez FR, Bush LJ, Goetsch AL, Owens FN. *Journal of dairy science*. 1986;69(6):1568-75. [http://dx.doi.org/10.3168/jds.S0022-0302\(86\)80573-2](http://dx.doi.org/10.3168/jds.S0022-0302(86)80573-2).
667. **Ribavirin in the treatment of severe acute respiratory syndrome (SARS).** van Vonderen MGA, Bos JC, Prins JM, Wertheim-van Dillen P, Speelman P. *Netherlands Journal of Medicine*. 2003;61(7):238-41.
668. **An increase in tryptase on the first day of hymenoptera venom immunotherapy might be a predictor of future systemic reactions during treatment.** Vega-Castro A, Alonso-Llamazares A, Cárdenas R, Beitia JM, Mateo B, Alvarez-Twose I, et al. *Journal of Investigational Allergology and Clinical Immunology*. 2018;28(5):305-11.
669. **Measurement of late-night salivary cortisol with an automated immunoassay system.** Vogeser M, Durner J, Seliger E, Auernhammer C. *Clinical Chemistry and Laboratory Medicine*. 2006;44(12):1441-5.
670. **[Infectious diseases].** Voide C, Asner S, Giulieri S, Cavassini M, Merz L, Tissot F, et al. *Revue medicale suisse*. 2014;10(412):61-5.
671. **Clinical description of a completed outbreak of SARS in Vietnam, February-May 2003.** Vu HT, Leitmeyer KC, Le DH, Miller MJ, Nguyen QH, Uyeki TM, et al. *Emerg Infect Dis*. 2004;10(2):334-8. <http://dx.doi.org/10.3201/eid1002.030761>.
672. **Experience with the Sarstedt Salivette in salivary steroid determinations.** Walker RF, Robinson JA, Roberts S, Ford PD, Riad-Fahmy D. *Annals of clinical biochemistry*. 1990;27:503-5. <http://dx.doi.org/10.1177/000456329002700517>.
673. **Some opinions on the use of glucocorticosteroids in severe acute respiratory syndrome.** Wang AX. *Zhonghua nei ke za zhi [Chinese journal of internal medicine]*. 2003;42(10):680-1.
674. **Design, synthesis and biological evaluation of nonsteroidal vitamin D3 receptor ligands as anti-tumor agents.** Wang B, Hao M, Zhang C. *Bioorganic & medicinal chemistry letters*. 2017;27(6):1428-36. <http://dx.doi.org/10.1016/j.bmcl.2017.01.084>. Epub 2017 Feb 1.
675. **[Several issues in study of severe acute respiratory syndrome].** Wang C. *Zhonghua yi xue za zhi*. 2004;84(19):1587-8.
676. **Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS.** Wang CH, Liu CY, Wan YL, Chou CL, Huang KH, Lin HC, et al. *Respiratory Research*. 2005;6.
677. **[Synthesis of tyrosine-related peptide and their effect on progesterone production].** Wang DX, Wang N, Lu GC, Xu QC, Wang NG, Guan MZ. *Yao xue xue bao = Acta pharmaceutica Sinica*. 1994;29(6):438-42.
678. **Acquired but reversible loss of erythrocyte complement receptor 1 (CR1, CD35) and its longitudinal**

- alteration in patients with severe acute respiratory syndrome.** Wang FS, Chu FL, Jin L, Li YG, Zhang Z, Xu D, et al. *Clinical and Experimental Immunology*. 2005;139(1):112-9.
679. **Personal views on treating severe acute respiratory syndrome with glucocorticosteroids.** Wang GF. *Zhonghua nei ke za zhi [Chinese journal of internal medicine]*. 2003;42(10):682-3.
680. **[The COX regression analysis on the use of corticosteroids in the treatment of SARS].** Wang GF, Li N, Wu YF, Xie GQ, Lin JT, Huang CB, et al. *Zhonghua yi xue za zhi*. 2004;84(13):1073-8.
681. **Fatal aspergillosis in a patient with SARS who was treated with corticosteroids.** Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W. *The New England journal of medicine*. 2003;349(5):507-8. <http://dx.doi.org/10.1056/NEJM200307313490519>.
682. **Death of a SARS case from secondary aspergillus infection.** Wang HJ, Ding YQ, Xu J, Li X, Li XF, Yang L, et al. *Chinese Medical Journal*. 2004;117(8):1278-80.
683. **A sensitive indirect competitive enzyme-linked immunosorbent assay for the detection of sarsasapogenin in rat plasma.** Wang J, Liu JH, Guo X, Zhang J, Yu BY. *Acta pharmacologica Sinica*. 2010;31(8):984-9. <http://dx.doi.org/10.1038/aps.2010.85>.
684. **Severe acute respiratory syndrome.** Wang JT, Chang SC. *Current Opinion in Infectious Diseases*. 2004;17(2):143-8.
685. **Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients.** Wang JT, Sheng WH, Fang CT, Chen YC, Wang JL, Yu CJ, et al. *Emerging Infectious Diseases*. 2004;10(5):818-24.
686. **Comparison of the clinical manifestations of severe acute respiratory syndrome and Mycoplasma pneumoniae pneumonia.** Wang JY, Lee CH, Cheng SL, Chang HT, Hsu YL, Wang HC, et al. *J Formos Med Assoc*. 2004;103(12):894-9.
687. **Simultaneous analysis of diosgenin and sarsasapogenin in Asparagus officinalis byproduct by thin-layer chromatography.** Wang L, Wang X, Yuan X, Zhao B. *Phytochemical analysis : PCA*. 2011;22(1):14-7. <http://dx.doi.org/10.1002/pca.1244>. Epub 2010 Aug 26.
688. **Design, synthesis and biological evaluation of caudatin analogs as potent hepatitis B virus inhibitors.** Wang LJ, Chen H, Ma YB, Huang XY, Geng CA, Zhang XM, et al. *Medicinal chemistry (Sharjah (United Arab Emirates))*. 2015;11(2):165-79. <http://dx.doi.org/10.2174/1573406410666140902111326>.
689. **Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.** Wang LJ, Geng CA, Ma YB, Huang XY, Luo J, Chen H, et al. *Bioorganic & medicinal chemistry*. 2012;20(9):2877-88. <http://dx.doi.org/10.1016/j.bmc.2012.03.023>. Epub 2012 Mar 16.
690. **Synthesis, biological evaluation and structure-activity relationships of glycyrrhetic acid derivatives as novel anti-hepatitis B virus agents.** Wang LJ, Geng CA, Ma YB, Huang XY, Luo J, Chen H, et al. *Bioorganic & medicinal chemistry letters*. 2012;22(10):3473-9. <http://dx.doi.org/10.1016/j.bmcl.2012.03.081>. Epub 2012 Mar 28.
691. **Investigation of ADRs in patients with SARS.** Wang R, Zhou XQ, Dong J, Wei R, Chen K, Zhou J, et al. *Chinese Pharmacological Bulletin*. 2004;20(12):1379-82.
692. **Preparation and Evaluation of mPEG-PLGA Block Copolymer Micelles Loaded with a Sarsasapogenin Derivative.** Wang S, Liu M, Wang W, Li T, Cui M, Sun W, et al. *AAPS PharmSciTech*. 2019;20(7):280. <http://dx.doi.org/10.1208/s12249-019-1491-z>.
693. **Roles of TNF-alpha gene polymorphisms in the occurrence and progress of SARS-Cov infection: a**

- case-control study.** Wang S, Wei M, Han Y, Zhang K, He L, Yang Z, et al. BMC Infect Dis. 2008;8:27. <http://dx.doi.org/10.1186/1471-2334-8-27>.
694. **Synthesis of new sarsasapogenin derivatives with cytotoxicity and apoptosis-inducing activities in human breast cancer MCF-7 cells.** Wang W, Wang D, Wang Z, Yao G, Li X, Gao P, et al. European journal of medicinal chemistry. 2017;127:62-71. <http://dx.doi.org/10.1016/j.ejmech.2016.12.011>. Epub 2016 Dec 20.
695. **Novel sarsasapogenin-triazolyl hybrids as potential anti-Alzheimer's agents: Design, synthesis and biological evaluation.** Wang W, Wang W, Yao G, Ren Q, Wang D, Wang Z, et al. European journal of medicinal chemistry. 2018;151:351-62. <http://dx.doi.org/10.1016/j.ejmech.2018.03.082>. Epub 2018 Apr 3.
696. **Synthesis of new ent-labdane diterpene derivatives from andrographolide and evaluation of their anti-inflammatory activities.** Wang W, Wu Y, Chen X, Zhang P, Li H, Chen L. European journal of medicinal chemistry. 2019;162:70-9. <http://dx.doi.org/10.1016/j.ejmech.2018.11.002>. Epub 2018 Nov 3.
697. **Combined pharmacotherapy for osteonecrosis of the femoral head after severe acute respiratory syndrome and interstitial pneumonia: two and a half to fourteen year follow-up.** Wang W, Zhang N, Guo W, Gao F. Int Orthop. 2018;42(7):1551-6. <http://dx.doi.org/10.1007/s00264-018-3907-x>. Epub 2018 Mar 28.
698. **Synthesis of new sarsasapogenin derivatives with antiproliferative and apoptotic effects in MCF-7 cells.** Wang W, Zhang Y, Yao G, Wang W, Shang X, Zhang Y, et al. Steroids. 2018;131:23-31. <http://dx.doi.org/10.1016/j.steroids.2018.01.001>. Epub 2018 Jan 11.
699. **[Clinical experience from treatment of seven SARS patients].** Wang XJ, Li YR, Yang LQ, Zhang WY, Li XH, Dong QH, et al. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2004;18(3):215-7.
700. **The genus Anemarrhena Bunge: A review on ethnopharmacology, phytochemistry and pharmacology.** Wang Y, Dan Y, Yang D, Hu Y, Zhang L, Zhang C, et al. J Ethnopharmacol. 2014;153(1):42-60. <http://dx.doi.org/10.1016/j.jep.2014.02.013>. Epub 2014 Feb 17.
701. **Synthesis and evaluation of 26-amino acid methyl ester substituted sarsasapogenin derivatives as neuroprotective agents for Alzheimer's disease.** Wang ZD, Yao GD, Wang W, Wang WB, Wang SJ, Song SJ. Steroids. 2017;125:93-106. <http://dx.doi.org/10.1016/j.steroids.2017.06.013>. Epub 2017 Jul 5.
702. **Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids.** Ward SE, Loutfy MR, Blatt LM, Siminovitch KA, Chen J, Hinek A, et al. Antivir Ther. 2005;10(2):263-75.
703. **Membrane estrogen and glucocorticoid receptors - Implications for hormonal control of immune function and autoimmunity.** Watson CS, Gametchu B. International Immunopharmacology. 2001;1(6):1049-63.
704. **Membrane estrogen and glucocorticoid receptors--implications for hormonal control of immune function and autoimmunity.** Watson CS, Gametchu B. International immunopharmacology. 2001;1(6):1049-63. [http://dx.doi.org/10.1016/s1567-5769\(01\)00036-4](http://dx.doi.org/10.1016/s1567-5769(01)00036-4).
705. **13C cross-polarization MAS NMR study of some steroidal sapogenins.** Wawer I, Nartowska A, Cichowlas AA. Solid state nuclear magnetic resonance. 2001;20(1):35-45. <http://dx.doi.org/10.1006/snmr.2001.0028>.
706. **The SARS outbreak in a general hospital in Tianjin, China: clinical aspects and risk factors for disease outcome.** Wei MT, de Vlas SJ, Yang Z, Borsboom GJ, Wang L, Li H, et al. Tropical medicine & international health : TM & IH. 2009;14:60-70. <http://dx.doi.org/10.1111/j.1365-3156.2009.02347.x>.
707. **Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute**

- respiratory syndrome coronavirus.** Wen CC, Kuo YH, Jan JT, Liang PH, Wang SY, Liu HG, et al. *Journal of medicinal chemistry*. 2007;50(17):4087-95. <http://dx.doi.org/10.1021/jm070295s>. Epub 2007 Jul 31.
708. **Managing SARS amidst uncertainty.** Wenzel RP, Edmond MB. *New England Journal of Medicine*. 2003;348(20):1947-8.
709. **Molecular mimicry of ACTH in SARS - Implications for corticosteroid treatment and prophylaxis.** Wheatland R. *Medical Hypotheses*. 2004;63(5):855-62.
710. **Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).** White J. *Clinical Microbiology Newsletter*. 2014;36(15):115-22.
711. **Mental health impact of severe acute respiratory syndrome: a prospective study.** Wing YK, Leung CM. *Hong Kong medical journal = Xianggang yi xue za zhi*. 2012;18:24-7.
712. **Ouabain stimulates slowly adapting pulmonary stretch receptors.** Winner E, Zhang JW, Proctor M, Yu J. *Sheng li xue bao : [Acta physiologica Sinica]*. 2005;57(6):689-95.
713. **Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.** Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. *Clinical and experimental immunology*. 2004;136(1):95-103. <http://dx.doi.org/10.1111/j.1365-2249.2004.02415.x>.
714. **Tuberculosis in a SARS outbreak.** Wong CY, Wong KY, Law TSG, Shum TT, Li YK, Pang WK. *Journal of the Chinese Medical Association*. 2004;67(11):579-82.
715. **Severe acute respiratory syndrome in children.** Wong GW, Li AM, Ng PC, Fok TF. *Pediatr Pulmonol*. 2003;36(4):261-6. <http://dx.doi.org/10.1002/ppul.10367>.
716. **Severe acute respiratory syndrome (SARS): Epidemiology, diagnosis and management.** Wong GWK, Hui DSC. *Thorax*. 2003;58(7):558-60.
717. **Current understanding of severe acute respiratory syndrome (SARS).** Wong GWK, Hui DSC. *Clinical Pulmonary Medicine*. 2005;12(6):337-40.
718. **Bird flu: lessons from SARS.** Wong GWK, Leung TF. *Paediatric Respiratory Reviews*. 2007;8(2):171-6.
719. **Radiological appearances of severe acute respiratory syndrome.** Wong KT, Antonio GE, Hui DSC, Lee N, Yuen EHY, Wu A, et al. *Journal of the Hong Kong College of Radiologists*. 2003;6(1):4-6.
720. **Clinical presentation and outcome of severe acute respiratory syndrome in dialysis patients.** Wong PN, Mak SK, Lo KY, Tong GM, Wong Y, Watt CL, et al. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2003;42(5):1075-81. <http://dx.doi.org/10.1016/j.ajkd.2003.08.005>.
721. **Severe acute respiratory syndrome in a doctor working at the Prince of Wales Hospital.** Wong RSM. *Hong Kong Medical Journal*. 2003;9(3):202-5.
722. **Haematological manifestations in patients with severe acute respiratory syndrome: Retrospective analysis.** Wong RSM, Wu A, To KF, Lee N, Lam CWK, Wong CK, et al. *British Medical Journal*. 2003;326(7403):1358-62.
723. **Severe Acute Respiratory Syndrome and pregnancy.** Wong SF, Chow KM, de Swiet M. *BJOG : an international journal of obstetrics and gynaecology*. 2003;110(7):641-2.
724. **The severe acute respiratory syndrome (SARS).** Wong SSY, Yuen KY. *Journal of NeuroVirology*. 2005;11(5):455-68.

725. **The management of coronavirus infections with particular reference to SARS.** Wong SSY, Yuen KY. *Journal of Antimicrobial Chemotherapy*. 2008;62(3):437-41.
726. **Antiviral therapy for respiratory tract infections.** Wong SSY, Yuen KY. *Respirology*. 2008;13(7):950-71.
727. **Cocktail therapy for hip necrosis in SARS patients.** Wong T, Wang CJ, Hsu SL, Chou WY, Lin PC, Huang CC. *Chang Gung Medical Journal*. 2008;31(6):546-53.
728. **Treatment of severe acute respiratory syndrome with convalescent plasma.** Wong VW, Dai D, Wu AK, Sung JJ. *Hong Kong medical journal = Xianggang yi xue za zhi*. 2003;9(3):199-201.
729. **IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms.** Wrensch F, Winkler M, Pohlmann S. *Viruses*. 2014;6(9):3683-98. <http://dx.doi.org/10.3390/v6093683>.
730. **Haemorrhagic-fever-like changes and normal chest radiograph in a doctor with SARS.** Wu EB, Sung JY. *Lancet*. 2003;361(9368):1520-1.
731. **Discovery and SARs of trans-3-aryl acrylic acids and their analogs as novel anti-tobacco mosaic virus (TMV) agents.** Wu M, Wang Z, Meng C, Wang K, Hu Y, Wang L, et al. *PLoS One*. 2013;8(2):e56475. <http://dx.doi.org/10.1371/journal.pone.0056475>. Epub 2013 Feb 13.
732. **Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection.** Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. *Sci Rep*. 2017;7(1):9110. <http://dx.doi.org/10.1038/s41598-017-09536-z>.
733. **Renal hypouricemia is an ominous sign in patients with severe acute respiratory syndrome.** Wu VC, Huang JW, Hsueh PR, Yang YF, Tsai HB, Kan WC, et al. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2005;45(1):88-95. <http://dx.doi.org/10.1053/j.ajkd.2004.09.031>.
734. **A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China.** Wu W, Wang J, Liu P, Chen W, Yin S, Hang S, et al. *Chinese Medical Journal*. 2003;116(6):811-8.
735. **[Clinical features of 96 patients with severe acute respiratory syndrome from a hospital outbreak].** Wu W, Wang JF, Liu PM, Chen WX, Yin SM, Jiang SP, et al. *Zhonghua nei ke za zhi*. 2003;42(7):453-7.
736. **Comparison of clinical course of patients with severe acute respiratory syndrome among the multiple generations of nosocomial transmission.** Wu W, Wang JF, Liu PM, Jiang SP, Chen QY, Chen WX, et al. *Chinese Medical Journal*. 2004;117(1):14-8.
737. **Thin-section computed tomography manifestations during convalescence and long-term follow-up of patients with severe acute respiratory syndrome (SARS).** Wu X, Dong D, Ma D. *Medical Science Monitor*. 2016;22:2793-9.
738. **Real time assay of Aspergillus should be used in SARS patients receiving corticosteroids.** Wu YP, Wei R, Verhoef J. *Bmj*. 2003;327(7428):1405. <http://dx.doi.org/10.1136/bmj.327.7428.1405>.
739. **[Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy].** Xiao JZ, Ma L, Gao J, Yang ZJ, Xing XY, Zhao HC, et al. *Zhonghua nei ke za zhi*. 2004;43(3):179-82.
740. **A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia.** Xiao SF, Xue HB, Li X, Chen C, Li GJ, Yuan CM, et al. *Neuroscience bulletin*. 2011;27(4):258-68. <http://dx.doi.org/10.1007/s12264-011-1417-6>.

741. **Estrogen in the anterior cingulate cortex contributes to pain-related aversion.** Xiao X, Yang Y, Zhang Y, Zhang XM, Zhao ZQ, Zhang YQ. *Cerebral cortex* (New York, NY : 1991). 2013;23(9):2190-203. <http://dx.doi.org/10.1093/cercor/bhs201>. Epub 2012 Jul 10.
742. **A retrospective study of 78 patients with severe acute respiratory syndrome.** Xiao Z, Li Y, Chen R, Li S, Zhong S, Zhong N. *Chinese Medical Journal*. 2003;116(6):805-10.
743. **[Clinical factors influencing the uses of cortisone in severe acute respiratory syndrome].** Xie GQ, Wang GF, Wu YF, Chen BW, Xiao F, Li N, et al. *Zhonghua yi xue za zhi*. 2004;84(13):1079-81.
744. **[Dynamic changes of plasma cytokine levels in patients with severe acute respiratory syndrome].** Xie J, Han Y, Li TS, Qiu ZF, Ma XJ, Fan HW, et al. *Zhonghua nei ke za zhi*. 2003;42(9):643-5.
745. **Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge.** Xie L, Liu Y, Xiao Y, Tian Q, Fan B, Zhao H, et al. *Chest*. 2005;127(6):2119-24. <http://dx.doi.org/10.1378/chest.127.6.2119>.
746. **[Prognostic analysis of lung function and chest X-ray changes of 258 patients with severe acute respiratory syndrome in rehabilitation after discharge].** Xie LX, Liu YN, Hao FY, Dong J, Cao L, Xu HM, et al. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases*. 2004;27(3):147-50.
747. **Design, Synthesis, and Biological Evaluation of Pyridineamide Derivatives Containing a 1,2,3-Triazole Fragment as Type II c-Met Inhibitors.** Xiong H, Cheng J, Zhang J, Zhang Q, Xiao Z, Zhang H, et al. *Molecules* (Basel, Switzerland). 2019;25(1).
748. **Therapeutic effect of integrative traditional Chinese and western medicine on 51 SARS patients and its influence on their T lymphocyte subsets.** Xiu-hui L, Jian-hua H, Ke Z, Jun Y, Chun-yan G. *Chinese Journal of Integrative Medicine*. 2003;9(4):263-5.
749. **[Clinical analysis of patients with severe acute respiratory syndrome in Beijing area].** Xu J, Yang M, Liu Z. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases*. 2003;26(11):683-5.
750. **Development and validation of a sensitive and rapid non-aqueous LC-ESI-MS/MS method for measurement of diosgenin in the plasma of normal and hyperlipidemic rats: a comparative study.** Xu L, Liu Y, Wang T, Qi Y, Han X, Xu Y, et al. *Journal of chromatography B, Analytical technologies in the biomedical and life sciences*. 2009;877(14):1530-6. <http://dx.doi.org/10.1016/j.jchromb.2009.03.039>. Epub 2009 Mar 31.
751. **A monoclonal antibody-based competitive ELISA for the determination of ruscogenin in Chinese traditional medicines and biological samples.** Xu Y, Liu JH, Wang J, Zhang J, Yu BY. *Chinese journal of natural medicines*. 2014;12(10):794-9. [http://dx.doi.org/10.1016/S1875-5364\(14\)60121-7](http://dx.doi.org/10.1016/S1875-5364(14)60121-7). Epub 2014 Oct 31.
752. **[Evaluation of the efficacy and safety of corticosteroid in the treatment of severe SARS in Guangdong province with multi-factor regression analysis].** Xu YD, Jiang M, Chen RC, Fang JQ. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiu yixue*. 2008;20(2):84-7.
753. **[Clinical therapy of severe acute respiratory syndrome: 38 cases retrospective analysis].** Xu YD, Li YM, Liu XQ, Chen SB, He WQ, Xiao ZL, et al. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiu yixue*. 2003;15(6):343-5.
754. **Muscle pain, fever, cough, and progressive dyspnea in a woman with eosinophilic pneumonia.** Xu Z, Fan Y, Wang GS, Wu GM. *Genetics and Molecular Research*. 2015;14(2):4189-94.

755. **Non-invasive versus invasive mechanical ventilation for respiratory failure in severe acute respiratory syndrome.** Yam LY, Chan AY, Cheung TM, Tsui EL, Chan JC, Wong VC. *Chin Med J (Engl)*. 2005;118(17):1413-21.
756. **Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong.** Yam LY, Lau AC, Lai FY, Shung E, Chan J, Wong V. *J Infect*. 2007;54(1):28-39. <http://dx.doi.org/10.1016/j.jinf.2006.01.005>. Epub 2006 Mar 15.
757. **Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.** Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue JI, et al. *Antimicrob Agents Chemother*. 2016;60(11):6532-9. <http://dx.doi.org/10.1128/AAC.01043-16>. Print 2016 Nov.
758. **Discussion about treatment of severe acute respiratory syndrome based on syndrome differentiation.** Yan DX, Yu XP, Shi KH, Song WB, Zhang HY, Wei JL. *Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine*. 2004;2(4):241-4.
759. **Cytotoxic steroids from *Sarcococca saligna*.** Yan YX, Sun Y, Chen JC, Wang YY, Li Y, Qiu MH. *Planta Med*. 2011;77(15):1725-9. <http://dx.doi.org/10.1055/s-0030-1271101>. Epub 2011 May 17.
760. **Quantitative determination of sarsasapogenin in rat plasma using liquid chromatography-tandem mass spectrometry.** Yang B, Liu Z, Hu J, Lai X, Xia P. *Journal of chromatography B, Analytical technologies in the biomedical and life sciences*. 2016;1022:213-9. <http://dx.doi.org/10.1016/j.jchromb.2016.04.020>. Epub 2016 Apr 14.
761. **[Patients of severe acute respiratory syndrome with hypoxemia treated by anisodamine].** Yang GD. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiu yixue*. 2003;15(8):452.
762. **Design, synthesis and biological evaluation of 3-piperazinecarboxylate sarsasapogenin derivatives as potential multifunctional anti-Alzheimer agents.** Yang GX, Ge SL, Wu Y, Huang J, Li SL, Wang R, et al. *European journal of medicinal chemistry*. 2018;156:206-15. <http://dx.doi.org/10.1016/j.ejmech.2018.04.054>. Epub 2018 May 1.
763. **Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS.** Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. *Diabetic medicine : a journal of the British Diabetic Association*. 2006;23(6):623-8. <http://dx.doi.org/10.1111/j.1464-5491.2006.01861.x>.
764. **Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes.** Yang JK, Lin SS, Ji XJ, Guo LM. *Acta diabetologica*. 2010;47(3):193-9. <http://dx.doi.org/10.1007/s00592-009-0109-4>. Epub 2009 Mar 31.
765. **Hematological findings in SARS patients and possible mechanisms (review).** Yang M, Li CK, Li K, Hon KL, Ng MH, Chan PK, et al. *International journal of molecular medicine*. 2004;14(2):311-5.
766. **Thrombocytopenia in patients with severe acute respiratory syndrome (review).** Yang M, Ng MHL, Chi KL. *Hematology*. 2005;10(2):101-5.
767. **An unusual presentation of infective endocarditis: Transient encephalopathy with reversible lesions in corpus callosum and white matter.** Yang SL, Zhu M, Wang F, Liu WJ, Wang Y, Wu YC. *Neurology Asia*. 2017;22(4):373-6.
768. **Steroidal alkaloids from *Holarrhena antidysenterica* as acetylcholinesterase inhibitors and the investigation for structure-activity relationships.** Yang ZD, Duan DZ, Xue WW, Yao XJ, Li S. *Life sciences*. 2012;90(23):929-33. <http://dx.doi.org/10.1016/j.lfs.2012.04.017>. Epub 2012 Apr 30.
769. **[Chest X-ray changes after discontinuation of glucocorticosteroids treatment on severe acute respiratory syndrome (5 cases report)].** Yao W, Chen Y, Zhang L, Wang X, Sun Y, Sun W, et al. *Beijing da xue xue*

bao Yi xue ban = Journal of Peking University Health sciences. 2003;35:26-8.

770. **Chest X ray changes in severe acute respiratory syndrome cases after discontinuation of glucocorticosteroids treatment.** Yao WZ, Chen YH, Zhang LQ, Wang XH, Sun YC, Sun W, et al. Chinese Medical Journal. 2004;117(1):143-4.
771. **Increase in methicillin-resistant Staphylococcus aureus acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome.** Yap FH, Gomersall CD, Fung KS, Ho PL, Ho OM, Lam PK, et al. Clin Infect Dis. 2004;39(4):511-6. <http://dx.doi.org/10.1086/422641>. Epub 2004 Aug 3.
772. **Therapeutic potential of spirooxindoles as antiviral agents.** Ye N, Chen H, Wold EA, Shi PY, Zhou J. ACS Infectious Diseases. 2016;2(6):382-92.
773. **Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital.** Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PKS, Peng MY, et al. Journal of Antimicrobial Chemotherapy. 2005;56(5):919-22.
774. **Synthesis and biological evaluation of novel sarsasapogenin derivatives as potential anti-tumor agents.** Yin Y, Zhao XC, Wang SJ, Gao PY, Li LZ, Ikejima T, et al. Steroids. 2015;93:25-31. <http://dx.doi.org/10.1016/j.steroids.2014.09.007>. Epub 2014 Oct 19.
775. **[Determination of sarsasapogenin in "tian dong" by TLCS].** Yu B, Luo X, Xu Y, Xu L, Xu G. Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials. 2001;24(8):577-8.
776. **Efficient synthesis of new antiproliferative steroidal hybrids using the molecular hybridization approach.** Yu B, Qi PP, Shi XJ, Huang R, Guo H, Zheng YC, et al. European journal of medicinal chemistry. 2016;117:241-55. <http://dx.doi.org/10.1016/j.ejmech.2016.04.024>. Epub 2016 Apr 12.
777. **Cardiovascular complications of severe acute respiratory syndrome.** Yu CM, Wong RSM, Wu EB, Kong SL, Wong J, Yip GWK, et al. Postgraduate Medical Journal. 2006;82(964):140-4.
778. **Antiviral agents and corticosteroids in the treatment of severe acute respiratory syndrome (SARS).** Yu WC, Hui DS, Chan-Yeung M. Thorax. 2004;59(8):643-5. <http://dx.doi.org/10.1136/thx.2003.017665>.
779. **Critical roles of platelets in lipopolysaccharide-induced lethality: effects of glycyrrhizin and possible strategy for acute respiratory distress syndrome.** Yu Z, Ohtaki Y, Kai K, Sasano T, Shimauchi H, Yokochi T, et al. International immunopharmacology. 2005;5(3):571-80. <http://dx.doi.org/10.1016/j.intimp.2004.11.004>.
780. **Mild encephalitis/encephalopathy with reversible splenic lesion (MERS) in adults-a case report and literature review.** Yuan J, Yang S, Wang S, Qin W, Yang L, Hu W. BMC Neurology. 2017;17(1).
781. **QSAR oriented computer representation of chemical compounds used in CISOC-SARSS.** Yuan SG, Zhao X, Zeng FY, Zheng CZ. Progress in clinical and biological research. 1989;291:195-8.
782. **Clinically mild encephalitis/encephalopathy with a reversible splenic lesion associated with Mycoplasma pneumoniae infection.** Yuan ZF, Shen J, Mao SS, Yu YL, Xu L, Jiang PF, et al. BMC Infectious Diseases. 2016;16(1).
783. **Ocular screening in severe acute respiratory syndrome.** Yuen KSC, Chan WM, Fan DSP, Chong KKL, Sung JY, Lam DSC. American Journal of Ophthalmology. 2004;137(4):773-4.
784. **Use of magnetic resonance imaging for screening for avascular necrosis post-SARS.** Yuen MK, Leong L, Wong Y, Antonio GE, Griffith JF, Lai YL, et al. Hong Kong Medical Journal. 2008;14(1):14-6.

785. **[Severe acute respiratory syndrome (SARS)--new, unknown disease?]**. Zajkowska JM, Hermanowska-Szpakowicz T, Pancewicz S, Kondrusik M, Grygorczuk S. *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego*. 2004;16(92):183-7.
786. **Impact of viral infections on lung transplant outcomes**. Zamora MR. *Current Opinion in Organ Transplantation*. 2006;11(5):475-82.
787. **Estrogens induce expression of membrane-associated estrogen receptor alpha isoforms in lactotropes**. Zarate S, Jaita G, Ferraris J, Eijo G, Magri ML, Pisera D, et al. *PLoS One*. 2012;7(7):e41299. <http://dx.doi.org/10.1371/journal.pone.0041299>. Epub 2012 Jul 23.
788. **Estrogens exert a rapid apoptotic action in anterior pituitary cells**. Zarate S, Jaita G, Zaldivar V, Radl DB, Eijo G, Ferraris J, et al. *American journal of physiology Endocrinology and metabolism*. 2009;296(4):E664-71. <http://dx.doi.org/10.1152/ajpendo.90785.2008>. Epub 2009 Jan 21.
789. **[Analyses of subset, activated state and expression pattern of 24 repertoire TCR Vbeta of peripheral blood T lymphocytes in convalescence patients with severe acute respiratory syndrome (SARS)]**. Zeng X, Cai C, Huang Y, Ou AH, Zhang X. *Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology*. 2005;21(1):114-7.
790. **Lymphocyte immunological function and 24 T cell receptor V beta subfamilies expression in convalescent patients with severe acute respiratory syndrome**. Zeng X, Cai C, Huang Y, Ou AH, Zhang X. *Journal of Clinical Rehabilitative Tissue Engineering Research*. 2007;11(43):8796-800.
791. **Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro**. Zhang CH, Wang YF, Liu XJ, Lu JH, Qian CW, Wan ZY, et al. *Chin Med J (Engl)*. 2005;118(6):493-6.
792. **[Corticosteroid therapy and changes in chest radiogram in five patients with severe acute respiratory syndrome]**. Zhang J, Yang X, Tan H, Zheng XW. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiu yixue*. 2003;15(6):346-8.
793. **[Clinical analysis of pregnancy in second and third trimesters complicated severe acute respiratory syndrome]**. Zhang JP, Wang YH, Chen LN, Zhang R, Xie YF. *Zhonghua Fu Chan Ke Za Zhi*. 2003;38(8):516-20.
794. **Effect of integrated traditional Chinese and Western medicine on SARS: A review of clinical evidence**. Zhang MM, Liu XM, He L. *World Journal of Gastroenterology*. 2004;10(23):3500-5.
795. **Sarsasapogenin suppresses Abeta overproduction induced by high glucose in HT-22 cells**. Zhang MY, Li Y, Yin SY, Kong L, Liu XL, Yin XX, et al. *Naunyn-Schmiedeberg's archives of pharmacology*. 2018;391(2):159-68. <http://dx.doi.org/10.1007/s00210-017-1445-5>. Epub 2017 Dec 23.
796. **Steroid-induced osteonecrosis: the number of lesions is related to the dosage**. Zhang NF, Li ZR, Wei HY, Liu ZH, Hernigou P. *The Journal of bone and joint surgery British volume*. 2008;90(9):1239-43. <http://dx.doi.org/10.1302/0301-620X.90B9.20056>.
797. **Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study**. Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, et al. *Bone Research*. 2020;8(1).
798. **Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine**. Zhang RL, Jiao Q, Wang BG. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban*. 2003;23(9):654-7.

799. **Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome.** Zhang X, Alekseev K, Jung K, Vlasova A, Hadya N, Saif LJ. *J Virol.* 2008;82(9):4420-8. <http://dx.doi.org/10.1128/JVI.02190-07>. Epub 2008 Feb 20.
800. **Analysis of serum cytokines in patients with severe acute respiratory syndrome.** Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, et al. *Infection and Immunity.* 2004;72(8):4410-5.
801. **Design, Synthesis and Investigation of the Potential Anti-Inflammatory Activity of 7-O-Amide Hesperetin Derivatives.** Zhang Y, Zheng Y, Shi W, Guo Y, Xu T, Li Z, et al. *Molecules (Basel, Switzerland).* 2019;24(20). <http://dx.doi.org/10.3390/molecules24203663>.
802. **[Characterization of peripheral dendritic cell subsets and its implication in patients infected with severe acute respiratory syndrome].** Zhang Z, Wang FS, Zhao M, Liu JC, Xu DP, Jin L, et al. *Zhonghua yi xue za zhi.* 2004;84(1):22-6.
803. **Longitudinal alteration of circulating dendritic cell subsets and its correlation with steroid treatment in patients with severe acute respiratory syndrome.** Zhang Z, Xu D, Li Y, Jin L, Shi M, Wang M, et al. *Clinical Immunology.* 2005;116(3):225-35.
804. **Osteonecrosis of the femoral head in SARS patients: seven years later.** Zhao FC, Guo KJ, Li ZR. *European journal of orthopaedic surgery & traumatology : orthopedie traumatologie.* 2013;23(6):671-7. <http://dx.doi.org/10.1007/s00590-012-1054-4>. Epub 2012 Jul 13.
805. **Lesion size changes in osteonecrosis of the femoral head: A long-term prospective study using MRI.** Zhao FC, Li ZR, Zhang NF, Wang BL, Sun W, Cheng LM, et al. *International Orthopaedics.* 2010;34(6):799-804.
806. **[Follow-up study of 147 cases of severe acute respiratory syndrome in Taiyuan City].** Zhao GM, Zhao BX, Deng XW, Mu LN, Gao MY, He JK, et al. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.* 2004;25(7):643.
807. **[3D-QSAR of antiinflammatory activities of 5,6-diaryl-2,3-dihydro-1-pyrrolizinone derivatives].** Zhao LQ, Yuan Y, Hu YD, Zhang T, Zhang SF, Li S. *Yao xue xue bao = Acta pharmaceutica Sinica.* 2001;36(5):343-6.
808. **Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis.** Zhao R, Wang H, Wang X, Feng F. *Osteoporosis International.* 2017;28(3):1027-34.
809. **Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China.** Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, et al. *Journal of Medical Microbiology.* 2003;52(8):715-20.
810. **Clinical analysis of 190 cases of outbreak with atypical pneumonia in Guangzhou in spring, 2003.** Zhao ZW, Zhang FC, Xu M, Huang K, Zhong WN, Cai WP, et al. *Zhonghua yi xue za zhi.* 2003;83(9):713-8.
811. **Antiviral treatment of SARS: can we draw any conclusions?** Zhaori G. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.* 2003;169(11):1165-6.
812. **An overview of treatment of SARS: urgency of prospective controlled clinical trial.** Zhaori GT. *Zhonghua er ke za zhi Chinese journal of pediatrics.* 2003;41(6):403-4.
813. **Serum neopterin for early assessment of severity of severe acute respiratory syndrome.** Zheng B, Cao KY, Chan CP, Choi JW, Leung W, Leung M, et al. *Clinical immunology (Orlando, Fla).* 2005;116(1):18-26. <http://dx.doi.org/10.1016/j.clim.2005.03.009>.
814. **The use of glucocorticosteroids in the treatment of severe acute respiratory syndrome.** Zheng ZG,

Zhong NS. Zhonghua nei ke za zhi [Chinese journal of internal medicine]. 2003;42(10):676-7.

815. **Management and prevention of SARS in China.** Zhong N. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2004;359(1447):1115-6. <http://dx.doi.org/10.1098/rstb.2004.1491>.

816. **Preparing for the next flu pandemic: From SARS to avian flu.** Zhong N. Singapore Medical Journal. 2008;49(8):595-8.

817. **Our strategies for fighting severe acute respiratory syndrome (SARS).** Zhong NS, Zeng GQ. Am J Respir Crit Care Med. 2003;168(1):7-9. <http://dx.doi.org/10.1164/rccm.200305-707OE>. Epub 2003 May 28.

818. **Biological activities and corresponding SARs of andrographolide and its derivatives.** Zhou B, Zhang D, Wu X. Mini reviews in medicinal chemistry. 2013;13(2):298-309.

819. **Synthesis and Biological Evaluation of Reniochalistatins A-E and a Reniochalistatin E Analogue.** Zhou R, Sun Y, Li H, Long W, Liao X, Feng P, et al. ChemMedChem. 2018;13(20):2202-7. <http://dx.doi.org/10.1002/cmdc.201800529>. Epub 2018 Sep 5.

820. **[Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area].** Zhou XZ, Zhao M, Wang FS, Jiang TJ, Li YG, Nie WM, et al. Zhonghua yi xue za zhi. 2003;83(12):1018-22.

821. **Coronaviruses-drug discovery and therapeutic options.** Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY. Nature Reviews Drug Discovery. 2016;15(5):327-47.